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ABSTRACT 
 Protein-protein interactions (PPI) represent a challenging target class in 
contemporary small molecule drug discovery. The difficulty arises because PPI sites are 
structurally and physicochemically different from conventional drug binding sites. 
Moreover, we currently lack a good understanding of the druggability of PPI targets: that 
is, how the structure and properties of a PPI interface site relates to the properties of small 
molecules that can bind to that site with high affinity. Efforts to achieve potent drug-like 
small molecule inhibitors of PPI interfaces, involving a wide range targets, historically 
have largely been unsuccessful, leading to the conclusion that new inhibitor chemotypes 
are needed to inhibit this class of target. In this thesis, I describe the application of two 
approaches to identify inhibitors of the PPI interface between Kelch-like ECH associated 
protein 1 (KEAP1) and Nuclear factor (erythroid-derived 2)-like 2 (Nrf2): (i) screening a 
library of synthetic macrocycles, and (ii) fragment-based lead discovery. I validate and 
characterize the hit compounds obtained. In the case of the fragment hits, I investigate what 
features of the compounds are required for binding to the target (Chapter Two). In parallel, 
I investigate the structure of the hot spot ensemble at the KEAP1/Nrf2 binding interface 
using three complementary methods: alanine scanning mutagenesis, fragment screening, 
  viii 
and in silico probe mapping using the FTMap algorithm (Chapter Three). This analysis 
brings insight into the druggability of KEAP1, and advances our understanding of the 
utility and limitations of those three widely used methods for characterizing the hot spot 
ensembles at PPI interfaces (Chapter Three). Finally, to gain additional insight into the 
energetics of KEAP1/Nrf2 binding, I probe the additivity of combinations of alanine 
mutants (Chapter Four). I use the results to propose a quantitative approach to categorizing 
the various degrees of additivity that can be observed at PPI interfaces, and discuss the 
possible structural basis for these behaviors. The model potentially provides a more general 
framework for understanding the binding energetics at PPI interfaces using combinations 
of mutations. 
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CHAPTER ONE. Targeting Protein-protein Interactions Using Macrocyclic 
Molecules and Fragment-based Approaches 
1.1 Introduction to the protein-protein interactome 
It has been widely recognized that the complex network of interactions between 
proteins is important in regulating biological systems and directly relevant to diseases. This 
complex network is termed the “interactome”. It is estimated that the human “interactome” 
contains between 130,000 and 650,000 binary protein-protein interactions (PPIs).1,2 
Although many databases have been constructed and established to provide and analyze 
the protein-protein interaction networks,3-7 a substantial subset still remains unmapped.2 
The PPI network in cells is dynamic, and cellular systems are highly sensitive and 
responsive to transient PPIs. Dysfunction of PPIs may lead to inflammatory, autoimmune 
and neurodegenerative diseases.8-15 The capability to selectively disrupt PPIs would 
provide new ways to regulate cell signal transduction, and potentially lead to therapeutic 
solutions to certain diseases.13,14,16,17 Nevertheless, this class of drug targets has not yet 
been exploited extensively using synthetic small-molecule drugs. The majority of 
conventional small molecule drugs target proteins such as enzymes or transporter proteins; 
these appear to have structurally evolved for binding of natural small molecule substrates, 
making the development of a synthetic organic small-molecule inhibitor or agonist of such 
targets less challenging.18,19 In contrast, the successful identification of oral small-molecule 
drugs that address PPI targets by directly disrupting the interaction between two proteins 
is exceedingly rare. As a consequence, PPIs are thought to be challenging drug targets, and 
in some cases are considered “undruggable”, in the drug discovery community.20-35 
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1.2 Targeting protein-protein interactions using small molecules 
A protein target is considered to be druggable if (i) it is capable of binding a small 
drug-like molecule with sufficient affinity and (ii) such binding leads to alteration of the 
function of the protein.36,37 Thus, the question of PPI druggability becomes a more 
amenable one: how the structure and properties of a PPI interface site relate to the 
properties of small molecules that can bind to that site with high affinity. 
The difficulty of inhibiting protein-protein interactions using small molecule drugs 
arises mainly from the structural and physicochemical features of PPI sites. Unlike the drug 
binding sites on conventional targets, which have evolved to contain deep cavities that can 
interact with small molecules with a pocket surface area of 300 – 500 Å2,38 protein-protein 
interaction interfaces tend to be large (800–2,000 Å2 per side)16,37,39-41 and typically lack a 
conventional small molecule drug binding pocket.36,40 What makes this problem even more 
challenging is the structural complexity at PPI interfaces – a primary linear protein 
sequence, a region with secondary structures or sometimes even a tertiary structure formed 
by multiple sequences is required to achieve sufficient binding between proteins.16,35 Thus, 
developing a small-molecule ligand with ideal drug-like properties that can be 
topologically complementary to the large, structurally complicated PPI interface and 
achieve sufficient contact area for providing requisite interaction energy was historically 
considered a challenging task.13,14,16,17,24,25,27,29,42 
 This challenge has more recently been mitigated by the discovery of binding 
energetic hot spots, where the interaction energy is not uniformly distributed at the PPI 
interface, and is instead mainly contributed by energetic ‘hotspots’ that comprise only a 
  
3 
small fraction of the total interface area.43-48 Therefore, it might not be necessary for a small 
molecule to cover the entire protein binding surface with complementary topology. Instead, 
enough overlap with strong hot spots will serve the goal of achieving sufficient binding 
energy. Approaches to probe such binding hot spots include alanine scanning mutagenesis, 
multiple solvent crystal structures, computational mapping, etc.  
The success in discovering a PPI-targeting drug candidate not only depends on the 
properties of the PPI interface, but also on the properties of the ligand.  In addition to high 
binding affinity and specificity, the structural and physicochemical characteristics that 
confer good pharmacological properties also need to be taken into consideration. Lead 
optimization often involves iterative rounds of synthesis and modification as well as in vivo 
preclinical pharmacology studies, where significant amounts of work are devoted to 
achieving desirable absorption (i.e. initial entry into the body through the oral or 
gastrointestinal administration into cells), distribution (i.e. transportation in the vasculature 
system and to the targeted tissue), metabolism (i.e. transformation to one or several 
metabolites) and excretion (i.e. elimination from the body) (ADME) properties. Parameters 
such as molecular weight, cLogP (octanol/water partition coefficient, an expression of 
lipophilicity of the molecule), hydrogen bond donors (HBD, such as NH and OH groups), 
hydrogen bond acceptors (HBA, such as O and N atoms), etc., were historically used to 
describe the characteristics of the compounds, and certain empirical constraints on those 
parameters were imposed to develop a general guideline in conventional drug design. 
Lipinski et al. concluded that a molecule is more likely to have good solubility and 
permeability if it satisfies the following criteria: (1) molecular weight ≤ 500 Da.; (2) cLogP  
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< 5; (3) HBD < 5; (4) HBA < 10 (Lipinski’s “Rule of 5”).49 It was also reported in this 
study that the oral bioavailability of the compounds investigated inversely correlated with 
their molecular weights. Since then, this guideline has greatly facilitated drug discovery 
for conventional targets (e.g. enzymes, transporters, etc.), yet has constrained the focus to 
be only on exploring the “Rule of 5” chemical space for many years. A dilemma arises 
when PPI targets are concerned. To reconcile the large PPI interface, a small molecule 
ligand is required to make contacts with multiples sites (i.e. hot spot regions) that might be 
scattered on the target protein surface to obtain requisite binding energy (as discussed 
above), leading to a relatively larger size with higher molecular weight compared to 
conventional drugs. However, the criteria listed above (Lipinski’s rules) generally 
constrain the size of the small molecule ligands, which is in part contradictory to the goal 
of achieving sufficient binding energy and specificity for targeting PPI interfaces. 
 
1.3 Macrocycles as PPI inhibitors 
1.3.1 “Beyond Rule-of-5” chemical space 
One possible resolution to the dilemma is to exploit the “beyond Rule-of-5” (bRo5) 
chemical space. This extended chemical space contains larger, more structurally complex 
organic molecules that can offer greater opportunities for finding a drug that is capable of 
binding strongly to a protein surface lacking conventional drug-sized pockets, meanwhile 
also possessing drug-like properties, based on recent analyses.50-61  
Compelling evidence for the utility of “bRo5” compounds as drugs is the 
observation that even though these compounds usually violate one or several of Lipinski’s 
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rules, they can still possess cell permeability and bioavailability. It has been shown that the 
parameters used in Lipinski’s “Rule of five” do not directly reflect the essential 
physicochemical and structural features required for drug-like properties. For example, 
based on the evaluation of 1100 drug candidates, Veber et al. employed two other 
parameters in their analysis: the number of rotatable bonds (NrotB) as an expression of 
molecular flexibility, and polar surface area (PSA) that correlates closely with the sum of 
HBDs and HBAs. They concluded that a molecule compliant with both criteria – (1) NrotB 
≤ 10 and (2) PSA ≤ 140 Å2 will probably demonstrate good oral bioavailability, 
independent of its molecular weight.62 This finding has also been extensively validated in 
other compound collections.63-67 Therefore, the traditional criteria limiting the exploration 
to only within Ro5 chemical space for drug-like molecules may have hampered the success 
in developing therapeutic solutions to the PPI targets. In fact, a substantial number of 
natural products or natural product derivatives have a MW > 500 Da yet are approved drugs 
including oral drugs, such as cyclosporine A (MW 1203 Da.).50,60,68-71  
 
1.3.2 Macrocycles as a privileged chemotype for inhibiting PPIs 
As discussed above, compounds belonging to “bRo5” chemical space (MW > 500 
Da.) are hypothesized to provide a broad solution for addressing difficult drug targets such 
as PPIs. Among those, macrocyclic structure presents as a recurring theme.69,71-76 
Macrocyclic scaffolds have been extensively validated to be a privileged chemotype 
achieving a balance between solubility, cell permeability, target binding potency and good 
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ADME properties to become drugs of difficult targets.70,71 The advantages of macrocycles 
as PPI-targeting drug candidates can be seen from at least four aspects: 
(i) Large surface-of-contact. Owing to their large size, macrocycles can bind more 
strongly to large, lack-of-drug-pocket PPI interfaces by making direct contact over a 
relatively larger area of a protein’s surface (up to 800 Å2),71,72 hence potentially occupying 
more binding hot spot regions and achieving more binding energy than would be possible 
for a conventional drug.  
(ii) Conformational rigidity. It has been extensively studied that pre-organizing a 
compound into the geometry optimal for binding through macrocyclization can improve 
binding affinity to the target protein. 
(iii) Chameleonic behavior. A properly designed macrocyclic structure can have 
certain properties that allow it to undergo “chameleonic” conformational changes, 
shielding polar groups for improved permeation through biological membranes, and 
exposing these polar groups for enhanced aqueous solubilty.77-79 This chameleonic 
property, together with other efforts to eliminate amide NH groups by capping with methyl 
groups in macrocycles and cyclic peptides, greatly compensates for the poor 
pharmacological properties typically associated with high MW compounds.75,80-85 
(iv) Metabolic stability. Cyclization can also reduce susceptibility to metabolism 
by proteolytic or oxidative enzymes, hence improving in vivo stability.71,73 
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1.3.3 How proteins bind macrocycles 
To elucidate the topology of macrocycle binding to proteins, Villar et al., performed 
a systematic analysis of a set of 22 distinct MC-protein complexes selected with the 
following criteria: (1) MC ligands with ring sizes ≥ 14 atoms; (2) high quality structures; 
(3) ligands not belonging to certain chemotypes considered to have low relevance for drug 
discovery. Considering that the MCs in their test set have a relatively wide range in ring 
size (14 – 35 atoms) and molecular weight (365 – 1291 Da.), they categorized these 19 
compounds into two groups using a molecular weight cut-off of 600 Da. The two groups 
of MCs bind to their protein target in distinct geometries: smaller MCs (MW < 600 Da.) 
tended to adopt a compact conformation suitable for a deep binding cavity, in a similar 
mode to conventional drugs; larger MCs (MW > 600 Da.) bound with either a face-on 
mode at a flat protein surface, or with an edge-on mode at a groove-shaped binding site 
(Figure 1.1). They also investigated the buried surface area of MCs upon binding to protein 
targets in comparison to the typical drugs, and results indicated that large MCs buried on 
average 630 ±  120 Å2 of solvent accessible surface area (SASA). This value is 
substantially greater than that of a “Ro5” drug (~300 Å2), approaching the value of the 
contacting area at a PPI interface (~ 800  Å2 per side).60 A more detailed analysis of the 
molecular properties of the contacting area on MCs revealed that: (1) polar/non-polar atom 
distribution remained the same as conventional drugs (30% polar atoms); (2) the 
substituent groups on the ring constituted half of the contact surface, with the remaining 
fulfilled by atoms from the ring scaffold and peripheral groups such as methyls, hydroxyls 
and carbonyls attached to the ring. The finding that the MCs encompass a large contacting 
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surface area, and similar to that observed for conventional drugs, has also been confirmed 
in Kihlberg and coworkers’ work with a larger set of MC oral drugs and clinical 
candidates.60 The result illustrating the amphipathic propensity of the contact regions on 
MCs provides strong evidence to argue against traditional thinking with regard to MCs, 
wherein the MC structure is assumed to comprise unevenly distributed polar/non-polar 
atoms along the ring structure. These in turn lead to two or more segments possessing 
distinct propensities and functions, as the hydrophobic regions interact with protein target 
and polar regions maintain the lipophilicity.  
 
 
Figure 1.1 Three major binding modes between MCs and proteins. Villar et al.3 categorized the binding 
geometries of natural product MCs into three modes: “face-on”, illustrated by pectenotoxin bound to actin 
(PDB 2Q0R); “edge-on”, illustrated by CsA bound to cyclophilin (PDB 1CWA); and “compact”, illustrated 
by macbecin bound to yeast HSP90 (PDB 2VWC). Proteins are shown in grey and MC ligands in yellow. 
 
It has been well-established that pre-organizing ligands and receptors by 
constraining the molecules to the bound conformations can, in principle, be energetically 
beneficial for binding.86 Therefore, efforts have been made to introduce the structural 
constraint by cyclizing linear ligands into macrocyclic scaffolds to enhance binding 
affinity. Multiple examples have shown success of using this strategy, wherein 
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macrocyclization of the acyclic ligand improved binding affinity by up to ~100-fold 
(Appendix XI). For example, Delorbe et al. showed that macrocyclization of linear Grb2 
SH2 domain binding peptides to give a 20-membered MC ring produced a 1.5-fold increase 
in potency at best.87 Similarly, Tao et al. found that cyclizing a urea-based Chk1 ligand to 
form a 15-membered ring MC improved binding only by 2-fold (from 22 nM to 10 nM).88 
In contrast, Pennington et al. cyclized hydroxyethylamine-based inhibitors of BACE1 by 
late-stage ring-closing metathesis to form 14-membered MCs, and saw improvements in 
affinity from 4-32-fold depending on substitute groups.89 In efforts against the same target, 
Stachel et al. improved binding of a very weak (IC50 > 100 µM) acyclic isophthalamide-
based inhibitor by more than 35-fold (IC50 = 2.9 µM) through cyclization to form a 15-
member MC, on their way to an optimized MC inhibitor with IC50 = 90 nM.90 Substantial 
affinity enhancement of 10-50-fold have also been reported by cyclizing of inhibitors of 
the hepatitis C virus NS3/4A protease,91 by cyclizing indole-based inhibitors targeting the 
NS5B RNA polymerase from the same organism,92 and by constraining peptide binders of 
uPA and acetylcholine esterase through formation of chemically cross-linked bicyclic 
structures.93 Recently, a peptide that binds menin at its PPI interface site with MLL1 was 
cyclized to give a 25-member MC, resulting in almost a 100-fold increase in binding 
affinity compared to a close acyclic analogue, and eventually an optimized final MC with 
KI = 4.7 nM was obtained.94 While these examples illustrate how cyclization can improve 
the binding affinity of an acyclic ligand in most cases, the magnitude of this beneficial 
outcome is not predictable. 
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One of the determinant factors of the magnitude of the binding energy gain from 
cyclization is how much the constrained ligand resembles the optimal bound conformation. 
In some cases, structural constraints may induce backbone scaffold distortion, resulting in 
the substituent group deviating from the ideal bound geometry. The extent of the deviation 
varies depending on the geometry of the acyclic precursor and the position of 
macrocyclization, therefore making the energetic outcome unpredictable. In some other 
cases, it is very hard to distinguish if the gain of binding energy arises from the geometrical 
constraint by cyclization or from introduction of other chemical features that benefit the 
binding. An illustrative example is provided by the MC inhibitor of farnesyl transferase 
(FTase), reported by Dinsmore et al. in 2001.95 The final compound, a 16-member MC, 
inhibited FTase with an IC50 of 0.1 nM, was compared to two open-chain analogues with 
close structural similarities and same number of rotatable bonds. The only difference was 
the position of ring cleavage. One acyclic analogue, in which the ring was broken by 
removal of a single methylene unit, showed a weakened binding affinity of ~50,000-fold 
(5490 nM), whereas the other inhibited with an IC50 = 2 nM, suggesting that the true 
affinity gain via cyclization was less (~20-fold). Possible explanations include (1) the weak 
acyclic analogue may have some subtle but energetically costly structural steric, and (2) 
the potent acyclic analogue may maintain very similar chemical features required for target 
binding in comparison to the reference macrocyclic compound. However, the actual cause 
of this substantial discrepancy in response to the cyclization remains unclear. 
Whether or not the gain of affinity upon macrocyclization is mainly caused by the 
reduced conformational entropy is still a matter of debate. In the analysis of the approved 
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MC drugs and MC clinical candidates by Kihlberg and coworkers, they concluded that 
those macrocycles in general were no more rigid in comparison to non-macrocycles in the 
bRo5 chemical space, based on root mean square deviation (RMSD) calculations of all 
available experimental conformers from crystal structures.60 Based on this observation, 
they reached a preliminary conclusion that decreased flexibility may not be the primary 
privilege for macrocycles. A recent study by Tran et al. attempted to address this question 
from another perspective.96 Using thiocillin as a model system, they generated a site-
saturation mutagenesis library, and evaluated their target activity coupled with 
computational modeling to identify ensembles of conformers for each variant. Their results 
revealed a strong reverse correlation between the target binding activity and the structural 
flexibility, suggesting that the formation of a macrocycle with reduced backbone entropy 
is, in part, required for potent binding in this system. The discrepancy in these observations 
can possibly be accounted for by the following two-fold explanation: (1) to achieve a good 
binding affinity to protein targets, a certain extent of structural constraint to reduce the 
conformational entropy is necessary; (2) this rigidifying effect can be introduced by 
approaches other than macrocyclization, as a similar number of low-energy conformers 
were seen in the acyclic approved oral drugs compared to MC drugs in bRo5 chemical 
space. These results allow us to think more precisely about what specific modes or aspects 
of molecular flexibility may contribute to binding and other properties of MCs.  
 
  
12 
1.3.4 Designing bioactive macrocycles 
Another feature that makes macrocycles appealing drug candidates is their ability 
to be orally bioavailable despite their high molecular weight. Like conventional drugs, 
macrocyclic structures can be both water-soluble and membrane-permeable at the same 
time. This contradicts the historical belief that compounds with molecular weight >> 500 
Da. are unlikely to achieve this goal (see Section 1.2). Good aqueous solubility usually 
requires the compound to have sufficient exposed polar surface area (PSA) for solvation 
by water; on the contrary, passing through the hydrophobic cell membrane requires that 
the compound shield polar atoms in order to reduce the desolvation energy. Analysis of 
successful macrocyclic drugs unveils two strategies that nature has employed to address 
this problem, which we discuss in detail below. 
One approach is to eliminate the amide NH groups via chemical modification to 
reduce the PSA when passing through the hydrophobic cell membrane. Amide bonds in 
the ring structure are usually seen in peptidic or nonpeptidic MC drugs owing to their 
natural product origins. It has been observed that many MCs possess a certain degree of N-
methylation. For example, cyclosporine A (CsA), a cyclic peptidic natural product oral 
drug that binds to cyclophilin, has seven of its eleven backbone amides N-methylated. 
Taking a cue from nature, efforts have been made ever since to understand how the pattern 
of N-methylation in cyclic compounds can improve membrane permeability. For example, 
Ovadia et al. investigated how the N-methylation on a polyalanine cyclic hexapeptide can 
affect the membrane permeability. The results revealed that the position rather than the 
number of N-methylation sites can have a significant impact on the cyclic peptide 
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membrane permeability.97 Other strategies such as using β- and γ-amino acids, substituting 
amides with ester bonds or with oxazole or thiazole rings, and utilizing D-amino acids and 
prolines, have also been shown to improve the cell permeability of macrocycles.75,80-85,98,99 
Evidenced by the work discussed above, good cell permeability of macrocycles can be 
achieved by means of eliminating exposed NH groups, shielding polar groups from solvent 
in nonpolar environments, and reducing MC flexibility. 
An alternative approach is to utilize the chameleonic properties of macrocycles and 
high molecular weight drugs, and incorporate this feature into future drug development. It 
has been proposed that since the poor membrane permeability arises from great 
conformational entropy and the exposure of polar groups in acyclic molecules, 
macrocyclization tends to be an ideal approach for providing significant structure rigidity, 
facilitating the formation of self-complementary hydrogen bonds, and consequently, 
improving membrane permeability.71 A classic example is again, CsA. Crystal structures 
in aqueous and several nonpolar solvents have shown that this compound can adopt 
multiple low-energy conformations, among which an expanded conformer exposing polar 
atoms to the environment and a relatively compact conformer with self-complementing 
hydrogen bonds were observed.100,101 The ability to undergo such an environment-
dependent conformational change, termed “chameleonic property”, allows for a large 
molecule to modulate the polarity of its solvent-exposed surface to achieve good aqueous 
solubility while also lowering the energetic cost of desolvating the molecule to enable 
sufficient permeation through cell membranes (Figure 1.2). Several groups have shown 
that this property can be generalized to other cyclic peptides of appropriate 
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structure.75,78,102-105 For instance, Vistoli et al. demonstrated that several molecular 
physicochemical properties (e.g. cLogP) are conformational-dependent. They introduced 
the concept of “molecular sensitivity”, namely a given computable physicochemical 
property as a function of flexibility, and used this parameter to quantitatively illustrate this 
dependence.105 Jacobson and coworkers showed that the membrane passive permeability 
of a set of cyclic peptides correlated strongly with the calculated transfer energy of the low 
dielectric conformation (the compact conformer, vide supra) from water to chloroform.78 
 
 
Figure 1.2 Illustration of the “chameleonic” property (adapted from Whitty et al.). CsA is used as an example 
to illustrate the conformational change to balance aqueous solubility and membrane permeability. CsA 
maintains an expanded conformer that allows the exposure of polar groups to maximize aqueous solubility, 
and a compact conformer that shields these groups from solvent to reduce exposed polar surface when in a 
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nonpolar environment, thereby reducing the desolvation energy and lowering the energy barrier for diffusion 
into and through the cell membrane. CsA structure in aqueous solution (left, from cyclophilin-bound 
structure, PDB 1CWA) and acetone (right, CCDC 1138505). Intramolecular hydrogen bonds are indicated in 
yellow dashed lines. Water molecules are shown for illustration, not included in the reported crystal 
structures. 
 
During my graduate research, we addressed the question of how to quantify the 
degree of chameleonic behavior and provided a guideline in terms of how to achieve the 
balance between aqueous solubility and membrane permeability, for large MCs and other 
high MW drug development. The results and conclusions are included in Appendix XII. A 
similar approach was reported by Kihlberg and coworkers shortly after our work.106,107 
In conclusion, macrocycles represent an appealing chemotype as drug candidates 
due to their high affinity, specificity, and favorable pharmacological properties. Current 
challenges include the lack of approaches to computationally predict suitable protein 
targets for MCs, refined guidelines for design of pharmaceutically useful synthetic MCs 
and methods for the efficient synthesis of MCs.73 
 
1.4 Biology and structure of KEAP1/Nrf2 
Reactive oxidants and electrophiles, from either internal metabolism or 
environmental exposure to toxins, trigger oxidative stress in cells. On the other hand, cells 
have complex antioxidant defense systems regulated by a network of signaling pathways 
to ensure the adaptive response to reactive oxygen species (ROS). Among these, the 
nuclear factor erythroid 2-related factor 2 (Nrf2) is a major activator of the cellular response 
to oxidative stress.108-110 In the presence of ROS, intracellular levels of Nrf2 increase and 
subsequently Nrf2 migrates into the nucleus, where it forms a heterodimer with the Maf 
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family member. The Nrf2/Maf complex then binds to the Antioxidant Response Element 
(ARE), an enhancer sequence in the promoter region of many genes that encode antioxidant 
and Phase II detoxifying enzymes/proteins, consequently upregulating the production of 
cytoprotective defenses against oxidative damage. A cytoplasmic redox-sensitive protein, 
Kelch-like ECH-associated protein 1 (KEAP1), functions as a repressor of the Nrf2 
signaling pathway.111 Elevated Nrf2 levels induced by KEAP1 mutations that abolish 
binding have been discovered in many types of cancerous cells such as those found in lung, 
breast, ovarian and endometrial cancers.112-119 On the contrary, up-regulation of Nrf2 has 
been shown to provide protection against inflammatory damage and be beneficial in a range 
of therapeutic areas, e.g. cardiovascular, neurodegeneration.108,120-122 
KEAP1 functions as an adaptor protein for the E3 ligase-mediated downregulation 
of Nrf2. Under basal conditions, Nrf2 is constantly degraded through the KEAP1-
dependent ubiquitin-proteasome pathway. KEAP1 is a cysteine-rich protein; human 
KEAP1 has 27 cysteines, most of which are susceptible to covalent modifications by 
oxidants and electrophiles.123 Among those, three cysteine residues, C151 in the Broad 
complex, Tramtrack, and Bric-a-Brac (BTB) domain, C273 and C288 in the intervening 
(IVR) domain, have been shown to be oxidized or adduct-forming with oxidative inducers, 
subsequently altering the conformation of KEAP1.124 Although the molecular details of 
how the cysteine modification leads to the outcome of Nrf2 activation still remain unclear, 
two different models have been proposed. The first is a “hinge-and-latch” model, in which 
upon the cysteine modification, the conformation of the KEAP1 homodimer is altered, 
leading to the dissociation of the DLG binding motif on Nrf2 and inducing a misalignment 
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of the region on Nrf2 for polyubiquitination, shown in Figure 1.3.125 Evidence for this 
model is supported by two experimental observations: (i) the DLG binding motif interacts 
with KEAP1 protein approximately 200-fold weaker compared to the DxETGE motif; (ii) 
mutations in the DLG region reduce levels of Nrf2 ubiquitination in cells.126,127 The second 
is a “Cul3 dissociation” model, in which the thiol modification induces a conformational 
change in KEAP1 that disrupts the Cullin3/Ring-box 1 (Cul3/Rbx1) binding.124 In both 
models, the suppression of Nrf2 ubiquitination leads to the accumulation of Nrf2, and 
eventually activates the cytoprotective gene expression. 
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Figure 1.3 Schematic model of Nrf2 regulation by KEAP1(adapted from Sun et al.)128. KEAP1 is a key 
repressor of the Nrf2-mediated antioxidant response. Under basal conditions, KEAP1 forms a homodimer 
and binds to Nrf2 with a 2:1 stoichiometry. The Nrf2-KEAP1 complex then associates with the Cul3-Rbx1 
core ubiquitin machinery, leading to degradation of Nrf2. Under induced conditions, oxidants or 
chemopreventive compounds cause a conformational change in the KEAP1-Cul3-E3 ubiquitin ligase by 
acting on specific cysteine residues of Keap1, preventing polyubiquitination of Nrf2, subsequently activating 
the cytoprotective response. 
 
 
Human KEAP1 is a 624 amino acid protein that consists of three domains: an N-
terminal BTB (Broad complex, Tramtrack, and Bric-a-Brac) domain, an intervening region 
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(IVR) or BACK domain, and a C-terminal Kelch repeat domain. The BTB domain serves 
as an adaptor region for KEAP1 homo-dimerization and for recognition of the E3 ubiquitin 
ligase Cullin3/Ring-box 1 (Cul3/Rbx1).129-131 The IVR domain, a cysteine-rich region, is 
responsible for redox sensing.132-135 Finally, the C-terminal Kelch repeat domain forms a 
β-propeller fold and acts as Nrf2 recognition module.136 
Human Nrf2 is a 589 amino acid protein that consists of seven Nrf2-ECH homology 
domains (Neh), among which the N-terminal Neh2 domain functions as the major 
regulatory domain. The Neh2 domain contains two KEAP1 recognition regions, named 
DLG motif and DxETGE motif,126,127,137 as well as a lysine-rich region in between that is 
responsible for ubiquitin conjugation.111,138 The domain architectures of KEAP1 and Nrf2 
are shown in Figure 1.4 A and B, respectively. 
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Figure 1.4 The domain architectures and structures of KEAP1 and Nrf2. Schemes show the domain 
architectures of (A) KEAP1 and (B) Nrf2. The locations of the DLG and DxETGE motifs of Nrf2 are 
indicated. (C) Crystal structure of the Kelch repeat domain of KEAP1 (grey) in complex with peptides 
corresponding to residues 69-84 of Nrf2 (green, PDB 2FLU) and residues 24-29 (yellow, PDB 2DYH), 
shown views from the side (left) and from the top (right). (D) A KEAP1/Nrf2 complex structure with binding 
details using an in-house developed Kelch repeat domain construct, solved by Dr. Andrew Lynch and Dr. 
James Carolan of the Allen lab.139 Nrf2 peptide corresponding to residues 76-85 is shown in green, with side 
chains shown in sticks. 
 
 
16 mouse and 17 human KEAP1 Kelch repeat domain crystal structures have been 
published and reported in the Protein Data Bank (PDB) so far, including unbound, Nrf2 
peptide-bound and small molecule-bound KEAP1. The overall structure of this domain 
consists of a six-bladed β-propeller fold, with each blade composed of four anti-parallel β-
sheets and a central channel. The central channel is enriched with hydrophobic residues 
such as Val, Ala, Gly, Ile and Leu. Peptides derived from the two KEAP1 binding regions 
on Nrf2, i.e. DLG and DxETGE motifs, have been successfully soaked or co-crystalized 
with KEAP1. Results have shown that the Nrf2 peptide encompassing the DxETGE motif 
forms a β-hairpin loop and binds to KEAP1 (PDB 2FLU, human KEAP1, shown in Figure 
1.4 C).137 Surprisingly, a hexamer peptide encompassing the DLG motif on Nrf2 
(WRQDID) has been shown to bind at the same pocket on KEAP1, even though the 
sequence components of the two recognition motifs are completely different (PDB 2DYH, 
mouse KEAP1 shown in Figure 1.4 C).126 In addition, our collaborators in Prof. Karen 
Allen’s laboratory at Boston University, Dr. Andrew Lynch and Dr. James Carolan, have 
successfully solved crystal structures of unbound Kelch repeat domain of KEAP1 and in 
complex with an Nrf2 9mer peptide (76-84) using a construct amenable for soaking 
experiments (Figure 1.4 D). These results provide critical information for the development 
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of small molecule inhibitors and investigation of the binding hot spots at the PPI interface.  
Given the essential role of the KEAP1/Nrf2 interaction in the cell antioxidant 
defense system and its relevance to certain types of diseases, finding an approach to disrupt 
the interaction of this complex will be therapeutically beneficial. In addition, this PPI target 
represents a protein binding to a region with secondary structures on its binding partner, 
which is hypothesized to be an amenable type of PPI target for small molecule ligands.17 
Furthermore, this protein complex represents the PPI class of a globular protein binding to 
a loop-shaped peptide with continuous epitopes.35,140 We propose that a macrocyclic 
scaffold, stabilizing the compound in a conformation that is complementary to the shape 
of the KEAP1 binding pocket, is likely to adequately mimic this type of interaction with 
pre-organized loop structure. Therefore, we would like to use this PPI target as a model to 
demonstrate the privilege of macrocyclic scaffolds in small molecule drug discovery 
targeting PPIs.  
 
1.5 Overview of thesis contents 
The ultimate goal of this research project is to understand the binding energetics 
and develop inhibitors of the KEAP1/Nrf2 protein-protein interaction in order to (1) 
understand the druggability of KEAP1/Nrf2 protein-protein interaction; (2) develop new 
guidelines to probe PPI hot spots and understand the druggability of other PPI targets, and 
(3) construct a framework for analyzing PPI energetics. The work discussed in this thesis 
involves characterizing the protein-protein interaction between KEAP1 and Nrf2 and 
screening for inhibitors. 
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Chapter 2 focuses on the inhibitor discovery of this PPI target. This work has 
resulted in several validated and characterized fragment-sized hits with structural 
information of binding to KEAP1, providing insight into further fragment elaboration to 
achieve more potent leads. Furthermore, the protein constructs and binding assay 
developed in this chapter supports the aims in subsequent chapters. 
Chapter 3 describes the comprehensive analysis of binding hot spots at the 
KEAP1/Nrf2 PPI interface. Key residues on Nrf2 and their energetic contributions to 
binding to KEAP1 were determined using alanine scanning mutagenesis. Results were 
compared to the FTMap-identified hot spots and experimental fragment binding sites. False 
positives and  negatives, along with their associated mechanism were also interrogated. 
Through this work, we conclude that KEAP1 is druggable, and have proposed a guideline 
for properly probing hot spots at PPI interfaces. 
Chapter 4 focuses on the additive and non-additive mutational effects and their 
structural basis. Further investigation of the binding energetics at the KEAP1/Nrf2 
interface utilizing a double-mutant cycle strategy has elucidated that pairs of mutations on 
two protein binding partners can behave distinctly depending on their structural 
relationship. Supported by structural information, a hypothetical model has been proposed 
to categorize the PPI additive/non-additive behavior upon mutagenesis. By introducing the 
term Additivity Index, we have developed a quantitative approach for analyzing pairs of 
mutations based on their binding energetics to associate the behavior with a defined 
structural relationship. This work provides a general framework on how to further interpret 
the PPI binding energetics using double mutant cycles in a quantitative way.  
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CHAPTER TWO. Discovery of New Inhibitors of KEAP1/Nrf2 Protein-protein 
Interaction 
2.1 Introduction 
The biological function and structure of KEAP1/Nrf2, and the superiority of 
exploring the macrocycle chemical space as a means to address this difficult class of drug 
targets (i.e. PPIs) have already been extensively studied in Chapter 1. In this section, I 
discuss the advantages of using fragment-based drug discovery to address this particular 
target, the feasibility of developing covalent ligands of KEAP1, and prior efforts to develop 
inhibitors of the KEAP1/Nrf2 interaction. 
 
2.1.1 Fragment-based drug discovery 
Fragment-based drug discovery (FBDD) has emerged as a widely employed 
approach to tackle difficult drug targets (e.g. PPIs) over the past two decades.37,141-148 
Unlike conventional high throughput screening (HTS) of compounds of molecular weight 
~ 300-500 Da, FBDD exploits compounds of relatively lower molecular weight (~150-250 
Da) as tools, therefore reducing the structural complexity of these compounds, and 
increasing the chemical and functional diversity. As a result, fragment screens require 
testing of fewer compounds to establish druggability of a target and identifying tractable 
hits that can complement the binding pocket.143-145 Due to its small size, the binding energy 
gained by such a small fragment structure is limited, typically with a KD ~ 1 mM. 
Subsequent steps involving extensive elaboration of the initial fragments into neighboring 
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pockets as well as fragment optimization to obtain other properties are required to achieve 
better complementarity to the binding site. 
One successful example of FBDD is ABT-737, a potent and selective Bcl-2 
inhibitor (KD < 1 nM). Initially, two hits, 4'-fluoro-[1,1'-biphenyl]-4-carboxylic acid (KD = 
300 µM) and [1,1'-biphenyl]-4-ol (KD = 6000 µM) were discovered to bind at two distinct 
sites on Bcl-2 using NMR-based screening. The two fragments were linked to yield a 
molecule with Ki = 1.4 µM. Further optimization of this molecule via iterative library 
synthesis led to the discovery of ABT737, and subsequently a highly potent, orally 
bioavailable and BCL-2-selective inhibitor, ABT199.149-151 
There is a broad spectrum of biophysical and biochemical approaches currently 
being applied for fragment discovery, such as protein Nuclear Magnetic Resonance 
spectroscopy (NMR),152 and the multiple solvent crystal structures (MSCS) method.153-155 
In both methods, structures of target proteins are solved in the presence of a variety of 
organic solvents. Each type of solvent molecule serves as a probe for complementary 
binding sites on the protein, and the identified consensus binding sites are potentially 
favored for ligand interactions. Other techniques being integrated in developments for 
fragment screening include Surface Plasmon Resonance (SPR), microscale 
thermophoresis, thermal shift assays (TSAs), weak affinity chromatography and disulfide 
trapping (Tethering).142-145,156 
Tethering is a fragment screening technique relying on reversible covalent bond 
formation between the fragment and protein of interest.142,156 In brief, a native or 
engineered solvent-exposed cysteine residue that is adjacent (~ 5 – 10 Å) to the active 
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binding site is utilized for thiol-disulfide exchange with the disulfide-containing fragments. 
Screens are carried out under partially reducing conditions allowing rapid disulfide-
exchange between the fragments and protein. The fragment having inherent affinity for the 
protein target that binds near the cysteine residue will be thermodynamically favored and 
accumulated (Figure 2.1). Detection by mass spectrometry can then reveal the dominant 
protein-fragment species and identify the hits by adduct mass. Upon covalent bond 
formation, Tethering enables screening of fragments at lower concentrations with 
detectable outcomes even if they bind to the proteins very weakly. In addition, Tethering 
can also be applied for target covalent inhibitor discovery (vide infra). 
 
Figure 2.1 Tethering fragment-based drug discovery (adapted from Erlanson et. al).156 The simplified scheme 
shows some of the equilibria in Tethering. Fragments with inherent affinity for the protein (pink) have a more 
stable disulfide bond and predominate at equilibrium. 
 
2.1.2 Targeted covalent inhibitors 
Covalent inhibitors, mostly discovered by chance in history, comprise a substantial 
portion of successful drugs in the market.157 Nevertheless, for many years, covalent 
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approaches are disfavored and avoided in drug discovery due to the toxicity risk associated 
with off-target activities. However, interest in covalent inhibitors, especially the concept 
of “targeted covalent inhibitors” (TCI), has reemerged in recent years.142,156-160 These 
compounds consist of two functional domains: (i) a moiety that can non-covalently 
recognize the binding site on the target protein to achieve specificity; and (ii) a weak 
electrophilic “warhead” that can sufficiently form a covalent bond with an adjacent specific 
nucleophilic residue (e.g. cysteine) but not nonspecifically labeling nucleophilic residues 
on unrelated proteins. Carefully designed TCIs have advantages that include sustained 
inhibition, lower and less frequent dose-requirement, and provide alternative solutions to 
mutations that are resistant to noncovalent drugs.157 The TCI approach was initially applied 
to kinase inhibitors with successful results.158,159,161-163 For difficult PPI targets, of which 
strategies using noncovalent inhibitors have not resulted in any success, the TCI approach 
offers opportunities toward developing inhibitors with high potency and specificity. Hence, 
initial screening using Tethering to discover disulfide-containing hits fulfills the goal of 
discovering molecules with both functional domains. Given the fact that KEAP1 Kelch 
repeat domain contains a native cysteine residue (position 434) in close proximity to the 
active Nrf2 binding site, we propose that the inhibitor development strategy using TCI is 
suitable for this PPI target (see 2.3.7 for a detailed explanation.) 
 
2.1.3 Known small molecule inhibitors of KEAP1 
Given the crucial role of the KEAP1/Nrf2 interaction in regulating cellular defenses 
against oxidative stress and its implications in multiple diseases, a therapeutic agent that 
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directly disrupts this particular PPI is highly desirable.125,164,165 Efforts have been made by 
multiple research groups and the pharmaceutical industry to search for a solution. 
Tecfidera® (dimethyl fumarate) is an approved drug for treating multiple sclerosis. A 
proposed mechanism of this drug is that dimethyl fumarate (DMF) and its primary 
metabolite monomethyl fumarate (MMF) both robustly modify specific critical cysteine 
residues on KEAP1 as well as deplete glutathione (GSH) in cells, consequently suppressing 
Nrf2 polyubiquitination and inducing nuclear translocation of Nrf2. This is followed by an 
increased transcriptional response (detailed KEAP1-Nrf2 regulation was shown in Chapter 
1).166-169 Marcotte et al. from Biogen, described the discovery of two noncovalent inhibitors 
binding to KEAP1 at micromolar affinity, with the complex crystal structure reported (PDB 
4IQK and 4IN4).170 In addition, Astex Inc. recently reported the first use of the fragment-
based approach to directly target KEAP1, which resulted in a molecule with nanomolar 
binding affinity.171 A list of reported inhibitors with crystal structures in complex with 
KEAP1 is shown in Appendix IV. 
 
2.1.4 Aims 
One of the major goals of my research project is to discover small molecule 
inhibitors of the KEAP1/Nrf2 PPI via two distinct approaches – fragment-based and 
macrocycle-based drug discovery. In this chapter, I describe my efforts of (1) developing 
a fluorescence anisotropy (FA)-based KEAP1/Nrf2 binding assay, (2) employing it as 
screening tool to discover fragment-sized and macrocyclic inhibitors of KEAP1/Nrf2 
interaction and (3) utilizing tethering-based screening technique to identify new fragment 
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ligands of KEAP1 suitable for the development of covalent inhibitors. The success in 
developing and optimizing a robust FA-based assay permitted the high throughput 
screening (HTS) of large compound libraries in subsequent studies and greatly accelerated 
the discovery efforts that led to the identification of 8 fragment hits in this study. With 
these results, I further describe the evaluation of these hits in biochemical assays in 
studying their inhibitory activities, as well as the crystallographic work in collaboration 
with the Allen lab to elucidate the molecular details of their interactions with KEAP1. 
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2.2 Materials and Methods 
2.2.1 Construction of KEAP1 and Nrf2 Bacterial Expression Vectors. 
The DNA encoding the human KEAP1 Kelch repeat domain (residues 312-624) 
was cloned into the pET-15b vector (Novagen, Billerica, MA) using NdeI and XhoI 
restriction sites to obtain a construct with an N-terminal six-histidine tag followed by an 
in-house engineered Tobacco Etch Virus (TEV) cleavage site. A double mutation of 
E540A/E542A, in a position far from the active binding site, was introduced to generate a 
protein form that has the active site available for soaking experiments.172 It was further 
validated that introduction of the E540A/E542A double mutation only caused a r.m.s.d. of 
0.26 Å for 1739 aligned atoms in comparison to a high-resolution structure of the wild-
type protein (PDB 1ZGK).173 This new construct also maintained the same binding mode 
to the Nrf2 peptide.172 Four cysteine-to-serine mutations were also introduced at positions 
319, 613, 622 and 624 to improve protein homogeneity and reduce aggregation (by Dr. 
Stefan Jehle, Allen Lab, Boston University, unpublished data). The DNA encoding human 
Neh2 domain, Nrf21-100 and Nrf234-100, were also inserted into backbone vector pET-15b 
using NdeI and BamHI restriction sites for bacterial expression. All PCRs were performed 
using the MJ Mini Personal Thermal Cycler (Bio-Rad, Hercules, CA) and the following 
protocols: 98 ̊C for 30 s, 35 cycles of 98 ̊C for 10 s, 50 ̊C for 30 s, 72  ̊C for 30 s, followed 
by 72 ̊C for 2 min for final extension at completion of the cycles, then 4 ̊C until the run was 
manually stopped. A total PCR volume of 50 µL consisted of 31.3 µL of water, 2 µL of 
DMSO, 10 µL of Q5 polymerase buffer, 0.5 µL of Q5 High-Fidelity DNA Polymerase 
(New England Biolabs, Ipswich, MA), 1 µL of dNTPs (10 µM), 0.2 µL of template plasmid 
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(10 ng/µL), 2.5 µL of forward primer (10 µM) and 2.5 µL of reverse primer (10 µM). PCR 
products were purified using the NucleoSpin Gel and PCR Clean-up kit (Macherey Nagel, 
Bethlehem, PA). Both the PCR products and blank pET-15b vector were digested under 
the following conditions: 32 µL of water, 1 µL of BSA, 1 µL of NdeI, 1 µL of BamHI 
(New England Biolabs, Ipswich, MA) and 10 µL of vector or PCR products (500 ng), 
incubated at 37  ̊C for 15 min. The digested vector and the PCR products were then ligated 
in a 20 µL ligation mix containing 2 µL of T4 ligase buffer, 1 µL of T4 DNA Ligase (400 
U/µL), 7 µL of PCR (35 ng) and 10 µL of digested vector (50 ng), incubated at room 
temperature for 10 min. The ligation products were then transformed into DH5α competent 
cells (New England Biolabs, Ipswich, MA) following the manufacturer’s protocol, and 
transformed colonies selected on LB agar plates containing Ampicillin (100 µg/mL). All 
plasmids were purified using the Zyppy Plasmid Miniprep Kit (Zymo research, Irvine, CA) 
and confirmed as correct by sequencing. 
 
2.2.2 Protein expression and purification 
All wild-type KEAP1, wild-type Nrf21-100 and Nrf234-100 constructs were 
transformed into BL21(DE3) Competent E. coli cells (New England Biolabs, Ipswich, 
MA) following the manufacturer’s instructions, and colonies selected on LB plates 
containing Ampicillin (100 µL/mL). A 50 mL overnight culture in LB media with 
Ampicillin was seeded by a single colony and grown overnight at 37 ̊C with shaking. A 
new large scale culture was inoculated with the overnight culture by a 1:200 dilution and 
were grown until the OD600 reached 0.4 – 0.6. Protein expression was induced using 1 mM 
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isopropyl-beta-D-thiogalactoside (IPTG, GoldBio, St. Louis, MO). KEAP1 protein was 
expressed under 20 ̊C with shaking at 200 rpm overnight, and the Nrf2 constructs expressed 
at 37 ̊C with shaking at 250 rpm for 4 h. Cells were pelleted via centrifugation and stored 
at -80  ̊C. 
Cells expressing Nrf21-100 and Nrf234-100 were lysed by sonication with addition of 
lysis buffer (20 mM sodium phosphate, 500 mM NaCl, 20 mM imidazole, 2.5 mM DTT, 
pH 7.5) at a concentration of 2 mL/g of the cell pellet together with 10% ethylene glycol, 
0.1% Pierce Universal Nuclease for Cell Lysis (Thermo Fisher Scientific, Waltham, MA) 
and cOmplete ULTRA Tablets, Mini, EDTA-free, EASYpack (1 tablet/2 L of cells, Roche 
Life Science, Indianapolis, IN). The cell lysate was then centrifuged at 27,000 g at 4 ̊C for 
30 min, and the supernatant with soluble proteins collected and filtered through 0.8 µm 
syringe filters. The prepared cell lysate was loaded onto gravity columns packed with 2 mL 
of HisPur Ni-NTA resin that had been pre-equilibrated with 10 resin-bed volumes of 
binding buffer. Samples were incubated with the Ni-NTA resin at 4 ̊C with rotation to 
maximize binding, after which the unbound flow-through was collected by gravity flow. 
The resin was then washed with 10 column volumes of the binding buffer after which the 
His-tagged proteins were eluted using 6 column volumes of elution buffer (20 mM sodium 
phosphate, 500 mM NaCl, 500 mM imidazole, 2.5 mM DTT, pH 7.5). The eluted His-
tagged proteins were then dialyzed against the lysis buffer (20 mM sodium phosphate, 500 
mM NaCl, 2.5 mM DTT, pH 7.5) overnight at 4 ̊C with addition of TEV protease at a 1:100 
dilution. The overnight reaction mixture was applied to the 2 mL of Ni-NTA resin again to 
separate untagged proteins from the Histidine tag and the TEV site. The wild-type KEAP1 
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construct was purified using the same protocol above, with the exception of a slightly 
different buffer system. For KEAP1 purification, a lysis buffer containing 50 mM Tris, 500 
mM NaCl, 20 mM imidazole, 2.5 mM DTT, pH 8.0 and an elution buffer containing 50 
mM Tris, 500 mM NaCl, 500 mM imidazole, 2.5 mM DTT, pH 8.0 were used in the two-
step Ni-NTA purification. 
The cleaved proteins, which included wild-type KEAP1, Nrf21-100 and Nrf234-100 
were then purified by gel filtration using HiPrep 26/60 Sephacryl S-300 column (GE 
Healthcare, Sunnyvale, CA) equilibrated with 25 mM Tris, 2.5 mM DTT for KEAP1, or 
20 mM sodium phosphate, 150 mM NaCl, 2.5 mM DTT for Nrf2 constructs, respectively. 
Purified proteins were then concentrated and quantified using the absorbance at 280 nm 
(NanoDrop, Thermo Fisher Scientific, Waltham, MA), aliquoted, flash-frozed and stored 
at -80 ̊C. 
 
2.2.3 Protein characterization by SDS-PAGE and circular dichroism 
All the recombinant proteins were characterized using sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE). Briefly, 5 µM KEAP1 or 10 µM Nrf2 
constructs were incubated with reducing SDS sample buffer containing 100 mM DTT and 
boiled for 5 min before loading on to the 10% Tris-tricine gel. 
 Circular dichroism (CD) spectra were measured using an Applied Photophysics 
CS/2 Chirascan instrument with a 1 mm path length quartz cuvette at a scan speed of 0.5 
nm/s. The CD spectra were measured at 5 µM of KEAP1 in 25 mM Tris, 2.5 mM DTT, 
pH 8.0 or 10 µM of Nrf2 in 20 mM sodium phosphate, 150 mM NaCl buffer at pH 7.5 at 
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20 ̊C from 180 to 260 nm. The buffer background was also subtracted. The measured 
ellipticity in millidegrees (θ) was normalized to mean residue ellipticity (θMRE) using the 
following equation: 
 
θ#$% = θ10Cnl 
 
where C is the molar concentration of protein, l is the length path in centimeters and n is 
the number of residues. The thermal stability of wild-type Nrf21-100 and Nrf234-100 was 
measured using the same sample preparation by monitoring the increase in magnitude of 
the CD signal at 208 nm as the temperature ramping from 10 ̊C to 70 ̊C at a rate of 
0.5 ̊C/min. A faster ramping rate of 1 ̊C/min was initially used and no significant difference 
was observed. To determine the reversibility of thermal denaturation, a CD spectrum of 
denatured protein at 70 ̊C was collected, followed by the same procedure at a ramping rate 
of 0.5 ̊C/min back down to 10 ̊C, before collecting the spectrum of the refolded protein. 
The thermal stability of wild-type KEAP1312-624 was assessed using a similar protocol as 
above. Because KEAP1 has no alpha helical secondary structure content, the CD signal at 
203 nm was utilized to monitor protein unfolding. The program CDSSTR provided by 
DichroWeb was used to deconvolute the CD spectrum of wild-type KEAP1 using reference 
dataset SP175.174 
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2.2.4 Fluorescence Anisotropy binding assay development 
Commercially synthesized FITC-labeled Nrf2 nonamer peptide (residues 76-84, 
FITC-Ahx-LDEETGEFL-NH2) with a C-terminal amidation (Genscript, Piscataway, NJ) 
was dissolved in water with 0.125% ammonium hydroxide. The concentration of the FITC-
Nrf2 peptide was determined from its absorbance at 493 nm (ε = 76900 M-1 cm-1)175, by 
NanoDrop. Fluorescence Anisotropy assays were performed in 96-well polypropylene 
black plates (Corning Costar, Corning, NY) in duplicates using a SpectraMax M5 
microtiter plate reader (Molecular Devices, Sunnyvale, CA). For binding assays, a total 
assay volume of 200 µL was used and consisted of 50 µL of water, 50 µL of 4X assay 
buffer (final concentration 50 mM HEPES, 150 mM NaCl, 0.01% v/v Triton, 1 mM DTT 
pH 7.4), and 50 µL of FITC-labeled tracer Nrf2 peptide at 20 nM to give a final constant 
concentration at 5 nM, and 50 µL of KEAP1 protein at varying concentrations. The assay 
mixture was incubated at 25 ̊C for 30 min, which control experiments showed was 
sufficient time to reach equilibrium prior to fluorescence anisotropy reading. Samples were 
read by excitation at 488 nm and emission at 520 nm in high sensitivity mode, with 100 
reads/well. Anisotropy values were calculated by measuring the intensity of the parallel 
(I∥) and perpendicular (I⊥) components of the fluorescence emission in each well, and then 
calculating anisotropy (r) using the following equation: 
 
𝑟 = 1000 𝐼∥ − 𝐼1𝐼∥ + 2𝐼1 
 
The direct binding experiments were fitted to a quadratic binding equation, shown below: 
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𝐴 = 𝐴5 + (789:;7<)> × 𝐾AB + [𝐿]F + 𝑅 F − 𝐾AB + [𝐿]F + 𝑅 F > − 4 𝐿 F 𝑅 F         Eq 2.1 
 
where A0 represents the baseline anisotropy signal observed in negative controls omitting 
KEAP1 protein and Amax corresponding to maximal anisotropy signal at saturation. [L]T 
and [R]T are the total concentrations of the ligand (FITC-Nrf2 peptide) and the protein 
(KEAP1) in the final assay, respectively, and KD1 stands for the dissociation constant of 
the interaction. The term (Amax – A0)/[L]T represents the extent of anisotropy signal change 
per molar of FITC-labeled ligand, as molar response of the assay. 
Competition experiments were carried out by keeping FITC-Nrf2 peptide at 5 nM 
and KEAP1 protein at 10 nM, respectively (constant final concentration), in the same assay 
buffer conditions and varying the concentration of unlabeled Nrf2 constructs. The 
unlabeled wild-type and mutant Nrf2 proteins, including an unlabeled Nrf2 nonamer 
peptide (LDEETGEFL-NH2), Nrf21-100 and Nrf234-100, were added into each well by two-
fold serial dilutions. Positive and negative control wells were included in each assay plates 
to provide a measure of the maximum binding signal corresponding to the fully bound 
complex (Abound) in absence of competitor and the minimum signal corresponding to free 
ligand in solution (Afree). Controls were used to normalize the competitor binding results 
and evaluate the quality of each assay. Competition binding results were fitted by 
numerical nonlinear regression software DYNAFIT 4 (BioKin Ltd., Watertown, MA) 
following a competitive binding model (Scheme 1): 
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By using this model, the FITC-labeled probe peptide concentration, KEAP1 
concentration and KD1 values were fixed, allowing the KD2 and molar response of the 
complex to be variable and obtained by fitting. The detailed fitting program has previously 
been reported.176 
 
2.2.5 Screening assay development 
Solvent tolerance test experiments were carried out by including various 
concentrations of DMSO to test the assay tolerance of this solvent. In brief, FITC-Nrf2 
peptide was kept at 5 nM and KEAP1 protein at 10 nM, respectively, in the same assay 
buffer conditions and varying concentration of DMSO, ranging from 2% to 10% (v/v) in 
2% increments. The DMSO tolerance test was performed for both 200 µL and 100 µL 
assay formats (see below). 
The initial screening assay was carried out in 200 µL format. Due to the limited 
supply of materials, especially the Asinex macrocycles, the assay was optimized by 
reducing the assay volume to 100 µL. In brief, all of the assay components were added in 
the same fashion, except for using a volume of 25 µL to give a final assay volume of 100 
µL without changing the final concentration or relative ratio of each component. Both cv% 
and Z’ scores were evaluated in this case.177 
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2.2.6 Macrocycle screening 
A subset of macrocycle compounds were selected from the Asinex’s (Winston-
Salem, NC) collection of 12,000 MCs using the criteria as follows: TPSA ≥ 0.2 × MW 
(solubility filter)178 and ring size ≥ 14 atoms (Prof. Adrian Whitty and Dr. Lauren Brown 
at the Center for Molecular Discovery at Boston University). Additional detailed analysis 
of the chemical structures was performed by Dr. Lauren Brown to select representative 
compounds that were structurally distinct, resulting in a collection of 800 macrocyclic 
compounds with statistics shown as below (calculated by Lauren Viarengo): 
 
Table 2.1 Statistics of macrocyclic compounds in the collection 
 Average Range 
Molecular weight (Da.) 573 350 – 822 
Hydrogen bond donors (HBD) 3.3 0 – 6 
Hydrogen bond acceptors (HBA) 6.8 4 – 11 
Topological surface area (TPSA, Å2) 136 80 – 222 
Ring size 16 14 – 23 
No. of Chiral center 2.2 0 – 6 
 
The selected 800 macrocycle compounds were supplied by Asinex (Winston-
Salem, NC) in dry powder format, 0.1 µmol per compound. For the screening of Asinex 
macrocycle library using FA competition assays, the compounds were prepared by the 
Center for Molecular Discovery (CMD) at Boston University in the format described 
below: 0.1 µmol of each compound in dry powder form was resuspended in 100 µL of 
DMSO to give a concentration of 1 mM in the original storage tubes. The compounds were 
then aliquoted and diluted from the original stock (1 mM in DMSO) to give a concentration 
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of 0.3 mM in 100 µL DMSO in a 96-well format (template plate). This stock of compounds 
at 0.3 mM was used as the template plate, and 10 µL of each compound was aliquoted into 
the assay plates. Prior to the assay, 15 µL of H2O and 25 µL of 4× assay buffer (final 
concentration 50 mM HEPES, 150 mM NaCl, 0.01% v/v Triton, 1 mM DTT, pH 7.4) was 
added into each well, the compounds were suspended and mixed well, then spun down at 
300×g at 25 ̊C for 1 min.  
Initial screening of the macrocycles against KEAP1/Nrf2 was carried out by adding 
25 µL of 40 nM KEAP1 and 25 µL of 20 nM FITC-labeled Nrf2 tracer probe in the 
prepared compounds, providing a final concentration of 30 µM in 10% DMSO in presence 
of 10 nM KEAP1 and 5 nM FITC-labeled Nrf2 peptide. The assay mixture was incubated 
at 25 ̊C for 30 min to reach equilibrium, prior to fluorescence anisotropy reading. A full 
spectrum from 350 nm to 750 nm of absorbance was taken under assay conditions in clear 
flat-bottom 96-well assay plates, to identify insoluble compounds that could potentially 
inhibit the interaction through a non-specific mechanism, such as aggregating on KEAP1. 
Meanwhile, compounds with fluorescence interference to the assay were ruled out by 
elevated raw fluorescence emission signal at 520 nm. Hits from the first round of screening 
were further verified in dose-response assays, starting from 100 µM with 10% DMSO in 
the assay, using the same competition assay set-up as described above. 
 
2.2.7 Cyclic peptide synthesis by rapid flow-based method 
 A flow-based solid phase peptide synthesis method was applied to prepare the 
linear Nrf2 peptide encompassing the DxETGE motif with two engineered cysteines that 
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were utilized for later peptide cyclization via intramolecular disulfide-bond linkage. Two 
cyclic peptides, a decamer peptide with two external engineered cysteines 
(CGDEETGEGC-NH2) and a nonamer peptide with two internal engineered cysteines 
(LCEECGEFL-NH2), were designed and synthesized. The peptides were prepared using a 
flow peptide reactor assembled in-house.179  
Peptide synthesis. Each peptide was synthesized at a scale using 200 mg of H-Rink 
Amide-ChemMatrix resin (Biostage, Charlotte, NC). Flow peptide reactor loaded with H-
Rink Amide-ChemMatrix resin was preheated in a 70 ̊C water bath for 20 min prior to 
coupling reactions. For the purpose of synthesizing a linear peptide that could be cyclized 
by disulfide bond later, a version of cysteine with side chain protected by Acetamidomethyl 
(Fmoc-Cys(Acm)) was used instead of triphenylmethyl protected cysteine (Fmoc-
Cys(Trt)). 1.1 mmol of each Fmoc-protected amino acids (Chem-Impex, Wood Dale, IL) 
was dissolved in 2.5 mL of DMF (N,N-Dimethylformamide, Fisher Scientific, Hampton, 
NH)) containing 0.4 M HATU (Oakwood chemical, Estill, SC) by mild sonication. Pre-
activation of the coupling mixture was performed by addition of DIEA (N,N-
Diisopropylethylamine, Fisher Scientific, Hampton, NH) at the amount of 1.72 mmol (300 
µL), except for His, Trp and Cys, where a lower dose of 1.2 mmol (210 µL) was used to 
prevent the racemization. The activated mixture was immediately pumped into the flow-
based peptide synthesis reactor using a syringe pump at a flow rate of 8 mL/min. Each 
coupling reaction was conducted using the following protocol at a flow rate of 20 mL/min: 
coupling of amino acid to the resin for 30 s, washing by DMF for 20 s, deprotecting N-
terminal Fmoc by 20% piperidine/DMF (v/v) for 20 s, followed by a washing step using 
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DMF for 1 min. A specific cycle of coupling one amino acid was approximately 3 min and 
the peptide was synthesized in the sequence from the C-terminal to the N-terminal. After 
synthesis completion, the resin was washed with DMF for another 2 min before being 
vacuum-dried overnight. 
Peptide deprotection. The peptide resin was side-chain deprotected and cleaved 
from the resin using TFA/H2O/TIS (94:2.5:2.5, 2h) with mild orbital shaking at room 
temperature. The side chain of Cys(Acm) was not deprotected during this step. Then 
peptides were then precipitated by adding 9 volumes of chilled diethyl ether, taken up in 
acetonitrile/H2O (50:50 v/v) and filtered using a Whatman 100K syringe filter 
(Buckinghamshire, UK) to remove the resin. Crude peptides were analyzed by mass 
spectrometry to confirm identity and successful synthesis, followed by lyophilization and 
storage at -20 ̊C for long-term use. 
Peptide cyclization. Crude peptides were resolubilized in 95% acetic acid/H2O 
(v/v) to a final concentration of 0.1 mM, followed by slow addition of an iodine solution 
(0.4 M) dissolved in glacial acetic acid (50-fold excess, final concentration 5 mM) and 60 
mM HCl (final concentration 3 mM). The mixture was then agitated vigorously at room 
temperature for 2.5 hrs, and the completion of the reaction was monitored by mass 
spectrometry. The iodine oxidation was then quenched by the addition of 9 volumes of 
chilled diethyl ether, which simultaneously precipitated the peptides. The precipitated 
peptides were then purged dry by N2 flow to remove the remaining acetic acid, and 
resolubilized in acetonitrile/H2O. The final oxidation products were verified by mass 
spectrometry to confirm successful cyclization by intact mass. 
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Peptide purification. Peptides were purified by preparative HPLC on a C18 column 
(20g, Interchim, San Diego, CA) in an Interchim HPLC system (San Diego, CA). Solvents 
A and B were 0.1% (v/v) TFA in H2O and acetonitrile, respectively. A linear gradient of 
A from 90% (10% B, v/v) to 0% (100% B, v/v) over 15 min at a 5 mL/min flow rate was 
used for elution, with UV detection at a range of 210 – 280 nm. Fractions were collected 
and confirmed by mass spectrometry (Waters qTOF Premier LCMS, Milford, MA) to 
identify the ones that contained the desired materials. Fractions corresponding to the cyclic 
peptides were pooled and the solvents evaporated using an EZ-2 Genevac centrifugal 
evaporator prior to lyophilization. Purified and lyophilized cyclic peptides were labeled 
and stored at -20 ̊C for long-term use. Peptide quantification was done by two means (i) 
using the mass of the dry power and volume of the solvent to calculate the concentration 
in mols; (ii) using the absorbance of the peptide bonds at 205 nm on an NanoDrop 
instrument (extinction coefficient ε = 31 mg/mL).180 Concentrations evaluated by two 
methods usually deviated by less than 10%, and an average value was used for future 
reference. 
 
2.2.8 Cyclic peptide characterization by mass spectrometry under reducing conditions 
 Purified cyclic peptides were resolubilized in H2O to give a concentration of 1 mM. 
To verify that the disulfide-linked cyclic peptide was resistant to reducing conditions in the 
assay (1 mM DTT), 100 µM of purified cyclic peptides in H2O were incubated with various 
concentrations of DTT (0, 1 and 10 mM) at ambient temperature overnight before 
verification by mass spectrometry (Waters qTOF Premier LCMS, Milford, MA). Peptide 
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samples were loaded onto a reverse-phase Atlantis dC18 HPLC column (100 Å, 3 µM, 
2.1× 30 mm, Waters, Milford, MA) using a binary solvent system of H2O/acetonitrile with 
0.1% formic acid, within a gradient of 90% H2O to 10% H2O, before being directed into 
mass spectrometry (Waters qTOF Premier LCMS, Milford, MA). Data were acquired by 
use of MassLynx Mass Spectrometry Software (Waters, Milford, MA). 
 
2.2.9 Evaluation of cyclic peptides in FA competition assay 
 Evaluation of the inhibitory activity of designed cyclic peptides against 
KEAP1/Nrf2 was carried out using the same competition assay set-up as described above, 
starting from 20 µM of cyclic peptide with a serial dilution of 2-fold. Control experiments 
with reduced linear peptides were included for direct comparison. The intact mass of all of 
the peptides, including cyclic and linear, was verified by ESI-qTOF mass spectrometry 
after incubation in assay buffer containing 1 mM DTT at 25 ̊C for 30 min. 
 
2.2.10 Fragment screen using FA assay and ThermoFluor assay 
For the fragment screen, we utilized a commercially available fragment library 
purchased from Zenobia (389) and a small collection of fragment-sized compounds (69) 
provided by the Boston University Center for Molecular Discovery (CMD). The 69 
fragment-sized compounds provided by the BU CMD have molecular weights ranging 
from 170 Da. to 420 Da. Because the Zenobia fragment library was designed for 
developing a therapeutic for central nervous system (CNS) diseases, the criteria for 
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compound selection were modified to allow for the lower average molecular weights 
observed for CNS drugs.141 Detailed criteria shown as below: 
 
Table 2.2 Criteria for the Zenobia library design 
Molecular weight (Da.) Avg ~155; upper limit 225 
cLogP 1-3 
Hydrogen bond donors (HBD) ≤ 3 
Hydrogen bond acceptors (HBA) ≤ 3 
Polar surface area (PSA) < 60 Å 
Aromatic features 
Primarily single ring aromatic; 
Includes fused ring; 
Some saturated or linked aromatic 
 
For the screening of the Zenobia fragment library using FA competition assays, the 
compounds were prepared by diluting from the original stock (200 mM in DMSO) to give 
a concentration of 20 mM in 40% v/v DMSO/water. Screening of the fragments against 
KEAP1/Nrf2 was carried out by holding the KEAP1 at 10 nM and FITC-labeled Nrf2 
tracer probe at 5 nM in the assay buffer. The prepared compounds were then added into 
the assays, providing a final concentration of 5 mM in 10% DMSO for the initial single 
dose screening. The assay mixture was incubated at 25 ̊C for 30 min to reach equilibrium, 
prior to fluorescence anisotropy reading. Compounds with fluorescence interference to the 
assay were ruled out by an observed elevated raw fluorescence emission signal at 520 nm. 
A full absorbance spectrum from 280 nm to 750 nm was taken under assay conditions, to 
identify insoluble compounds that could potentially inhibit the interaction through a non-
specific mechanism, such as aggregating on KEAP1. Screening of the BU CMD fragment 
collection of 69 compounds was carried out using the same protocol described above, 
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except that the compounds were at a concentration of 4 mM in 10% DMSO in the initial 
screening. Hits from the first round of screening were further verified in dose-response 
assays, starting from 10 mM with 10% DMSO in the assay, using the same competition 
assay set-up as described above. 
Screening of the Zenobia fragment library using ThermoFluor assays was 
conducted in parallel by Dr. Andrew Lynch in Prof. Karen Allen’s lab at Boston University 
as an alternative tool to discover fragment hits that regulate Nrf2 binding by directly 
interacting with KEAP1 protein.139 ThermoFluor experiments were performed using a 
Realplex EP Mastercycler RT PCR instrument (Eppendorf, Hauppauge, NY) in a 96-well 
PCR plate format.  A total assay volume of 20 µL contained 10 µM of KEAP1, Sypro 
Orange dye (5X, Thermo Fisher Scientific) and 10 mM Zenobia compounds in KEAP1 
storage buffer (25 mM Tris, 2.5 mM DTT, pH 8.0). The plate was then sealed with clear 
seal film to prevent evaporation. Results were collected by monitoring the fluorescence at 
520 nm as the temperature ramped up at a rate of 1 ̊C/min. The Tm values were derived 
from the first derivative of the melting curve using Realplex software version 2.2. An 
elevated melting temperature (Tm) indicated a stabilization effect, and the corresponding 
compound was considered as a hit. The top hits with ≥ 2 ̊C stabilization effect were 
followed up with efforts in FA dose-response assays and soaking experiments. 
Three of the top fragment hits that were discovered by both FA-based and 
ThermoFluor-based screens were successfully soaked with KEAP1 protein and the 
complex structures resolved via X-ray crystallography by Dr. Andrew Lynch.139 
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2.2.11 Fragment screen using tethering 
 The tethering facilitated fragment screen against KEAP1/Nrf2 was conducted in 
collaboration with Prof. Michelle Arkin’s lab at the University of California San Francisco 
(UCSF).142,156,160. This collection of compounds, named monophores, were designed for 
tethering screening by the Small Molecule Discovery Center (SMDC) at UCSF, each 
comprising three functional components: a fragment-sized moiety for non-covalent 
recognition of the target (molecular weight ranging from 200 to 400 Da.), a flexible linker, 
and a thiol electrophile capped by the dimethyl cysteamine through a disulfide linkage. The 
fragment-sized moiety of each compound generally complies with the “rule of three” for 
fragments, that is: MW ≤ 300 Da., cLogP ≤ 3, HBD ≤ 3, HBA ≤ 3, NrotB ≤ 3, PSA ≤ 60 
Å2.160,181 The initial single concentration screening was carried out using 1280 monophore 
compounds. 
General protocols of mass spectrometry-based screening were initially developed 
by the Arkin lab,156,160 and adapted and modified for the case of KEAP1, shown as follows: 
 A KEAP1 variant, C434A, as a negative control for tethering screening was 
designed and generated by following a 2-round PCR procedure to improve the success in 
codon change using the wild-type KEAP1 Kelch repeat domain (312-624) construct as the 
template; primers used for this site-directed mutagenesis can be found in Appendix I. A 
detailed protocol is described in Chapter 4 (4.2.1), wherein all the other KEAP1 variants 
were generated. This variant was expressed, purified and characterized using the standard 
protocol (2.2.2). It was validated that substitution of this solvent-exposed cysteine residue 
near the active site does not affect the binding property. Wild-type KEAP1 and the negative 
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control variant C434A were prepared using the protocol described above. Prior to 
screening, proteins were desalted into tethering screening buffer (100 mM NH4Ac, pH 8.3) 
using Zeba™ Spin Desalting Columns (7K MWCO, 0.5 mL, Thermo Fisher Scientific, 
Waltham, MA) following the manufacturer’s protocol. Initial screening was carried out by 
incubating 250 nM of wild-type KEAP1 with 250 µM β-mercaptoethanol (βME) and 100 
µM monophore compounds in 100 mM NH4Ac, pH 8.3 for 1 h at room temperature prior 
to detection by mass spectrometry. Negative controls using the C434A variant were carried 
out in parallel. The extent of covalent modification was assessed by electrospray mass 
spectrometry using Waters Xeno LC/ESI-MS. By setting a threshold of 70% modification, 
we achieved a hit rate of 3.4%, namely 43 hits for follow-up dose-response experiments. 
The DR50 values of the monophore compounds were determined by titrating 
compounds from 500 µM by a 3-fold dilution at a constant concentration of βME (250 
µM). The DR50 was reported as the concentration at which 50% of the protein was 
covalently modified by the compound, as observed by protein mass spectrometry. 
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2.3 Results 
2.3.1 Protein design, expression, purification and characterization 
We generated a recombinant construct of KEAP1 residues 312-624, encompassing 
the entire Kelch repeat domain that interacts with Nrf2 (Figure 2.2 A).136,137 We also cloned 
and expressed two Nrf2 Neh2 domain constructs. The longer of these, Nrf21-100, 
encompasses both the high affinity DxETGE KEAP1-binding motif and the low affinity 
DLG motif regions,127,137 while the shorter construct, Nrf234-100, lacks the DLG motif 
(Figure 2.2 B). All three constructs were subcloned into a pET15b vector, which appends 
an N-terminal His6 tag followed by a tobacco etch virus (TEV) protease cleavage site. 
Constructs were expressed in E. coli and purified by Ni-NTA affinity chromatography. 
After treatment with TEV protease, the proteins were again passed over a Ni-NTA affinity 
column to remove the cleaved His6 tag, and followed by gel filtration as a final purification 
step to remove any protein aggregates. 
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Figure 2.2 Schemes showing the domain architectures of (A) KEAP1 and (B) Nrf2, with the fusion constructs 
of each that were used in this study. The locations of the DLG and DxETGE motifs of Nrf2 are indicated. 
 
The proteins were characterized by SDS-PAGE, MALDI-MS, circular dichroism 
(CD) spectrometry, and thermal denaturation, as described in Materials and Methods, to 
establish their identity, purity, homogeneity, and structural integrity. The secondary 
structure content of the wild-type KEAP1 was determined by CDSSTR analysis method 
provided by the Dichroweb website.174 The results indicate that the Kelch repeat domain 
of KEAP1 is comprised of 46% β-strand, 50% disordered/turn and 4% helical structure in 
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25 mM Tris buffer with 2.5 mM DTT at pH 8.0. Thermal denaturation analysis of 
KEAP1312-624 showed this construct had a stable tertiary structure as expected (Figure 2.3). 
In thermal denaturation monitored by both ThermoFluor and CD, KEAP1 presented a 
cooperative melting transition, giving very similar Tm values. 
 
 
Figure 2.3 Characterization of KEAP1312-624 construct. (A) SDS-PAGE analysis of the KEAP1312-624 construct 
used in the study. Shown is a representation of the purity of the KEAP1312-624 construct achieved using the 
expression and purification conditions described in the text. Samples were run under reducing and denaturing 
conditions. (B) Thermal denaturation curve of KEAP1312-624 construct using ThermoFluor assay, monitored 
by the change in fluorescence signal at 480 nm of the Sypro Orange dye. Data are representative of three 
independent experiments. The Tm value for the KEAP1312-624 construct is 49.5 ± 2.6 ̊C. (C) Circular Dichroism 
spectra of KEAP1312-624 in 25 mM Tris, pH 8.0 revealed a β-sheet secondary structure content. The method 
CDSSTR provided by the DichroWeb was used to deconvolute the CD spectrum using reference dataset 
SP175.174 (D) Thermal denaturation data of KEAP1312-624 using CD, monitored by the change in θ203. Data 
are representative of two independent experiments. The Tm value for the KEAP1312-624 construct determined 
in CD is 44.2 ̊C. The thermal denaturation process is irreversible. 
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However, Nrf21-100 and Nrf234-100 showed no cooperative melting transition, and 
the CD spectra of these constructs indicated structures that were largely random coil 
(Figure 2.4), consistent with the notion that the Neh2 domain of Nrf2 is intrinsically 
disordered.127,182,183 
 
Figure 2.4 Characterization of Nrf234-100 construct. (A) SDS-PAGE analysis of the Nrf234-100 constructs used 
in the study. Shown is a representation of the purity of the Nrf234-100 wild-type and variant proteins produced 
using expression and purification conditions described in the text. Samples were run under reducing and 
denaturing conditions. (B) Circular dichroism spectrum of Nrf234-100 in 20mM phosphate, 200mM NaCl, pH 
7.4, shown in blue. Thermal denaturation was performed by ramping the temperature from 10 ̊C to 90 ̊C by 
1 ̊C/min, shown in blue. After 30 min of stabilizing at 90 ̊C, a full spectrum was taken, shown in red. The 
temperature was then ramped down to 10 ̊C by 1 ̊C/min, the full CD spectrum of refolded protein is shown 
in green. The thermal denaturation process is reversible. (C) Thermal denaturation data of Nrf234-100 using 
CD, monitored by the change in θ208. Data are representative of two independent experiments. No cooperative 
denaturation was observed. 
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2.3.2 KEAP1 binding to Nrf2 constructs 
The binding activities of the recombinant proteins were characterized using a 
fluorescence anisotropy (FA) competition binding assay. For the tracer probe, we used a 
fluorescein isothiocyanate (FITC) labeled 9-mer synthetic peptide, LDEETGEFL, derived 
from Nrf2 residues 76-84 which encompass the DxETGE binding motif.170,184,185 Titration 
of recombinant KEAP1312-624 against a fixed concentration of the FITC-Nrf2 peptide gave 
a dose-dependent increase in anisotropy (Figure 2.5 A), consistent with KEAP1 binding to 
FITC-Nrf2 and restricting its tumbling rate in solution.176,186 Fitting the data from this 
experiment to a quadratic binding equation, as described in Materials and Methods, showed 
that KEAP1312-624 binds FITC-Nrf2 with a KD = 11 ± 1 nM (n = 5), consistent with 
previously reported values for Nrf2 peptides binding to KEAP1.127,137,170,184 Incubation of 
unlabeled synthetic Nrf276-84 peptide, at various concentrations, with fixed, subsaturating 
concentrations of KEAP1 (10 nM) and FITC-Nrf2 (5 nM) gave a dose-dependent inhibition 
of the anisotropy signal (Figure 2.5 B). The binding affinity of this unlabeled Nrf2 peptide 
was quantified by fitting the inhibition data to a competitive equilibrium binding model 
using the curve fitting software DYNAFIT,176 as described in Materials and Methods. This 
approach to data analysis was required because under our experimental conditions, all three 
binding components are present at concentrations close to their KD values. Consequently, 
the approximation that total concentration ≈ free concentration is not valid for any binding 
component, and therefore accurate KD values cannot be determined from IC50 values from 
simply applying a Cheng-Prusoff correction factor.176,187 Analyzing the binding data as 
described gave a KD = 13 ± 2 nM (n = 3) for the unlabeled 9-mer Nrf2 peptide. The 
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similarity in KD values measured for the FITC-labeled and unlabeled 9-mer peptides 
showed that addition of the fluorescein label did not greatly affect binding affinity. 
 
Figure 2.5 Binding curves of KEAP1 to Nrf2 constructs. (A) Binding of 5 nM FITC-Nrf276-84 to various 
concentrations of KEAP1312-624 measured by fluorescence anisotropy. The solid line shows the best fit of the 
data to a quadratic binding equation. (B) Inhibition of the interaction of FITC-Nrf276-84 (5 nM) to KEAP1312-
624 (10 nM) by unlabeled Nrf276-84. The solid line is the best fit of the data to an inhibition binding model, 
using DYNAFIT 4. (C) Nrf21-100 encompassing both the DLG and the DxETGE motifs (red) was evaluated 
in the FA competition assay in parallel with Nrf234-100 (blue) that only contains the DxETGE sequence. 
Anisotropy values were normalized to reflect the fractional changes between maximum and minimum 
anisotropy signal. Data were fitted to a competitive equilibrium binding model using DYNAFIT 4 software, 
shown in solid lines. Error bars show the range of duplicate experiments. Results shown represent at least 
four independent experiments. 
 
To validate the binding activity of the recombinant Nrf2 constructs, unlabeled 
Nrf21-100 and Nrf234-100, were tested as inhibitors in the FA assay (Figure 2.5 C). Analyzing 
the inhibition data as described above gave affinity values of KD = 10 ± 2 nM (n = 4) for 
Nrf234-100, and KD = 10 ± 1 nM (n = 3) for Nrf21-100. The similar KD values observed for the 
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two recombinant Nrf2 constructs, as compared to the 9-mer peptide, suggest that the 9-mer 
comprises the entirety of the high affinity KEAP1 binding motif. Moreover, the 
insensitivity of binding affinity to the presence or absence of the portion of Nrf2 containing 
the DLG motif indicates that, for the longer construct in which both binding motifs are 
present, binding to KEAP1 is primarily through DxETGE, as expected given its higher 
affinity for KEAP1.126,127 
 
2.3.3 Screening assay development 
The KEAP1/Nrf2 FA competition binding assay was employed and optimized to 
suit the needs of compound screening. A competent screening assay needs to be robust, 
sensitive, and if possible, in a high or moderate throughput format. 
  The accuracy and precision of the assay are closely related to its robustness. The 
assay robustness can be measured and reported by the coefficient of variation (% cv) and 
the Z’ score. Calculations as below: 
 %	𝑐𝑣 = 	100 𝜎𝑥  𝑍P = 	1 −	 3𝜎R + 3𝜎;𝑥R +	𝑥;  
 
Shown above, 𝑥R and  𝑥; are the average assay signals measured for positive and 
negative control samples, respectively. 𝜎R  and 𝜎;  represent the corresponding standard 
deviation. Usually, a %cv value below 10% suggests a good signal precision. The Z’ score 
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is another widely used measure of assay quality, representing the error distribution around 
the positive and negative control signals, and whether or not this range (assay window) 
allows the experimental signals to be statistically distinct from each other. In general, a Z’ 
score is in a scale of 0 to 1; a value above 0.5 corresponds to a robust assay with good 
precision and quality.177 
 Another challenge in practice that we encountered came from the limited amount 
of each macrocyclic compound provided for screening. Therefore, efforts were made to 
reduce the assay volume to 100 µL in order to use less compound. The list of assay statistics 
of the KEAP1/Nrf2 FA assay is shown in Table 2.3.  
 
Table 2.3 Assay statistics of the KEAP1 FA assays 
 
Positive control 
Protein + tracer peptide 
Negative control 
Tracer peptide alone 
 
Anisotropy Average 
Standard 
Deviation 
%cv Average 
Standard 
Deviation 
%cv 
Z’ 
score 
200 µL 118.2 3.1 2.5% 50.7 3.1 6.0% 0.8 
200 µL 
with 10% 
DMSO 
91.9 3.3 3.6% 58.1 3.3 5.7% 0.7 
100 µL 107.5 3.7 3.4% 54.4 3.5 6.4% 0.6 
100 µL 
with 10% 
DMSO 
93.7 3.4 3.6% 62.5 3.3 5.3% 0.4 
1. The coefficient of variation and Z’ score were calculated for the KEAP1 FA assay at 100 µL and 200 µL. 
The 200 µL FA assay had a greater Z’ score than the 100 µL assay, suggesting that well-to-well variation is 
low. Inclusion of the 10% DMSO reduces the assay quality by lowering the maximal signal and elevating 
the minimal signal, therefore narrowing the assay window. 
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It can be concluded from the table that, both assays at 200 µL and 100 µL present 
sufficient robustness, with the Z’ score being 0.8 and 0.6, respectively. However, the assays 
were susceptible to the presence of 10% v/v DMSO, which is reflected by a reduced Z’ 
score in both scenario. Since any compounds tested in the assays will require a certain 
amount of DMSO to remain soluble at the high concentrations, especially macrocyclic 
compounds above 500 Da, we measured the assay signal at various DMSO concentrations 
to investigate its effect on assay robustness (Figure 2.6). The results showed that a 
sufficient assay window can be maintained with up to 10% DMSO before the anisotropy 
signals are compromised.  
 
 
Figure 2.6 Tolerance of the KEAP1 FA assay to DMSO. DMSO was titrated in the KEAP1/Nrf2 FA 
inhibition assay to measure the point at which the signals degrade due to interference from the solvent. The 
maximal signal in the 200 µL assay (blue circle), minimal signal in the 200 µL assay (red square), maximal 
signal in the 100 µL assay (green triangle), and minimal signal in the 100 µL assay (purple triangle) are 
shown. Error bars indicate the range of 96 measurements in each case. 
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Figure 2.6 illustrates how increased DMSO concentration interfered with the 
maximal and minimal assay signals, and eventually narrowed the assay window. DMSO 
appeared to have two opposite effects on the maximal and minimal assay signal. The 
minimal signal measured from the unbound FITC-Nrf2 tracer probe in solution, increased 
at high DMSO concentrations, suggesting the increased viscosity slows down the tumbling 
rate of the fluorescein-labeled probe and increases the anisotropy. The maximal signal, 
measured from the KEAP1 in complex with FITC-Nrf2 peptide, decreased at high DMSO 
concentrations. This can potentially be explained by disruption of binding or denaturation 
of the protein at high DMSO concentrations. 
On the basis of these results, I chose to continue the fragment screening in a 200 
µL assay format with inclusion of 10% v/v DMSO, and the macrocyclic compound 
screening in a 100 µL assay format with 10% v/v DMSO. Although the later assay did not 
exhibit an ideal robustness (Z’ = 0.4), considering the potential solubility issues and the 
limited amount of the macrocyclic compounds, we compromised the assay quality in order 
to include higher concentrations of macrocyclic compounds in the screening. Potential 
false positives from the FA assays were examined using other methods, including solubility 
screening, ThermoFluor assays and dose-response validation in the binding assay.  
 
2.3.4 Macrocyclic compound screening and validation 
 A set of 800 macrocyclic compounds provided by Asinex (Winston-Salem, NC) 
was initially screened against KEAP1/Nrf2 in the FA assay at a single concentration of 30 
µM, followed by UV-Vis screen ranging from 280 to 750 nm. Detailed description of the 
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selection criteria of this MC collection can be found in Material and Methods. Any 
compounds giving an absorbance greater than 0.05 at 700 nm (through light scattering by 
insoluble aggregates) were identified as not fully soluble under these conditions, and were 
not considered in any further validation steps. The data from the initial screening of 800 
macrocycles are shown in Figure 2.7. Only seven macrocyclic compounds showed weak 
inhibitory activity (< 30%) at 30 µM with satisfying solubility, and were further 
characterized in a dose-response experiment. The compounds’ ID numbers are shown in 
the figure below. 
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Figure 2.7 Initial screen and dose-response validation of macrocyclic compounds. (A) Initial screen of 800 
macrocycles at 30 µM in the KEAP1 FA assay. The percent binding activity of the complex in the presence 
of 30 µM compound was plotted against the absorbance at 700 nm of the compounds. The threshold for 
classification as a hit was set at < 80% binding activity. The cutoff for indication of poor solubility was set 
as Abs700 = 0.05. The square with a green dashed line defines the region where the hit compounds are located. 
Seven compounds that satisfied both criteria were included in the dose-response validation. (B) Dose-
response validation of 7 hits from the initial screen. The dashed line shows the signal of the positive control 𝑥 ̅± 3σ. No inhibitory activity was observed. Error bars show the range of duplicate measurements. 
 
While the hit rate of 0.9% from the initial screening of 800 macrocycles was 
relatively high, further investigations revealed this to likely be an artefact. All seven 
compounds from the primary screen exhibit very weak inhibition, with the best inhibitory 
activity at 30 µM being less than 30% (BDH 33730635). Unfortunately, no dose-response 
inhibition was observed among the seven compounds, even with the macrocycles at a high 
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concentration of 100 µM. Thus, the weak inhibition (< 30%) observed in the initial screen 
was likely an artefact due to the compromised assay robustness. 
 
2.3.5 Designed cyclic peptides as KEAP1/Nrf2 inhibitors 
In addition to attempts to explore macrocycles as inhibitors of KEAP1/Nrf2, two 
synthetic cyclic peptides mimicking the Nrf2 DxETGE peptide were designed and tested. 
By introducing two cysteine residues flanking the DxETGE motif, the peptide can be 
cyclized via formation of an intramolecular disulfide bond. The rationale of this design was 
based on the fact that Nrf276-84 presents a β-hairpin loop conformation in complex with 
KEAP1, orienting several main chain carboxyl groups towards the main chain amides, 
shown as the dashed yellow lines in Figure 2.8. This compact loop conformation allows 
multiple main chain and side chain nitrogen and oxygen atoms to be within hydrogen bond-
forming distance (< 3.2 Å). Thus, the design introducing two external cysteine residues 
was based on the assumption that the intramolecular disulfide bond can mimic the 
intramolecular hydrogen bond in the native peptide and promote binding affinity by pre-
organizing and stabilizing the favored loop structure. Successful substitution of the 
hydrogen bonds with a covalent bond to maintain the preferred loop conformation for 
binding will be beneficial for the further non-peptidic macrocyclic inhibitor design of 
KEAP1. 
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Figure 2.8 Structures of a 16-mer Nrf2 peptide in the bound 
conformation (PDB 4IFL). The peptide chain is shown in green 
sticks. Dashed yellow lines shows the possible hydrogen bonds 
between main chain atoms in the bound conformation. 
 
When the wild-type peptide is in the bound 
conformation, the main chain amide NH of Q75 and 
main chain carbonyl of L84 are in close proximity 
with a distance of 2.7 Å, likely forming a main chain 
hydrogen bond (shown in Figure 2.8). Hence, in this 
conformation, the distance between the carbon atom 
of the carbonyl on L84 and the nitrogen atom of the 
main chain amide on Q75 is 5.3 Å. Peptide 1 was designed by introducing one cysteine 
residue at each end of the DEETGE sequence, with additional Gly residues serving as a 
flexible linker (CGDEETGEGC). This allows the peptide to cyclize via an external 
disulfide mimicking the main chain hydrogen bond between Q75 and L84, while keeping 
the entire DxETGE consensus motif intact and not disturbed. Formation of the side chain 
disulfide bond would lead to a distance of ~6 Å between the Cβ atoms of the two cysteines, 
similar to that in the native conformation (5 Å, vide supra). Peptide 2 was designed by 
replacing D77 and T80 on Nrf2 with cysteine residues (LCEECGEFL), mimicking the 
intramolecular hydrogen bonds between the side chain oxygen atoms of D77 and T80 with 
the nitrogen atoms of the main chain amides (2.9 Å and 3.2 Å, respectively). Replacing 
those two residues with cysteines allows the pre-formation of this intramolecular linkage, 
hence stabilizing the loop conformation prior to binding to KEAP1. 
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Both peptides were synthesized using the flow-based solid phase peptide synthesis 
method, followed by I2 oxidation in solution to form the intramolecular disulfide bond. 
Cyclized peptides were purified using a C18 reverse phase column on HPLC and 
characterized by ESI-qTOF mass spectrometry to confirm successful synthesis and 
cyclization (Figure 2.9 A and B).  
 
Figure 2.9 Cyclic peptide characterization by mass spectrometry. Mass spectra of (A) cyclized peptide 1 and 
(B) cyclized peptide 2. Theoretical monoisotopic mass values are shown below the spectra. (C) DTT 
tolerance experiments of cyclic peptide 1 incubated at 25 C̊ overnight in the presence of 0 mM, 1mM and 20 
mM DTT. The intramolecular disulfide bond is resistant to 1mM DTT and fully reduced in the presence of 
20 mM DTT. 
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Due to the redox-sensitive nature of the disulfide bond, both cyclic peptides were 
tested in a DTT-tolerance experiment to determine if they could remain in the monomeric 
cyclic form under the reducing assay conditions. Both peptides were resistant to 1 mM 
DTT at 25 ̊C even after overnight incubation, only fully reduced to the linear form in the 
presence of 20 mM DTT (Figure 2.9 C). 
Cyclic peptides were evaluated in the FA competition binding assay. Figure 2.10 A 
shows the results of cyclic peptide 1 binding to KEAP1. A linear version of this peptide 
was included as a control. Surprisingly, this cyclic peptide (peptide 1, CGDEETGEGC) 
exhibited a much weaker binding affinity to KEAP1 in comparison to the wild-type Nrf2 
peptide (KDpeptide 1/KDWT = 66) even though it encompassed the entire consensus sequence 
for KEAP1 binding (DxETGE). However, it was still a better binder to KEAP1 compared 
to its linear form, supported by the more than 2-fold increase in binding affinity by 
cyclization. Both cyclic and linear peptides were validated by mass spectrometry before 
and after the assay to confirm no disulfide bond exchange occurred under the assay 
conditions (Figure 2.10 B). The results support our hypothesis that cyclization of the Nrf2-
derived peptide promotes binding to KEAP1 even though the cyclic peptide does not bind 
as potently as wild-type Nrf2. The second cyclic peptide (peptide 2, LCEECGEFL) showed 
much weaker binding to KEAP1, with an IC50 around 4 µM, therefore it was not pursued 
in the future characterization. 
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Figure 2.10 Binding curves of cyclic and linear peptide 1 to KEAP1. (A) Inhibition of the interaction of 
FITC-Nrf276-84 (5 nM) to KEAP1312-624 (10 nM) by unlabeled cyclic peptide 1 (green) and a acyclic control 
(purple). The solid line is the best fit of the data to an inhibition binding model, using DYNAFIT 4. Results 
represent three independent experiments. (B) Mass spectra of the cyclic peptide and linear peptide under the 
assay condition. Error bars show the range of duplicate measurements. Results shown in each case are 
representative of three independent experiments. 
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2.3.6 Fragment-based screening against KEAP1/Nrf2 and further validation by dose-
response assay and soaking experiments 
In a separate endeavor to discover inhibitors of KEAP1/Nrf2, and also as an 
alternative means to probe of the locations of binding energy hot spots at the Nrf2 binding 
site on KEAP1 (Chapter 3), we screened a library of 458 fragment-sized compounds 
against our KEAP1 construct,143,145-148 389 of which were obtained commercially and the 
remaining 69 derived from our internal BU-CMD compound collection. To identify 
fragment binders, we employed two orthogonal screening assays in parallel – a 
ThermoFluor assay (by Dr. Andrew Lynch, Allen lab) that measures the ability of small 
molecule binders to stabilize the protein target, indicated by elevated melting temperatures 
(Tm),188-191 and the FA competition assay described above. For the ThermoFluor screen, 
fragments were tested individually at a single concentration of 10 mM. Fifty fragments 
were found to increase the melting temperature of KEAP1, with 6 increasing Tm by ≥ 3 °C 
and a further 7 fragments causing a 2-3 °C increase (Appendix V).139 Compared to the 
ThermoFluor method, the FA assay is more sensitive to artefacts resulting from poor 
compound solubility.192,193 Screening the fragment collection in the FA assay was therefore 
done at a slightly lower compound concentration of 5 mM in a buffer containing 10 % v/v 
DMSO (as described in the 2.3.3). Compounds that were not fully soluble under these 
conditions, defined as those giving an absorbance (through light scattering by insoluble 
aggregates) of > 0.1 at 700 nm, were not considered further. The FA screen identified 38 
hits (Appendix V), 8 of which were also among the hits found in the ThermoFluor assay 
(Figure 2.11 A). Attempts to demonstrate dose-dependent inhibition for these fragment 
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hits, using the FA inhibition assay were largely unsuccessful. In most of the cases, the 
limited solubility or interference with the fluorescence signal of the compounds prevented 
us from testing them at sufficiently high concentrations to define an inhibition curve. 
However, the chromone hit 4-oxo-4H-1-benzopyran-2-carboxylic acid (ZT0256) showed 
a dose-dependent inhibition, and analysis of the inhibition data using the equilibrium 
binding model described above gave a binding affinity for KEAP1 of KD ~ 1.4 mM (Figure 
2.11 B). 
 
 
Figure 2.11 Hits from fragment screening. (A) Structures of the eight fragment hits that showed activity in 
both the ThermoFluor and FA screening assays. (B) Fragment, ZT0256 gave dose-dependent inhibition of 
KEAP1/Nrf2 binding in the FA competition assay. The IC50 was ~4.3 mM, and analysis of the data using the 
competition binding model gave a binding affinity for KEAP1 of KD = 1.4 mM. Error bars show the range of 
duplicate measurements. Results shown in each case are representative of two independent experiments. 
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In collaboration with Dr. Andrew Lynch in Prof. Karen Allen’s lab, the detailed 
binding modes of the confirmed fragment hits were characterized using X-ray 
crystallography by soaking the crystals of our KEAP1 protein construct with solutions of 
the fragments.139  
Soaking was attempted with 13 fragments, resulting in three solved complex 
structures. All three of these fragments bound at the same region of the active site of 
KEAP1 (Figure 2.12 B). The first fragment hit, the Chromone derivative ZT0256, forms 
electrostatic interactions with the guanidine group of R415 and R483, and hydrogen bonds 
with S508 via its carboxyl group. The chromone carbonyl group makes a hydrogen bonding 
interaction with the side chain of S555, and the aromatic moiety of ZT0256 engages in p-
stacking with the side chain of Y525 (Figure 2.12 C). A second fragment hit, 4-amino-1,7-
dihydro-6H-pyrazolo[3,4-d]pyrimidine-6-thione (ZT0017), also hydrogen bonds with 
S555 via its amino group, and π-stacks with Y525 (Figure 2.12 D). The third fragment, 3-
(4-hydroxyphenyl) propanoic acid (ZT0633), like the chromone ZT0256, containing a 
carboxylate group which forms electrostatic interactions with R483 and hydrogen bonds 
with S508. The phenyl ring of ZT0633 does not stack with Y525, but instead binds in a 
slightly different location that induces a conformational change in the side chain of R415. 
The phenol group of ZT0633 protrudes into the pocket adjacent to S555, and potentially 
forms a hydrogen bond with the hydroxyl group of this residue (Figure 2.12 E). Both 
ZT0256 and ZT0633 successfully mimic the interaction of Nrf2 residue E79 with R415, 
R483 and S508 on KEAP1. The coordinating arginine and serine residues on KEAP1 adopt 
similar conformations when interacting with the carboxyl group of ZT0256 and ZT0633 as 
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seen for the interaction with E79 of Nrf2. The π-stacking interactions of ZT0256 and 
ZT0017 with Y525 are unique to the fragments; no similar interaction is observed with 
Nrf2. 
 
 
Figure 2.12 Structures of fragments in complex with KEAP1. (A) The structure of Nrf2 nonamer peptide 
(LDEETGEFL) in complex with KEAP1 was obtained: the Nrf2 peptide is shown in green. (B) The three 
fragment hits for which X-ray complex structures were obtained, ZT0017 (magenta), ZT0256 (green), and 
ZT0633 (blue). KEAP1 residues that interact with (C) ZT0256, (D) ZT0017 and (E) ZT0633 (yellow dashed 
lines indicate polar interactions) are shown as sticks. 
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2.3.7 Fragment hits discovered by tethering 
In pursuit of targeted covalent inhibitors of KEAP1/Nrf2, we employed a native 
cysteine residue (at position 434) adjacent to the active binding site on KEAP1 as an 
“anchor” site for covalent bond formation, of which the side chain thiol group can be 
chemically modified by electrophiles such as acrylamide. The principle of Tethering is 
shown in Figure 2.1.This cysteine residue is proposed to be a suitable nucleophilic site for 
TCI design against KEAP1 for the following reasons: (i) it is in close proximity to the 
active site, approximately 13 Å away from the active binding site on KEAP1, measured 
from the thiol sulfur to the fragment binding site described in the previous subsection; (ii) 
it is the only solvent-exposed cysteine residue located on Kelch repeat domain of KEAP1, 
whereas the remaining seven cysteines all reside in distal regions from the active site and 
are largely buried (Figure 2.13); (iii) it has been identified as a site of modification by 
several different Nrf2 inducers.194-196  
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Figure 2.13 Structures of the Kelch repeat domain of KEAP1 with cysteine residues highlighted, based on 
the KEAP1/Nrf2 complex resolved by Dr. James Carolan. KEAP1 protein is shown in grey, Nrf2 peptide is 
shown in green, and side chain atoms of cysteine residues are shown in yellow spheres. 
 
A cysteine-to-alanine mutation was introduced at position 434 by site-directed 
mutagenesis, as a negative control for the tethering experiments. Compounds that 
covalently label the wild-type KEAP1 but not the C434A exhibit the selectivity of this 
anchor site. On the contrary, if a compound also labels the C434A variant, it possibly reacts 
with one of the buried cysteine residues that is remote from the active site, or just randomly 
labels nucleophilic residues on KEAP1 due to its high reactivity. This C434A substitution 
was confirmed to not perturb the protein folding or function, as determined by CD, 
ThermoFluor and FA binding assay in comparison to the wild-type (KDC434A = 17.5 ± 4.3 
nM). 
We then screened a library of 1280 fragment-sized compounds from the SMDC 
collections at UCSF against our KEAP1 constructs. This collection of compounds, named 
monophores, were designed for tethering screening and each comprised three functional 
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components: a fragment-sized moiety for non-covalent recognition of the target, a flexible 
linker, and a thiol electrophile capped by the dimethyl cysteamine through a disulfide 
linkage. In the assay, a relatively high concentration of reducing agent, βME in this case, 
was included. This allows disulfide exchange between the thiol group on the monophore, 
the dimethyl cysteamine protecting group, and the cysteine thiol group on the protein 
target. As a result, compounds that can specifically recognize the active binding site on the 
target protein via a non-covalent interaction through its fragment moiety and then form a 
disulfide bond with the thiol group of the anchor cysteine are thermodynamically favored 
and accumulated over time. A representative tethering experiment is shown in Figure 2.14. 
Figure 2.14 A shows the deconvoluted mass spectrum of wild-type KEAP1 incubated with 
500 µM β-mercaptoethanol (βME). The large peak on the far left of the spectrum is 
unmodified KEAP1 (mass of 34586 Da.). The slightly larger peak is KEAP1 disulfide-
bonded to βME (adduct mass of 34662 Da.). In the absence of any compounds, KEAP1 
only reacts with the βME forming adduct via disulfide bond. The other small mass peaks 
correspond to the potassium adduct and dimethyl cysteamine adduct of the protein. The 
spectrum on the right shows the result of reacting wild-type KEAP1 with 250 µM of 
compound 917833 in the presence of 500 µM βME. In this case, the predominant peak 
corresponds to KEAP1 disulfide bonded to 917833 (mass 34998 Da.), leading to many 
minor unmodified or βME modified protein peaks. Detection by mass spectrometry enables 
calculation of the labeling efficiency, using the ratio of the intensity of the peak 
corresponding to the protein-compound adduct of the total protein species: 
 
  
72 
 
Figure 2.14 Representative tethering experiment. The protein KEAP1 presented at a concentration of 250 
µM and compound 917833 presented at 250 µM. The buffer contained 100 mM ammonium acetate (pH 8.3) 
and 500 µM 2-mercaptoethanol, and the samples were allowed to equilibrate at ambient temperature for 1 h 
before analysis. 
 
𝐿𝑎𝑏𝑒𝑙𝑖𝑛𝑔	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 = 	100%× 𝑎𝑑𝑑𝑢𝑐𝑡𝑎𝑑𝑑𝑢𝑐𝑡	 + 	𝑖𝑛𝑡𝑎𝑐𝑡	𝑝𝑟𝑜𝑡𝑒𝑖𝑛 
 
In the initial screen at 100 µM, compounds that showed a labeling efficiency > 15% 
on the C434A negative control, indicating a nonspecific labeling manner, and were not 
considered further. Among the remaining set, compounds with a labeling efficiency > 40% 
were selected for dose-response experiments. Out of the 43 initial hits, 19 compounds 
representing several different chemotypes, exhibited labeling in a dose-response fashion, 
with the DR50 ranging from 30 to 100 µM. Examples of the dose-response curves are shown 
in Figure 2.15. In some cases, compounds showed an elevated labeling efficiency on the 
C434A control at high concentrations as they started to aggregate and precipitate on the 
protein samples. Among those 19 hits, we identified 11 compounds representative of 
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discrete chemotypes and started a collaborative project with the Karen Allen lab to obtain 
co-crystal structures with KEAP1 to understand the details of their binding. A full list of 
11 compounds with their DR50 values are shown in Appendix VI. 
 
Figure 2.15 Examples of hits from the tethering screen. (A) SMDC 917833 and (B) SMDC 917726, gave 
dose-dependent labeling on KEAP1 in the tethering screening. The DR50 values were 36.3 µM and 32.3 µM, 
respectively. Structures are shown above the curves, with statistics are shown in the table below. Results 
shown in each case are representative of at least two independent experiments.  
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2.4 Discussion 
2.4.1 Lessons from macrocyclic and cyclic peptide inhibitor development 
 KEAP1 has been proposed to be a suitable target for macrocycles and cyclic 
peptides by us and others.35,140,172,197 As a proof of concept, two cyclic peptides were 
designed in this study to mimic the linear Nrf2 DxETGE peptide with a constrained ring 
structure through an intramolecular disulfide bond. Unfortunately, neither resembled the 
binding behavior of the wild-type Nrf2. Currently, we do not have structures of those 
peptides in complex with KEAP1 to provide any explanations at the molecular level. One 
hypothesis to explain cyclic peptide 1 (CGDEETGEGC) being a weaker binder is that 
introducing an external disulfide linkage to mimic the main chain hydrogen bond between 
Q75 and L84 (Figure 2.8) actually distorts the loop structure. Upon forming a side chain 
disulfide bond, it introduces a length of about 6 Å between the Cβ atoms of the two 
cysteines, whereas in the bound conformation of the wild-type Nrf2, the distance between 
the carbonyl carbon on L84 and the nitrogen atom of the main chain amide on Q75 is 
approximately 5 Å. The extra length or cyclization via disulfide bond may introduce a 
backbone distortion, locking the peptide in a disfavored conformation, therefore the cyclic 
peptide no longer resembles the natural ligand in the bound conformation. New cyclic 
peptide designs will be carried out using the strategy of side chain on-resin 
macrocyclization (lactam formation) that allows adjustable linkages by using different 
amino acids. For example, introducing an external Glu for the peptide cyclization via 
lactam formation provides a longer linkage by approximately 1.5 Å than Asp due to the 
additional carbon in the side chain. 
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A successful example illustrating the proposal above is that of a macrocyclic 
peptide (cycloGD77EETGE82), derived from the DxETGE region of Nrf2, being reported 
to have an IC50 about 15 nM.172 In the complex crystal structure, this cyclic peptide 
resembles the binding mode of wild-type Nrf2. The side chains of T80 and E82 perfectly 
superimpose with the linear peptide (Figure 2.16). Minor differences were observed in the 
side chain conformation of E79. The greatest Cα deviation was seen in D77 and E78 (1.5 
Å), which can be explained by the limited degree of conformational freedom and backbone 
distortion upon macrocyclization. 
 
 
Figure 2.16 Superimposition of the cyclic Nrf2 peptide (grey, PDB 3ZGC) with a linear Nrf2 peptide (yellow, 
PDB 2FLU) in the bound conformation. The major Cα deviation is seen for Asp77 and Glu78 (1.5 Å). In 
2FLU, the side chain of E78 is not well-defined in the electron density. 
 
This hypothesis of KEAP1 being a good macrocycle target has also been proposed 
by others.35,140,172,197 In an analysis by Scott et.al.35, the authors classified PPIs according 
to their structural basis and concluded that KEAP1/Nrf2 falls into the category of 
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interaction between a globular protein and a peptide with a continuous epitope. They’ve 
also observed in a major subset in this class of PPIs that, peptides undergo substantial 
conformational changes upon binding. Thus, pre-organization of the peptide in the optimal 
binding conformation by cyclization could potentially benefit the binding in terms of 
reducing ligand flexibility and conformational entropy. Krizter and coworkers developed 
an algorithm, LoopFinder, that can identify loop-mediated PPIs among all of the reported 
protein-protein complex structures in the Protein Data Bank (PDB).140 By using this 
algorithm, they identified that the interaction of KEAP1/Nrf2 is mediated by a loop 
architecture with wide and diverse three-dimensional orientations, indicating that the loop 
has an expanded conformation and all of the side chains are not in a plain surface. 
Therefore, utilizing the macrocyclic scaffold in the inhibitor design against this type of 
protein-protein complex targets and mimicking the native ligand conformation will be 
beneficial. 
 While the screening of the 800 Asinex macrocyclic compounds and developing of 
disulfide-linked cyclic peptides resulted in no success, we still consider this protein-protein 
interaction as a good target for macrocycles. Because macrocycles do not represent a single 
chemotype but can span over a vast chemical space, we believe that a larger library 
comprising a broader spectrum of scaffolds and compound functionalities will lead to a 
higher probability of success. The failure in the screening efforts of the collection of Asinex 
800 macrocyclic compounds was possibly due to the limited coverage of chemotypes in 
the library. The results shown here do not contradict with our hypothesis of KEAP1 being 
a suitable target for macrocyclic scaffolds (vide supra). A better designed library with 
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compounds of appropriate macrocyclic ring size will potentially result in a higher hit rate. 
Future efforts in discovering macrocyclic inhibitors will be pursued in the direction of 
exploring other available compound collections. 
 
2.4.2 Lessons from fragment screen 
The detailed binding modes of the three fragment hits discovered in our study were 
extensively discussed in the previous results section. To better understand the fragment 
binding features of the KEAP1 binding site, I discuss several successful fragment hits from 
other people’s work in comparison to ours. 
Astex Pharmaceuticals (Cambridge, UK) reported a small molecule that binds to 
KEAP1 with nanomolar affinity through a fragment-based drug discovery strategy. Their 
initial screen resulted in three fragments that bind at distinct locations within the KEAP1 
binding site (Figure 2.17 A). From there, they utilized fragment 1 as the “anchor” and 
linked this fragment with two other fragments through a few rounds of medicinal chemistry 
optimization. Fragment 1 (3-(4-chlorophenyl) propanoic acid), like ZT0633, forms 
electrostatic interactions with the guanidine group of R483 and potentially hydrogen bonds 
with S508 (Figure 2.17 B). However, the phenyl chloride ring of this fragment binds in a 
different location compared to ZT0633, but still induces a conformational change in the 
side chain of R415. Fragment 2 (2,6-dimethyl-4H-pyrano[3,4-d]oxazol-4-one), which 
binds in a very similar mode as ZT0017, 𝜋 -stacks with Y525 and hydrogen bonds with 
R483, Q530 and S555 (Figure 2.17 C). The binding mode of fragment 3 
(benzenesulfonamide) is unseen in our fragment hits, majorly hydrogen bonding with 
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S363, Y334 and S602 through its sulfonamide group (Figure 2.17 D). Fragments with three 
distinct binding modes allowed them to develop a more potent lead by chemical elaboration 
mimicking the three fragments. 
 
 
Figure 2.17 Structures of Astex fragments in complex with KEAP1. (A) Overlay of Astex 3 fragment hits 
with the fragments reported in this study (colored as in Figure 2.12). The molecular details of the three Astex 
fragment hits that bind to KEAP1, (B) fragment 1 (cyan, PDB 5FNQ), (C) fragment 2 (white, PDB 5FZJ), 
and (D) fragment 3 (yellow, PDB 5FZN). 
 
It is notable that two of our fragments, ZT0633 and ZT0256, and an Astex fragment 
(compound 1) coincide at the binding subpocket, all interacting with R483 and S508. This 
kind of interaction is also seen in Nrf2, wherein E79 projects its carboxylate group into this 
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subpocket. This result indicates that the binding site is energetically favored and dominated 
by polar interactions. Proper design of chemicals with polar groups to substitute the 
carboxylate group seen in the current fragment hit set will gain binding energy. Another 
interesting fragment binding feature is that our fragment ZT0017, ZT0256, and Astex 
fragment 2 comprise a dinuclear aromatic moiety, forming π-stacking interactions with 
Y525. This is unseen in the PPI complex, given that the DxETGE binding motif on Nrf2 
contains no aromatic structures. This observation suggests that unlike the interaction with 
the natural ligand that is driven by polar interactions, fragments are capable of binding to 
KEAP1 by forming hydrophobic interactions. This provides alternatives in the inhibitor 
design of KEAP1 to achieve good binding affinity and potentially improves the membrane 
permeability. The third observation is that Astex fragment 3 binds at the site that none of 
our fragments exploit, with its sulfonamide group forming polar interactions (e.g. hydrogen 
bonds) with Y334, S363 and S602. This provides insight in two aspects: (i) fragment 
elaboration into this binding site will gain additional binding energy; (ii) the sulfonamide 
group can be used to as an alternative to the carboxylates in inhibitor design for this protein 
target, mitigating the issues in pharmacokinetic properties caused by acidic groups. 
 
2.4.3 Lessons from Tethering screen 
In the pursuit of targeted covalent inhibitor development of KEAP1, we performed 
a screen of 1280 monophore compounds using Tethering. Tethering-facilitated fragment 
screening resulted in a set of 19 compounds representing various chemotypes (Figure 2.18), 
among which scaffolds containing benzotriazole and sulfones/sulfonamides were 
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repeatedly seen. This trend likely indicates the specificity of such moieties in recognizing 
the active site of KEAP1. The sulfonamide functional group has been reported to be seen 
in hit compounds against this target in multiple studies, including the Biogen inhibitor 15 
and the Astex fragment 3.170,171 Our hypothesis for explaining this preference of chemotype 
is detailed as follows. The KEAP1 binding interface is atypical – polar and charged groups 
are enriched at this site. To accommodate this feature, the natural ligand Nrf2 binding 
region consists of negatively charged residues, such as Asp and Glu. Therefore, small 
molecule ligands identified from screening efforts usually contains similar elements, i.e. a 
carboxylic acid group to mimic the side chain interaction of E79 and E82 on Nrf2. 
However, carboxylic acids are generally avoided even at the early stage of drug discovery, 
due to their poor pharmacokinetic properties. Sulfonamide, an uncharged hydrogen bond 
acceptor, can still satisfy the required polar interactions with the target to achieve requisite 
binding energy without failing pharmacokinetic liabilities. Another interesting observation 
is that 917994 possesses a scaffold that resembles the chromone moiety as seen in the 
fragment hit ZT0256 (section 2.3.6). The former contains a spacer ~19 Å from the thiol 
sulfur to the chromone scaffold that allows its scaffold to reach the fragment binding site 
while forming a disulfide bond with C434, given that the two sites are approximately 15 Å 
apart. Additional structural evidence, such as that from obtaining the crystal structure of 
this compound in complex with KEAP1, is needed to support this hypothesis. The 
convergence of results from two orthogonal screening techniques with two distinct sets of 
fragments on the same chromone scaffold suggests that this scaffold favors the KEAP1 
binding site with adequate specificity. 
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Figure 2.18 Hits from tethering screening grouped by chemotypes 
 
Indeed, development of targeted covalent inhibitors of KEAP1 using Tethering is 
still at its early stage. Out of 1280 compounds, we successfully identified 19 hits 
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representing several chemotypes with DR50 values ranging from 30 µM to 110 µM. These 
results are within the range seen in previous examples for hits from the initial Tethering 
screen, which were subsequently optimized to potent inhibitors.156,198 In general, fragment-
sized compounds (MW < 300 Da.) bind very weakly, with a KD ~ 1 mM, as seen with 
ZT0256 from our study, for example, which only inhibits with a KD = 1.4 mM. However, 
monophore hits from Tethering present DR50 values generally one or two magnitudes lower 
than noncovalent fragment hits. The target binding potency is enhanced by the co-
occurrence of the covalent bond formation and the noncovalent interaction.157 Preliminary 
results from the initial screen revealed some critical information for further inhibitor 
development. For example, the KEAP1 binding site specifically recognizes certain 
chemotypes such as sulfonamides and sulfones. These chemicals contain an aromatic 
moiety that potentially 𝜋-stacks with Y525, as well as a sulfonyl group that can interact 
with the arginine and serine residues on the PPI interface of KEAP1 (e.g. R415, R483, 
S508). Therefore, the monophore hits may occupy one of the favored fragment binding 
sites on KEAP1 and achieve binding energies from both nonpolar and polar interactions. 
Another outcome of observing the chromone scaffold in hits from two distinct screening 
approaches using two different collections of compounds validates the specific recognition 
of this structure by KEAP1. Further development by elaborating the chromone derivative 
hits (ZT0256 and 917994) towards the adjacent binding pocket, i.e. where Astex 3 binds, 
will lead to a more potent inhibitor. 
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Further hit validation and characterization are proposed using X-ray 
crystallography in collaboration with the Allen lab. The information from the crystal 
structures will be vital to the optimization of targeted covalent inhibitors, which involves 
two aspects: (i) elaborating fragments to larger and more specific lead molecules for a 
better noncovalent binding property (i.e. the portion of binding energy provided by the 
ligand independent of the covalent bond formation); (ii) replacing the thiol group with other 
Michael acceptors, such as acrylamides, to provide irreversible covalent inhibitors. To 
fulfill the last goal, designing electrophiles that contain carefully tuned reactivity will be 
required.  Appending a highly reactive electrophile to the scaffold will raise the issue of 
off-target activity, such as irreversible reactions occurring with other thiol containing 
molecules. The covalent bond formation should only occur when the electrophile is at an 
optimal distance and favorable orientation relative to the nucleophile on the protein upon 
specific non-covalent binding. 
 
2.4.4 Conclusions and future directions for inhibitor discovery against KEAP1/Nrf2 
In this chapter, I described my efforts in developing robust fluorescence anisotropy-
based binding and screening assays for protein construct characterization and compound 
screening. Using this tool, I screened a collection of 800 macrocyclic compounds and 
another of 458 fragment-sized compounds. The former resulted in no hits. However, as 
evidenced by our analysis and others’, we were able to conclude that KEAP1 remains a 
suitable target for MC scaffolds (section 2.4.1), with the current failure owing to the fact 
that only a limited subset of macrocycles among the vast chemical space was exploited for 
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this target at this stage. The latter resulted in a subset of well-validated fragments hits, 
among which 3 were successfully soaked with KEAP1 protein and extensively 
characterized using X-ray crystallography. With the structural information, we found a 
binding subpocket formed by R415, R483 and S508 that is favored by fragment scaffolds. 
Analysis of the hit compounds from the primary screen informed us about the binding 
features of this PPI interface, and provided insight into the lead development. In the 
meantime, we noticed a 𝜋-stacking interaction with Tyr525 among several hits, which is 
unseen in the natural ligand Nrf2. In addition, tethering-based fragment screening resulted 
in 19 compounds that can specifically recognize KEAP1 as well as covalently label Cys434 
adjacent to the binding site. It is notable that the other seven cysteines on the KEAP1 
construct were not labeled by these tethering hits (no labeling in the C434A variant), 
illustrating their specificities for this binding site and suitabilities as potential 
pharmacophores for KEAP1. Several tethering hits contain similar chemical and structural 
features seen in the fragment hits from our earlier screens. Future directions of this project 
include (i) characterization of the tethering hits by X-ray crystallography; (ii) optimization 
of fragments by chemical modifications (e.g. introducing additional uncharged 
functionalities that can hydrogen bond with R415 and Y572) based on the structural details 
revealed by X-ray crystallography and by linking the noncovalent portions of fragment hits 
(from both the fragment and tethering screens) that bind at adjacent locations (if any) for a 
higher affinity inhibitor; (iii) conversion of disulfide-based hits into irreversible covalent 
inhibitors with acrylamide or chloroacetamide functional groups; (iv) screening of 
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macrocycles utilizing other compound collections and rational design of cyclic peptide 
inhibitors. 
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CHAPTER THREE. Druggability of KEAP1/Nrf2 Protein-protein Interaction 
Interface 
3.1 Introduction 
3.1.1 Hot spots at protein-protein interfaces 
Protein-protein interactions (PPI) mediate a broad spectrum of crucial biological 
processes, which makes them compelling drug targets. However, years of efforts towards 
regulating such interactions with small molecules have been rewarded with only an 
inadequately small number of successes. The challenge of this task primarily is thought to 
originate from the physicochemical properties of the PPI interface.14,16,17,25,27,38,39 In other 
words, PPI interfaces lack the topology to accommodate a drug-sized small molecule (< 
500 Da) and to achieve sufficient binding energy with a small molecule ligand. For this 
reason, screening of large conventional compound libraries has more often than not led to 
no useful compounds to the target PPI,20-35 leaving behind a more important question – 
whether the failures result from the selection of the inappropriate chemical spaces for 
screening, or the undruggability of the protein target. The later possibility is more related 
to the intrinsic properties of the PPI interface, thus understanding the druggability of a 
particular PPI target is crucial in drug development. An important concept in studying the 
problem of druggability is the binding hot spots, a term introduced by Clackson and Wells 
in 1995.43 It was uncovered that the binding energy is not uniformly distributed over the 
PPI interface, but instead mainly dominated by a subset of residues – these residues are 
defined as “hot spot residues” of PPI interfaces.45-48 
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3.1.2 Alanine scanning mutagenesis as a method for identifying PPI hot spots 
Methods to map the locations and strengths of the binding energy hot spots provide 
crucial information to guide the small molecule drug design and development for PPI 
targets. Among these, the most established approach is alanine scanning mutagenesis 
(ASM). By serially mutating each residue at the interface to alanine and examining the 
impact on binding affinity to the partner protein, this method can evaluate the energetic 
contribution of atoms beyond Cβ of each residue. A residue is considered to be a hot spot 
residue if its alanine mutant binds substantially weaker than the wild-type protein. For 
instance, in an analysis of the interface of human growth hormone and its receptor, 
Clackson and Wells defined the hot spot residue as: a residue that interacts with the partner 
protein for more than 12-fold weaker, corresponding to a change ≥ 1.5 kcal/mol in binding 
free energy (ΔGmut – ΔGWT = ΔΔGmut ≥ 1.5 kcal/mol),  when mutated to alanine.43 This 
approach has been widely used to dissect the origins of the binding energetics at PPI 
interfaces. However, it has been realized that the ASM results sometimes can be under- or 
over- interpreted. DeLano pointed out that using alanine substitutions is measuring the 
effect of structural perturbations instead of directly determining energy contributions. 
Therefore, structural information such as interface plasticity should also be taken into 
consideration to fully understand the energetic properties of protein-protein interactions.199 
 
 
  
88 
3.1.3 Fragment screening and its relation to hot spots 
To better understand how fragments bind to protein surfaces, Ciulli and coworkers 
probed hot spots at the cofactor-binding site of E. coli ketopantoate reductase by breaking 
down NADPH into smaller fragment structures.200,201 Coupled with alanine scanning 
mutagenesis on the enzyme, they discovered that the locations at which the deconstructed 
ligands remain binding represent the energetic hot spot regions on protein surface 
discovered by alanine scanning mutagenesis (ASM). They also showed that the small 
fragments usually tend to have a substantially higher ligand efficiency (LE = ∆G/(number 
of heavy atoms)), than the larger ligands. The combination of ITC and site-directed 
mutagenesis as a tool provided the complete thermodynamic characterization of the effect 
of mutations to ligand binding. In addition, the authors not only identified the location of 
hot spots on protein surfaces but also revealed their structural and energetic properties 
using this method. The approach defined a guideline for future inhibitor design of 
ketopantoate reductase and provided an objective and useful framework for fragment-
based drug discovery of other enzymes.37,201 
 
3.1.4 Computational approaches to identifying hot spots 
In addition to the experimental approaches discussed above, efforts have been made 
to identify binding hot spots on PPI interfaces using computational tools. For example, 
Zerbe et al. recently reported that the FTMap algorithm, a computational solvent mapping 
algorithm to identify fragment binding hot spots on PPI interfaces developed by Vajda and 
coworkers,202,203 can precisely identify binding hot spots. In this study, they applied the 
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algorithm to 15 proteins and compared the results to published experimental alanine 
scanning results.204 Their results revealed a strong relationship between FTMap-identified 
hot spots on the concave side of the protein interface and hot spot residues on the binding 
partner identified by alanine scanning mutagenesis (ASM). However, they validated that 
only a subset of hot spots identified by alanine scanning have the potential to bind small 
organic ligands. Potential fragment recognition sites that are not involved in the protein-
protein interactions are usually omitted by ASM. This finding raises the question of how 
should we justify the hot spot residues mapping results by alanine scanning mutagenesis in 
order to properly think about the true hot spot ensemble on PPI interfaces. 
On another aspect, computational algorithms have recently been employed to 
predict the suitability of protein targets for FBDD and to assist the experimental fragment 
screening. Dima Kozakov et al. performed computational ligand deconstruction using 
FTMap on eight PPI cases and showed that when a large ligand is deconstructed into small 
fragments, only fragments binding at the top-ranked hot spot (termed “anchor site” by 
Camacho and coworkers205) can remain in the same binding mode.206 They proposed that 
this top-ranked fragment binding site can be considered as an anchor site, which dominates 
the binding free energy, surrounded by several weaker satellite fragment binding sites that 
confer improved selectivity and affinity for the ligand. Therefore, in a FBDD campaign, 
the screening hits that occupy the anchor sites are the most suitable for subsequent 
expansion. Similar hypothesis has been supported by Tom Blundell et al.. They described 
a new computational method capable of providing fragment interaction information from 
a global search of the apo protein target crystal structure based on SuperStar algorithm.207 
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In comparison with experimental binding positions of fragments and lead molecules, they 
discovered that fragments are more frequently found in high scoring areas of the fragment 
hotspot maps, i.e. top-ranked binding hot spots identified by their method.208  
 
3.1.5 Aims  
While a plethora of methods are available to identify hot spots on PPI interfaces, 
three questions remain unanswered: (i) how does the information provided by each of these 
approaches relate to the true structure of the hot spot ensemble; (ii) what are the strengths 
and limitations of each approach; (iii) how can we properly analyze and utilize that 
information to develop a general guideline that can facilitate the PPI drug design. In this 
chapter, I address these questions by employing the PPI between KEAP1 and Nrf2 as a test 
system. I investigate the binding hot spot ensemble at the KEAP1/Nrf2 interface using 
three discrete approaches: (i) comprehensive alanine scanning mutagenesis, (ii) FBDD 
assisted by X-ray crystallography and (iii) computational hot spot mapping with FTMap. 
By comparing the FTMapping results on KEAP1 to the hot spot regions identified by the 
other two approaches, I categorize experimentally detected binding hot spots into five 
groups, among which only a subset represents the true hot spot ensemble. In addition, I 
discuss the mechanism causing the false positives and false negatives from each method. 
Collectively, I present a scheme that describes the overlap and differences in the 
information provided by these three methods, and a guideline for using the combination of 
these three methods to accurately evaluate PPI druggability. During this work, I have also 
identified and characterized the location and strength of each binding hot spot on KEAP1, 
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and described a previously unidentified binding hot spot favored by hydrophobic moieties 
that can be utilized in the further drug development of this target. 
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3.2 Materials and Methods 
3.2.1 Site-directed mutagenesis on Nrf234-100 
All site-directed mutagenesis in bacterial expression plasmids for Nrf234-100 
variants were generated by following a 2-round PCR procedure to improve the success in 
codon change. In the first round of reaction, a T7 promoter forward primer and a reverse 
primer encompassing the mutation were used to create a mega-primer containing the 
mutation, using the following the condition: 98 ̊C for 30 s, 35 cycles of 98 ̊C for 10 s, 59 ̊C 
for 30 s, 72 ̊C for 30 s, followed by 72 ̊C for 2 min for final extension at the completion of 
the cycles, and then 4 ̊C until the run was manually stopped. Components of PCR reactions 
were as described in Chapter 2. The products of the first round PCR reaction were then 
purified and used as mega-primers for the second round of reaction, under a slight different 
condition: 98 ̊C for 30 s, 35 cycles of 98 ̊C for 10 s, 72 ̊C for 4 min, followed by 72 ̊C for 
2 min for final extension at the completion of the cycles, and then kept at 4 ̊C until the run 
was manually stopped. After PCR, the products were purified, then 1 µL of DpnI was added 
and the samples were incubated at 37 ̊C for 1 h. A volume of 2 µL reaction was then 
transformed into DH5α competent cells. Plasmids with the successful mutagenesis were 
selected and confirmed by sequencing as described above. Primers used for site-directed 
mutagenesis can be found in Appendix I.  
 
  
93 
3.2.2 Protein expression, purification and characterization 
All the Nrf2 variants were expressed and purified using the same protocol as the 
wild-type Nrf234-100 construct, described in Chapter 2. In brief, large scale protein 
expression was carried out using BL21(DE3) Competent E.coli cells. Cells were grown at 
37 ̊C in the presence of Ampicillin (100 µg/mL) until the OD600 value reached 0.4 - 0.6, 
then induced by 1 mM IPTG and expressed at 37 ̊C with shaking (250 rpm) for 4 h. Cells 
were pelleted by centrifugation and stored at -80  ̊C before purification. 
The Nrf2 variants were purified using a similar 2-step Ni-NTA purification 
strategy. Proteins with His6 tag were purified using the Ni-NTA resin, followed by an 
overnight dialysis in the presence of the TEV protease to cleave the His6 tag. In the next 
step, the untagged proteins were then applied on the Ni-NTA resin again to remove the 
His6 tag. The cleaved proteins were then purified by gel filtration using HiPrep 26/60 
Sephacryl S-300 column (GE Healthcare, Sunnyvale, CA) to obtain the monomeric 
homogenous species using the storage buffer (20 mM sodium phosphate, 150 mM NaCl, 
2.5 mM DTT, pH 7.5). Purified proteins were then concentrated, quantified, aliquoted, 
flash-frozen and stored at -80 ̊C for future use. 
All the Nrf2 variants were characterized using sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE) to verify the purity. In brief, 10 µM of 
wild-type Nrf234-100 or mutants were incubated with SDS sample buffer in the presence of 
10 mM DTT with boiling for 5 min before loading on to the 10% Tris-tricine gel. 
To verify the identity of each Nrf234-100 variants, all the proteins were characterized 
using liquid chromatography-mass spectrometry (LC-MS). An aliquot of each purified 
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Nrf234-100 variants at 20 µM was desalted into water using Zeba™ Spin Desalting Columns 
(7K MWCO, 0.5 mL, Thermo Fisher Scientific) following the manufacturer’s protocol. 
Desalted protein samples were then quantified and diluted to 10 µM in water. Protein 
samples were loaded onto a reverse-phase Atlantis dC18 HPLC column (100 Å, 3 µM, 
2.1× 30 mm, Waters, Milford, MA)  using a binary solvent system of H2O/acetonitrile with 
0.1% formic acid, within a gradient of 90% H2O to 10% H2O, before being directed into 
mass spectrometry (Waters qTOF Premier LCMS, Milford, MA). Data were acquired by 
use of MassLynx Mass Spectrometry Software (Waters, Milford, MA). The identity of 
each Nrf2 variant was confirmed by their corresponding intact mass.  
CD spectra of wild-type Nrf2 and variants were measured as described in Chapter 
2. In brief, the CD spectra were collected using 10 µM of Nrf2 constructs in the storage 
buffer (20 mM sodium phosphate, 150 mM NaCl, 2.5 mM DTT, pH 7.5) at 20 ̊C from 180 
to 260 nm. The buffer background was subtracted. The measured ellipticity in millidegrees 
(θ) was normalized to mean residue ellipticity (θMRE) using the following equation: 
 
θ#$% = θ10Cnl 
 
where C is the molar concentration of protein, l is the length path in centimeters and n is 
the number of residues.  
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3.2.3 Nrf2 mutants binding assay 
Competitive experiments to evaluate the Nrf234-100 mutants binding properties were 
carried out in the same way as described in Chapter 2. In brief, the fixed concentration 
components, FITC-Nrf2 peptide and KEAP1 protein, were kept at 5 nM and 10 nM 
respectively. The unlabeled Nrf2 variants were added into each well by a 2-fold serial 
dilution. The highest concentration of the competitor was kept below 50 µM, to avoid 
elevated viscosity in assay solution. The assay mixtures were incubated at 25 ̊C for 30 min 
prior to reading. Error bars are calculated from duplicate measurements. Each mutant was 
tested in FA assay in at least three independent experiments. The competition binding 
results were fitted by a competitive binding model using a numerical nonlinear regression 
software DYNAFIT 4 (BioKin Ltd., Watertown, MA).176  
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3.3 Results 
3.3.1 Preparation and characterization of Nrf2 variants 
To probe the molecular origins of the interaction energy that drives the 
KEAP1/Nrf2 interaction, I systematically assessed the contribution made by each residue 
in and around the high affinity Nrf2 DxETGE binding motif using the technique of alanine 
scanning mutagenesis.43,44,209,210 I used the shorter construct, Nrf234-100, as the template for 
the alanine mutants, so that mutants in which DxETGE binding was severely reduced could 
not simply bind to KEAP1 through the DLG motif, as this outcome would have set a lower 
limit to the range of binding affinities that could be measured for mutant DxETGE motifs. 
Figure 3.1 shows the residues of Nrf234-100 selected for mutagenesis. Analysis of the 
published co-crystal structure of KEAP1 with a DxETGE motif peptide showed that each 
residue from D77 to F83 makes some contact with the protein, as measured by a reduction 
in solvent accessible surface area (SASA) upon complex formation (Table 3.1).136,137 
Glycine lacks any side chain, and therefore G81 was not amenable to alanine scanning 
mutagenesis. I mutated each of the remaining six residues within the DEETGEF region of 
Nrf234-100 individually to alanine. These six mutant proteins were cloned, expressed and 
purified using a protocol similar to that described above for wild-type Nrf234-100. Each 
mutant protein was analyzed to confirm identity, purity and proper folding, as described in 
Material and Methods. Results shown in Figure 3.2. 
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Figure 3.1 Residues of Nrf2 DxETGE motif selected for alanine scanning mutagenesis. Close-up view of the 
Nrf2 β-hairpin loop structure with (left) and without (right) KEAP1 protein. Residues selected for alanine 
scanning mutagenesis analysis are highlighted in red. The KEAP1/Nrf2 complex structure was solved by Dr. 
Andrew Lynch and Dr. James Carolan in the Allen lab. 
 
 
Table 3.1 Extent of contact with KEAP1 for each residue in the Nrf2 DxETGE binding motif 
Nrf2 
Residue 
Contact Area 
(ΔASA, Å2)1 ΔASA/total 
SASA beyond Cβ 
(% buried) All atoms2 
Side-chain atoms 
after Cβ3 
SASA beyond Cβ 
when free in 
solution 
L76 14.9 14.9 126.9 11.7 
D77 18.5 16.2 100.2 16.2 
E78 83.7 34.4 130.1 26.4 
E79 172.3 126.7 130.1 97.4 
T80 82.0 37.9 103.4 36.7 
G81 41.7 n/a n/a n/a 
E82 117.2 104.6 130.1 80.4 
F83 32.8 3.4 158.8 2.1 
1Burial of solvent-accessible surface area in the KEAP1/Nrf2 complex (4IFL) attributable to the Nrf2 residue 
in question, calculated using PyMOL as described in Materials and Methods. 2Buried of solvent-accessible 
surface area attributable to all atoms of the residue in question. 3Burial of solvent-accessible surface area 
attributable to the side-chain atoms beyond Cβ; i.e. those atoms eliminated when the residue is mutated to 
alanine.  
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Figure 3.2 SDS-PAGE and CD spectra of Nrf2 variants. (A) Reducing SDS-PAGE of purified Nrf234-100 variants. 
All constructs appeared to be monomer under denaturing conditions with high purity. (B) Circular dichroism 
spectra of wild-type Nrf234-100 and the alanine mutants. The normalized spectra of the alanine mutants 
appeared to overlap with the wild-type, suggesting no significant changes occur in the protein secondary 
structure upon the introduction of the mutations. 
 
3.3.2 Hot spots on Nrf2 identified by ASM 
 The binding affinities of the six Nrf2 mutants were measured in the FA assay, as 
described for wild-type Nrf2 in Chapter 2. The results are shown in Table 3.2. Four residues 
within the binding motif of Nrf2 caused substantial reductions in binding affinity when 
mutated to alanine. These were D77, E79, T80 and E82, which showed KDmut/KDWT ratios 
ranging from 170-2600, corresponding to a reduction in interaction energy with KEAP1 of 
ΔΔG = -RTln(KDWT/KDmut) = 3.0 - 4.5 kcal/mol (Figure 3.3). In contrast, mutation of either 
E78 or F83 to alanine resulted in ΔΔG < 0.5 kcal/mol, indicating that these residues do not 
play a significant role in stabilizing the KEAP1/Nrf2 interaction.  
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Table 3.2 Collected binding affinities and binding energetics of Nrf234-100 alanine mutants  
Nrf2 WT D77A E78A E79A T80A E82A F83A 
KD (nM) 10 ± 2 
(4.4 ± 1.8) 
×10
3
 
25 ± 3 
(1.7 ± 0.2) 
×10
3
 
(2.6 ± 1.5) 
×10
4
 
(2.2 ± 1.3) 
×10
4
 
18 ± 3 
ΔΔG 
(kcal/mol) / 3.5 ± 0.3 0.5 ± 0.1 3.0 ± 0.1 4.5 ± 0.4 4.4 ± 0.4 0.3 ± 0.1 
 
 
Figure 3.3 Binding affinities and binding energetics of Nrf234-100 alanine mutants. (A) Inhibitory dose-
response curves for wild-type Nrf34-100 and the six alanine mutants. Solid lines are best fit of the data to an 
inhibition binding model using DYNAFIT 4. (B) The decrease in KEAP1/Nrf2 interaction energy for each 
alanine mutant, calculated from ΔΔG = -RTln(KDWT/KDmut). Error bars of the binding curves show the range 
of duplicate measurements. Results shown in each case are representative of at least three independent 
experiments. Standard deviations of ΔΔG are calculated from at least three independent experiments. 
 
 
Among the four residues found to be important for binding, the carboxyl group of 
E79 engages in direct charge-charge hydrogen bonding with KEAP1 residues R380 and 
R483. Similarly, the carboxylate group of E82 engages in charge-charge hydrogen bonding 
interactions with KEAP1 residues R380 and S362. Interestingly, the other two residues that 
were found to be important for binding, D77 and T80, appear to make relatively little 
contact with KEAP1, burying only 16 and 38 Å2 of SASA, respectively (Table 3.1).  
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The published X-ray co-crystal structure (PDB 2FLU) shows that the carboxyl 
group of D77 and the hydroxyl group of T80 engage in hydrogen bonding interactions with 
Nrf2 backbone amide groups, and with each other across the hairpin loop of the Nrf2 
peptide (Figure 3.4). I investigated the role of T80 further by mutating it to serine to 
eliminate the T80 methyl group but preserve its ability to hydrogen bond through its 
hydroxyl group to the carboxylate side-chain of D77. Compared to the T80A mutant, T80S 
showed a substantial restoration of the binding affinity, giving KDT80S/KDWT ≈ 30 
(corresponding to ΔΔG = 2.0 kcal/mol), compared to KDT80A/KDWT ≈ 2600 (ΔΔG = 4.5 
kcal/mol) for the T80 alanine mutant (Figure 3.4 B and C). This result confirms that the 
major effect on binding of mutating T80 to alanine arises from loss of the T80 hydroxyl 
group rather than its methyl group. Taken together, these observations suggested that D77 
and T80 affect binding not primarily by forming key interactions with KEAP1, but rather 
by stabilizing the bound conformation of the DxETGE loop. 
 
Figure 3.4 Illustration of the indirect mechanism of D77 and T80. (A) The intramolecular interactions 
between D77 and T80 (polar interactions are indicated as the yellow dashed lines). (B) Inhibitory dose-
response curves for wild-type. Nrf34-100, T80A and T80S mutants. Solid lines are best fit of the data to an 
inhibition binding model using DYNAFIT 4. (C) The decrease in KEAP1/Nrf2 interaction energy for each 
mutant, calculated from ΔΔG = -RTln(KDWT/KDmut). Error bars show the range of duplicate measurements. 
Results shown in each case are representative of at least three independent experiments. 
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3.3.3 Hot Spots on KEAP1 identified by FTMap 
To better understand the origins of binding energy at the KEAP1-Nrf2 interface, 
we additionally characterized the binding site on KEAP1 using the FTMap computational 
hot spot mapping algorithm.211,212 This part of work was done in collaboration with Dr. 
David Hall and Lingqi Luo in Prof. Sandor Vajda’s lab. FTMap identifies binding energy 
hot spots by finding sites on a protein surface that interact favorably with a set of small 
molecular probes.203 Briefly, the algorithm places many copies of a given probe structure 
on a dense grid around the surface of the protein, then performs a series of energy 
minimization and clustering steps to identify sites on the protein where the probe tends to 
cluster due to energetically favorable binding interactions. This process is repeated for 
multiple different probe structures, and the results from all probes are then superimposed 
to identify “Consensus Clusters” (CC) that represent sites on the protein that possess a 
general tendency to bind small organic molecules. CCs are ranked according to the number 
of probe clusters they contain, from CC1, which contains the highest number of probe 
clusters, to CC2, containing the second highest number, and so on. It has been extensively 
validated, over many hundreds of proteins, that the locations of the CCs identified by 
FTMap coincide with sites on a protein surface where known ligands bind,202,204 and that 
the number of probe clusters a given CC contains correlates with its energetic 
importance.176,206,213 The method has been shown to correctly identify hot spots at protein-
protein interface sites,214 and identify sites bound by fragment hits resulting from fragment-
based lead identification methods.206,215 Proteins typically undergo small structural changes 
upon ligand binding. It has previously been shown that FTMap analysis of the structure of 
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the unbound protein is most informative about its druggability213,214 and for identifying 
binding sites for compounds discovered through experimental fragment screening,214 
whereas mapping the ligand-bound structure gives good agreement with experimental 
alanine scanning data.176,204 We therefore applied FTMap to both apo and Nrf2 peptide-
bound crystal structures of the Kelch repeat domain of KEAP1. 
 
 
Figure 3.5 Results of mapping of Nrf2 peptide bound KEAP1 by FTMap. (A) The consensus clusters (binding 
energy hot spots) that were identified by FTMap. (B) Close-up view of the hot spot regions, FTMap identified 
hot spots are labeled as A, B, C and D, defined by consensus clusters (shown in lines). Consensus clusters 
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are colored as follows: CC1 (30 probe clusters), red; CC2 (16) pink; CC3 (16), cyan; CC4 (14), yellow; CC5 
(7), green; CC6 (4), blue. (C) Results of focused mapping shown with the KEAP1 structure removed, viewed 
from the side (left) and top (right), showing that the side chains of E79 and E82 overlap with hot spot B and 
hot spot C, respectively. In contrast, the side chains of D77 and T80 point in towards the center of the hairpin 
loop, and away from any CCs. The hot spot A defined by CC1 is not exploited by Nrf2. In (C) hot spots are 
colored as in (A) and (B). 
 
Mapping the ligand bound KEAP1 structure identified four main binding energy 
hotspots at the binding site (Figure 3.5 A, B). The strongest hot spot, which is termed hot 
spot A (CC1, 30 probe clusters), resides deep at the bottom of the binding site, inside the 
tunnel that passes through the middle of the 6-bladed β-propeller structure of KEAP1. This 
hot spot occupies a hydrophobic interior region of KEAP1, surrounded by L365, A366, 
I416, V418, V465 and A556, and is not exploited by the natural ligand Nrf2, no atom of 
which approaches within 6 Å of this hot spot (Figure 3.5 C). The next strongest hot spot, 
hot spot B (CC2, 16 clusters plus CC6, 4 clusters), lies in the Nrf2 binding groove, at a site 
defined by KEAP1 residues R415, R483 and S508 and Y525 that in the KEAP1/Nrf2 
complex is partly occupied by the carboxylate side chain of E79. Another hot spot of 
comparable strength, hot spot C (CC3, 16 clusters plus CC5, 7 clusters) also lies in the 
Nrf2 binding groove, close to the polar side chain of KEAP1 residue R380 in a site that in 
the complex is occupied by the side chain of Nrf2 residue E82. Finally, a fourth, weaker 
hot spot, hot spot D, is identified by CC4 (14 clusters), located nearby in the shallower part 
of the binding site adjacent to the Nrf2 binding groove, flanked by residues N414, S421, 
G433, H436 and I461. Mapping the crystal structure of apo-KEAP1 gave very similar 
results, identifying the same four hot spots, A-D (Table 3.3). As was seen from the mapping 
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results obtained using the peptide-bound KEAP1 structure, for the apo-KEAP1 structure 
hot spot A is the strongest, B and C are of comparable strength, and D is the weakest. 
 
Table 3.3 Consensus clusters analysis on both apo and peptide-bound KEAP1 structure 
apo KEAP1 
(No. of clusters) 
Compared to fragment 
binding 
Peptide-bound KEAP1 
Compared to ASM 
Location 
(apo/Bound) 
Color in figure 
CC1 (28) CC1 (30) Hot spot A Red 
CC2 (16) CC2 (16) Hot spot B Pink 
CC4 (14) CC3 (16) Hot spot C Cyan 
CC5 (12) CC4 (14) Hot spot D Yellow 
CC3 (15) CC5 (7) Hot spot C Green 
CC6 (9) CC6 (4) Hot spot B Blue 
 
3.3.4 Conformational mobility at the binding site on KEAP1 
It has been noted previously that KEAP1 residue R415, which is important for the 
high affinity interaction with Nrf2,136,137,169,216 can be seen to adopt distinct conformations 
in different X-ray crystal structures of the protein.170,171,217-220 However, the effect that the 
mobility of R415 might have on the shape and properties of the binding site has not 
previously been described. Examination of the five new KEAP1 crystal structures reported 
here, together with 17 previously reported crystal structures for human KEAP1, either 
alone or in complex with various ligands, and 3 fragment-bound mouse KEAP1 reported 
by Astex171 (Appendix IV), shows that the side-chain atoms of R415 can adopt three 
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different orientations. In unbound KEAP1, the guanidine group of R415 lies almost flat on 
the floor of the binding site, largely covering the deep hole that contains hot spot A. In the 
co-crystal structure with ETGE-derived peptides, the guanidine group is rotated ~60° from 
this position, allowing it to make a polar interaction with the carboxylate side chain of Nrf2 
residue E79. Interestingly, in several structures of KEAP1 bound by small molecule 
ligands, the side chain of R415 adopts a third conformation in which the guanidine group 
points directly out towards solvent (Figure 3.6). The movement of the R415 side chain 
appears quite facile; the guanidine moiety does not appear to engage in any specific polar 
interactions with other residues on KEAP1, and all three orientations can be seen in 
structures obtained by soaking ligands into unbound KEAP1. The positions of other 
residues at the KEAP1 binding site are essentially identical across the different crystal 
structures. 
 
 
Figure 3.6 Examples illustrating the flexibility of Arg415, named as “Up”, “Side” and “Down”. (A) Ensemble 
of three major poses of Arg415. The arginine side chains are shown as sticks in our unbound (blue), our Nrf2 
peptide-bound (wheat) and a small molecule inhibitor-bound (yellow) crystal structure (PDB 4IQK). Nrf2 
peptide is shown as cartoon with side chain as sticks (white) and the small molecule inhibitor is shown as 
sticks (yellow). Comparison of unbound pose to (B) peptide bound and (C) small molecule bound poses. We 
term the side chain conformation of Arg415 in the unbound KEAP1 as “Down”, the pose in peptide bound 
KEAP1 as “Side” and the one induced by small molecule as “Up”. 
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 Comparing the FTMap results for the unbound and peptide-bound KEAP1 
structures indicates that movement of the R415 side chain from its basal position into a 
position that allows interaction with Nrf2 residue E79 causes the location of hot spot B to 
shift slightly, as R415 occupies part of its original volume, and also causes a small shift in 
the location of hot spot C. Perhaps more importantly, this movement of R415 opens access 
to the very strong hot spot A, which in unbound KEAP1 is almost entirely occluded. In the 
third conformation observed for R415, access to hot spot A is even more open. These 
observations suggest that the conformation of R415 has a major impact on which 
components of the KEAP1 hot spot ensemble are accessible to ligands. 
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3.4 Discussion 
3.4.1 Comparison of alanine scanning with FTMap 
Interpreting a result of alanine scanning mutagenesis in terms of binding energy hot 
spots requires the assumption that the mutation affects interaction affinity exclusively by 
eliminating stabilizing interactions involving side-chain atoms of the substituted residue. 
43,44,209,210 Under this assumption, the interaction energy contributed by a given side chain 
can be equated to the difference in binding energy between the wild-type and mutant 
proteins, ΔΔG = -RTln(KDWT/KDmut). However, it is well recognized that sometimes 
mutating an interface residue to alanine can also have indirect effects, for example by 
altering the conformation or mobility of neighboring residues, leading to longer range 
perturbation of the interface structure.199,210 Unless significant longer-range effects of this 
type can be ruled out, interpreting the derived ΔΔG values in terms of the strengths and 
locations of binding energy hot spots can be problematic. Mutating a residue to alanine 
most likely to have only local effects if the side chain of the residue is highly solvent 
exposed, with only limited interactions with neighboring residues on the same protein, 
thereby reducing the likelihood that eliminating the side-chain atoms beyond Cβ will 
disrupt the surrounding protein structure.  
Comparing alanine scanning results with the locations of binding energy hot spots 
determined by FTMap provides insight into which alanine scanning results can likely be 
interpreted primarily in terms of lost binding interactions and which are due to other 
factors.176 To do this we calculated the overlap of the six mutated side chains with the 
FTMap hot spots (Table 3.4). The results confirm that the side-chain atoms of E79 and E82 
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overlap with the two major hot spots, B and C, on KEAP1 (Figure 3.5 C). This result was 
robust to whether we used unbound KEAP1 for the FTMap analysis, or the KEAP1/Nrf2 
complex structure with the Nrf2 peptide atoms removed, and is consistent with the large 
loss in binding energy observed when E79 or E82 is mutated to alanine. The hot spot 
overlap is substantially greater for E82, consistent with the observation that the loss of 
binding energy observed upon mutating this residue (ΔΔG = 4.3 kcal/mol) is significantly 
larger than the 2.9 kcal/mol seen upon mutating E79. The side chains of E78 and F83 also 
reside within the KEAP1 binding site, but make only limited direct contact with KEAP1 
(ΔASA < 40 Å2), and neither overlaps with any FTMap hot spot. Mutation of each of these 
residues to alanine caused negligible loss of binding energy (< 0.5 kcal/mol). The results 
for all four of these residues therefore show good agreement between alanine scanning and 
FTMap in their descriptions of the hot spot ensemble on KEAP1. 
 
Table 3.4 Extent of overlap with FTMap hot spots, for each residue in the Nrf2 binding motif 
Nrf2 Residue 
Overlap with FTMap Clusters 
(Probe atoms within 2 Å of specified side-chain atom) 
Atom 11 Atom 21 Total2 
L76 Cγ, 0 - 0 
D77 Oδ1, 92 Oδ2, 74 166 
E78 Oγ1, 0 Oγ2, 0 0 
E79 Oγ1, 6514 Oγ2, 3212 9726 
T80 Oγ1, 1453 Cδ1, 1207 2660 
G81 n/a n/a n/a 
E82 Oγ1, 1272 Oγ2, 6536 7808 
F83 Cγ, 0 Cζ, 0 0 
1Specific side-chain atoms that were used to calculate overlap with FTMap hot spots. 2Overlap with FTMap 
hot spots, summed for all side-chain atoms that were evaluated. 
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Interpreting the results for D77 and T80 is more complicated. D77 makes very little 
direct contact with KEAP1 (ΔASA = 16 Å2), and has no significant overlap with any 
FTMap hot spot, and yet its mutation to alanine caused a ~400-fold reduction in binding 
affinity (ΔΔG = 3.5 kcal/mol). This result can therefore be considered as an alanine 
scanning “false positive” outcome, in that the substantial reduction in binding affinity 
observed upon mutation to alanine is not primarily due the loss of stabilizing contacts 
between atoms of the D77 side chain and KEAP1, and therefore does not identify a hot 
spot. Instead, the carboxylate group of D77 engages in an intramolecular charged-neutral 
hydrogen bond with the hydroxyl group of T80, which likely stabilizes the local 
conformation of the β-hairpin loop (Figure 3.4). Mutating T80 to alanine also resulted in a 
very large reduction in binding affinity. Moreover, mutating T80 to serine, rather than to 
alanine, restored approximately half of this lost affinity for KEAP1, supporting the notion 
that the D77-T80 polar interaction is critical. However, the observation that a substantial 
amount of binding energy was lost upon mutating T80 to serine, even though the hydroxyl 
group required for the polar interaction with D77 is preserved, suggests that T80 plays a 
dual role in stabilizing the Nrf2/KEAP1 complex, with a significant contribution also being 
made by the substantial overlap seen for the T80 side-chain atoms with hot spot C. As a 
result of this dual role, mutation of T80 to alanine gives, albeit by a small margin over E82, 
the single largest large loss in binding affinity for any Nrf2 residue. Interestingly, the 
conformational change of R415 between unbound and peptide-bound KEAP1 not only 
brings the R415 side chain into a position where it can form a salt bridge with E79, but also 
shifts the locations of hot spots B and C to achieve substantially greater overlap with the 
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side-chain methyl group of T80 (Figure 3.7). Thus, there is a significant element of induced 
fit in the binding of Nrf2 to KEAP1, mediated by the movement of R415. 
 
 
Figure 3.7 The movement of R415 upon Nrf2 binding indicates the induced fit mechanism, R415 
conformations (sticks), relative position and strength of hot spot B and C (lines) in (A) unbound KEAP1 and 
(B) Nrf2-bound KEAP1 crystal structure. Ligand binding brings the R415 side chain into a position enabling 
the formation of a salt bridge with E79, and also shifts the locations of hot spots B and C to achieve 
substantially greater overlap with the side-chain methyl group of T80. 
 
Overall, among the six Nrf2 residues we investigated by alanine scanning 
mutagenesis, two results can be categorized as “true positives”, that correctly identified hot 
spot residues in the classical sense of residues that make direct, stabilizing interactions with 
KEAP1. Two results were “true negatives”, which correctly identified residue as making 
no significantly contribution to binding (Table 3.5). One result, for D77A, can be 
considered as an alanine scanning “false positive” in that, absent structural information, 
the large ΔΔG value observed upon mutation of D77 would suggest the presence of a strong 
hot spot, but D77 does not in fact exert its effect by binding at any hot spot on KEAP1. 
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The alanine scanning result for T80 is a true positive result in a qualitative but not a 
quantitative sense, in that this residue does overlap with a hot spot, but the impact of this 
mutation is also amplified by other, indirect effects. No “false negative” results – that is, 
residues that interact at hot spots on KEAP1 but do not give a large decrease in binding 
affinity when mutated to alanine – were found. In assessing the agreement between alanine 
scanning and FTMap, it is additionally necessary to consider a fifth class of outcome, in 
which the existence of a hot spot cannot be tested by alanine mutagenesis because no ligand 
residue makes contact with the protein receptor at the site in question. An example of such 
a “null” result is provided by hot spot A, which FTMap indicates to be the strongest hot 
spot, but which lies deep in the binding site in a location that no residue of Nrf2 contacts 
(Figure 3.5). This situation could be common, as there is no reason to suppose that a natural 
ligand must exploit every hot spot available on its binding partner. 
 
Table 3.5 Category of alanine scanning mutagenesis results on Nrf2 
 ASM results FTMap results 
True Positives Glu79, Glu82 and Thr80* Hot spot B and C 
False Positives Asp 77 No probes overlap 
True Negatives Glu78 and Phe83 No probes overlap 
False Negatives / / 
Null results 
No ligand residue makes contact 
with the protein receptor at the 
site in question 
Hot spot A 
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The overall picture of Nrf2/KEAP1 binding that results from the above analysis is 
that, in spite of the high density of charged residues that comprise the DEETGE binding 
motif on Nrf2, the interaction is essentially “two-pronged”, with E79 engaging with hot 
spot B, and E82 (and to some extent T80) interacting with hot spot C. The function of the 
remainder of the motif, comprising D77, the hydroxyl group of T80, and presumably also 
G81, appears to be simply to ensure that E79 and E82 are correctly positioned for optimal 
interaction with KEAP1. 
 
3.4.2 Fragment binding hot spots 
In Chapter 2, I described the experimental fragment screening that resulted in the 
structural characterization of three fragment hits, all of which bound at the strong hot spot, 
B, on KEAP1. Previously, it has been shown that the top-ranked hot spot at a protein 
surface site dominates the free energy of binding, and that the vast majority of fragment 
hits will bind at this location.206 However, unlike the examples described in the previous 
work, the binding site on KEAP1 contains two equally strong hot spots, B and C, that are 
readily accessible for fragment binding, as well as a third one, A, that is occluded by R415 
(vide infra), shown in Figure 3.8 A. Moreover, other investigators have reported that more 
than one distinct site can be seen to bind fragment hits.221 Thus, a priori there is no clear 
reason why all three of our fragment hits should bind at hot spot B while none bound at hot 
spot C. The binding modes of the three fragment hits against KEAP1 from Astex 
Pharmaceuticals were described in Chapter 2.171 Figure 3.8 provides additional insight into 
the relationship between fragment binding and hot spot locations on KEAP1. Superposition 
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of the binding poses of these fragments on our FTMap results shows that two of them (1 
and 2) also bound at hot spot B, while the third bound at hot spot C (Figure 3.8 B). This 
result confirms that both of the strong and sterically accessible hot spots present on KEAP1 
can serve as binding sites for fragment hits. The 𝜋-stacking interaction between Astex 
fragment 2 and Y525 closely coincides with the binding mode seen for a prominent cluster 
of aromatic FTMap probes in hot spot B (Figure 3.8 D). In the cases of ZT0017 and Astex 
fragment 2, which bind at hot spot B but contain no carboxylate, this π-stacking interaction 
appears to be a main driver of binding. Thus, hot spot B is occupied in distinct ways by 
fragments with chemically diverse structures. This result is consistent with the notion that 
the binding subsites that comprise individual hot spots are relatively nonspecific in their 
binding properties. The notion that individual subsites are promiscuous reconciles the 
established findings that druggable targets are characterized by a high hit rate in 
experimental fragment screens,143 yet for most targets fragment hits tend to bind at the 
same, top-ranked hot spot.206 For four fragments, ZT0256, ZT0017, and Astex fragments 
2 and 3, R415 remained in the position seen in unbound KEAP1. However, for ZT0633 
and Astex fragment 1 different conformations of R415 are seen (Figure 3.8 C). In 
particular, fragment 1 induces a slightly different side chain conformation of R415, in 
which the guanidine group points directly out towards solvent (Figure 3.8 C). Fragment 1 
exploits the shift in R415 to extend from hot spot B to reach down towards the now 
accessible hot spot A. This finding shows that R415 is sufficiently mobile that even low 
affinity fragment hits can induce a change in its position that opens access to the strong hot 
spot A. 
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Figure 3.8 Superposition of bound fragments (sticks) with FTMap Consensus Clusters (colored lines). The 
KEAP1 protein shown (wheat) is the unbound structure (by Dr. Andrew Lynch and Dr. James Carolan, Allen 
lab, Boston University) that was used for the FTMap analysis. (A) Binding modes of the three fragment hits 
reported in this study overlaid with FTMap results. ZT0017, magenta; ZT0256 green, ZT0633, blue. (B) 
Binding modes of the three fragment hits recently reported by Astex,171 overlaid on the FTMap hot spots. 
Fragment 1, cyan; fragment 2, white; fragment 3, yellow. (C) ZT0256 and ZT0633, together with fragment 
1 reported by Astex, contain a carboxylate that mimics the interaction made by E79 of Nrf2. (D) ZT0017, 
ZT0633 and Astex fragment 2 contain dinuclear aromatic functions, that can π-stack with Y525. 
 
The relationship between FTMap, alanine scanning mutagenesis, and experimental 
fragment screening, as methods for characterizing the hot spot ensemble that exists at a 
protein surface site, is summarized in Figure 3.9. Alanine scanning identifies the subset of 
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hot spots that are exploited by the natural ligand (Figure 3.9, categories a, b, g), but is also 
susceptible to false positive results (category e) in cases where the mutation causes indirect 
structural effects. Fragment screening typically identifies only the strongest hot spot(s) in 
the ensemble, whether or not they are exploited by the natural ligand. FTMap detects both 
strong and weaker hot spots, whether or not they are exploited by the natural ligand. 
Therefore, among these methods FTMap is expected to provide the most comprehensive 
picture of the overall hot spot ensemble, with alanine scanning identifying the subset that 
is engaged by the natural ligand, and fragment screening identifying the one or two 
strongest hot spots but providing no information on the existence of other, nearby hot spots 
that may be important for strong ligand binding. 
 
 
Figure 3.9 Venn diagram illustrating the relationship between the information on the hot spot ensemble that 
is revealed by each of the complementary techniques of FTMap, alanine scanning mutagenesis (ASM), and 
fragment-based screening (FBS). The sectors of the diagram are designated as follows: (a) Strong hot spots 
that are exploited by the natural protein ligand. (b) Secondary hot spots that are exploited by the natural 
ligand. (c) Strong hot spots that are not exploited by the natural ligand. (d) Secondary hot spots that are not 
exploited by the natural ligand. (e) Alanine mutations that affect binding through indirect mechanisms. (f) 
FBS artifacts (nonexistent or rare for fragments for which experimental complex structures have been 
determined). (g) Hot spots that FTMap fails to detect (nonexistent or rare).204,215 The shaded area with red 
labels represents the true hot spot ensemble.  
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3.4.3 Conservation of Nrf2/KEAP1 Binding Energetics 
The DxETGE motif is strictly conserved across approximately 60 Nrf2 paralogs 
contained in the National Center for Biotechnology Information (NCBI) Gene database 
(Appendix VII). Among these sequences, the two residues that we identified to be 
energetically unimportant for binding, E78 and F83, are frequently replaced by Gly and 
Ser, respectively. It is also observed that the four energetically important residues on 
KEAP1 are highly conserved across 37 paralogs, including the highly mobile R415 which 
is conserved. This finding supports the notion that the detailed binding energetics of the 
Nrf2 DxETGE motif, including occupancy of hot spots B and C by Glu side chains, and 
stabilization of the hairpin loop by polar interactions involving D77 and T80, are highly 
conserved across different species encompassing a wide range of evolutionary complexity. 
In human, in addition to Nrf2, several other proteins have been identified to bind KEAP1 
through a motif resembling DxETGE (Figure 3.10). These ligands include Inhibitor of 
nuclear factor Kappa-B Kinase subunit beta (IKKβ), Partner and Localizer of BRCA2 
(PALB2), PGAM Family Member 5, Mitochondrial Serine/Threonine Protein Phosphatase 
(PGAM5) and Nucleoporin p62.222-226 In both IKKβ and PGAM5, Asp77 is replaced by 
Asn, suggesting that the charged-neutral hydrogen bonding interaction between D77 and 
T80 of Nrf2 can be substituted by a neutral-neutral hydrogen bonding pair. In PGAM5, 
T80 is replaced by a serine, in keeping with our observation that it is the hydroxyl group 
of this Thr on Nrf2, and not the methyl group, that is most important for binding. Both 
Glutamates, E79 and E82, are strictly conserved in the binding motif among these other 
KEAP1 ligands. The sole exception is p62, which contains a serine in place of E79. 
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However, phosphorylation of this Ser is required for more potent (> 30-fold) KEAP1 
binding,225,226 such that E79 has been substituted by a different anionic functionality. 
Comparison of the Nrf2 ortholog sequences therefore suggests that these other ligands 
exploit the hot spot ensemble at the KEAP1 binding sites in very similar ways to achieve 
binding, despite minor variations in the sequence of the binding motif. 
 
 
Figure 3.10 Consensus binding motif in other KEAP1 binding proteins. Several other KEAP1 substrates have 
been identified to bind KEAP1 through a motif resembling DxETGE as well. 
 
3.4.4 Druggability of KEAP1 
The FTMap analysis revealed that KEAP1 easily fulfills our extensively 
benchmarked criteria for being druggable by small molecules,213 by possessing a primary 
hot spot with ≥16 FTMap probe clusters plus at least one secondary hot spot within ≤ 8 Å 
of the main hot spot. However, the Nrf2 binding site on KEAP1 is unusual for a target site 
in drug discovery, in that the interaction is dominated by polar interactions on Nrf2 
involving charged groups. This feature is apparent from the abundance of acidic amino 
acids in the DEETGEF sequence motif that occupies the KEAP1 binding pocket. 
Moreover, our alanine scanning results show that E79 and E82 are the major contributors 
to binding, interacting at two strong hot spots. Alanine scanning further showed that F83 
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does not contribute to binding, and that the only other nonpolar feature of the motif, the 
methyl group of T80, contributes only modestly. The highly charged nature of the binding 
site thus raises questions about whether it will be truly druggable, in the sense of binding 
strongly to a drug-like small molecule that cannot contain multiple charged groups. 
 Considered overall, however, our results support the notion that KEAP1 is likely 
druggable, and provide some guidance as to how a high affinity, drug-like ligand might be 
achieved. Specifically, the alanine scanning results show that E78 makes no contribution 
to binding, and D77 and the hydroxyl group of T80 contribute only indirectly, by 
stabilizing the loop structure of the motif. In a synthetic ligand, maintaining the shape 
required to optimally complement the binding site could presumably be achieved by other 
means. Thus, much of the charged and polar functionality of the Nrf2 binding motif is, in 
principle, dispensable, without greatly affecting the interaction energy that can be gained 
at the site. Moreover, the results of the fragment screening indicate that it is not necessary 
to place a carboxylate group in hot spot B. The fragment hit ZT0017 binds at hot spot B, 
but contains no carbonyl or similar anionic substituent, and instead projects a thiocarbonyl 
towards the region of KEAP1 flanked by R415 and R483 that in the complex with Nrf2 is 
occupied by E79. Fragment 2 (2,6-dimethyl-4H-pyrano[3,4-d]oxazol-4-one), from the 
recent Astex publication,171 provides another example of an uncharged molecule that 
occupies hot spot B. These fragments instead stack against Y525, and make additional 
polar contacts with Q530 and S555. In the complexes with these two fragments, the 
hydrogen bond donor groups of R415 and R483 are satisfied by solvent water. That is not 
to say that the binding of these fragments might not be improved if they were modified to 
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extend polar groups to engage with R415 and/or R483. But the identification of these 
fragments indicates that occupancy of the crucial hot spot B does not require a charged 
group be placed in this position, and that a dinuclear aromatic moiety that stacks against 
Y525 and that projects an uncharged hydrogen bond acceptor, such as a tetrazole, towards 
R415/R483 might effectively complement this key binding subsite. Indeed, a synthetic 
ligand for KEAP1 has been described that does exactly this.170 Similarly, the binding pose 
of Astex fragment 3, benzenesulfonamide, shows that the site that in the complex with Nrf2 
is occupied by E82 can be satisfied by an uncharged hydrogen bond acceptor such as a 
sulfonamide, and this conclusion too is supported by binding modes observed for published 
synthetic ligands for KEAP1.171 
 Most importantly, the FTMap analysis revealed the presence of a strong hot spot, 
A, that is not exploited at all by the natural ligand, and therefore provides an opportunity 
for a synthetic ligand to attain additional binding energy beyond that achieved by ligands 
that mimic the DxETGE motif of Nrf2. Despite its strength, this hot spot was not identified 
by alanine scanning mutagenesis because no portion of the natural ligand projects into it, 
and did not constitute the primary binding site for fragment hits presumably because access 
to this subsite is blocked by the side chain of R415 in the unbound protein. Thus, the first 
clear evidence for the existence of this hot spot was from FTMap. However, strong 
evidence that hot spot A is real is provided by the binding modes observed for small 
molecule inhibitors of KEAP1 that have been reported in the literature, several of which 
derive substantial binding energy by positioning an aromatic moiety in or close to this 
strong hot spot (Figure 3.11).170 Overall, therefore, the alanine scanning, FTMap and 
  
120 
fragment screening results support the idea that, despite the highly charged nature of the 
binding motif on Nrf2, the binding site on KEAP1 can be well complemented by a suitably 
designed neutral ligand. 
 
 
Figure 3.11 Example of developed small molecule inhibitor approaching hot spot A by positioning an 
aromatic moiety in or close to this strong hot spot. KEAP1 shown as wheat surface, compound shown as 
sticks (yellow), FTMap hot spots shown as lines. 
 
3.4.5 Conclusions and future directions 
In this chapter, I investigated the structure of the hot spot ensemble at the 
KEAP1/Nrf2 binding interface using three complementary methods: alanine scanning 
mutagenesis, fragment screening, and in silico probe mapping using the FTMap algorithm. 
Mapping the apo and ligand bound KEAP1 structure both identified four main 
binding energy hot spots at the binding site with subtle deviations in the relative strengths, 
among which two major hot spots, B and C, overlap with side-chain atoms of key residues 
identified by alanine scan (E79 and E82, respectively). FTMap also discovered two novel 
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binding hot spots, A and D, that are not exploited by the natural ligand Nrf2, yet can be 
utilized in small molecule inhibitor designs to gain additional binding energies. Comparing 
the FTMap hot spots with reported fragment hits, both from our study and others’, we 
obtained further insight into the lead design against the KEAP1/Nrf2 interaction. The 
results suggested that key features of such a compound should be (i) occupancy of hot spot 
B with an aromatic moiety that engages in a p-stacking interaction with Y525, plus a 
hydrogen bond acceptor to interact with R415 and R483 and likely additional polar 
interactions with some or all of S508, S555 and Q530; (ii) penetration deep into the binding 
site to position a largely hydrophobic moiety into hot spot A; (iii) occupancy of hot spot C 
by functionality that contains a neutral hydrogen bond acceptor; and (iv) a conformational 
constraint, such as a macrocyclic structure, that fulfils the role of the D77/T80 interaction 
in Nrf2 by stabilizing the compound in a conformation that is complementary to the shape 
of the KEAP1 binding pocket. In using structure-based computational techniques to aid 
inhibitor design, it is crucial to properly consider the orientation of Arg415, taking into 
account the fact that access to hot spot A is not available for the conformation of this 
residue that is seen in structures of unbound KEAP1. The results additionally show how 
the three complementary methods for probing the structure of the hot spot ensemble at a 
PPI binding interface, alanine scanning mutagenesis, FTMap, and fragment screening, can 
together provide a detailed understanding of the druggability of the site. In particular, I 
conclude that FTMap can identify hot spots that are not found by either of the two 
experimental approaches, but that can provide critical information for fully exploiting the 
binding potential of the site towards synthetic ligands. Future directions include: probing 
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the hot spot ensembles and evaluating druggability on other PPI targets using the guideline 
developed in this study; incorporation our knowledge of the druggability of KEAP1 in the 
further inhibitor development following the four major points described above. 
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CHAPTER FOUR. Additivity of Mutational Effects 
4.1 Introduction 
 In the previous chapter, I discussed the results of alanine scanning mutagenesis 
(ASM) on Nrf2. In this chapter, I describe my efforts on the systematic examination of the 
binding energetics at the KEAP1 binding interface by ASM. The effect of each mutation 
on the stability of the KEAP1/Nrf2 binary complex allows us to evaluate the contribution 
of each residue to the overall binding energy. On the basis of these results, I further study 
the additivity of the mutational effect; namely, how the energetic outcome of two 
concurrent mutations compares to the sum of those of the respective single mutations. 
Through the analysis of those pairs of double mutant, I discuss the structural basis of the 
additive or non-additive behavior, and propose a general framework to understand and 
interpret the binding energetics at the interface of protein-protein complexes using the 
combination of mutations. 
 
4.1.1 Mutational analysis on KEAP1 
 KEAP1 functions as an adaptor protein for the binding of its substrates to the E3 
ubiquitin ligase complexes,119,126,127,217,219,222-227 and is essential for the proper regulation 
of Nrf2 and other signaling pathways. Multiple disease-related mutations of KEAP1 have 
been reported and the detailed mutation-induced biological outcomes have been 
investigated.137,216,227 However, the majority of mutational analyses were conducted by 
evaluating the biological outcomes of the mutations in a cellular context, and usually 
provided only qualitative understanding on whether or not a certain residue or a segment 
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is essential for binding. For instance, in one of the earliest efforts made by Lo et al., an 
extensive alanine scanning mutagenesis of KEAP1 was performed in cells to determine the 
contribution of specific amino acids in KEAP1 to its binding to Nrf2. The authors evaluated 
the binding ability of KEAP1 mutants by co-immunoprecipitation and determined their 
functions of repressing Nrf2 signaling by an ARE-dependent luciferase reporter gene 
assay.137 This study resulted in the successful identification of a subset of residues on 
KEAP1 that were involved in Nrf2 binding. However, such qualitative information about 
the effect of mutations in KEAP1 on its interaction with Nrf2 couldn’t provide detailed 
understanding of the origin of binding energetics at this interface. Choy and coworkers 
studied the somatic mutations in KEAP1 from a biochemistry perspective. By using protein 
Nuclear Magnetic Resonance (NMR) and isothermal titration calorimetry (ITC), they 
successfully elucidated the molecular effects of cancer-associated somatic mutations of 
KEAP1 on its structural integrity and target recognition properties.216 Their findings 
suggested that most of the somatic mutations of the Kelch repeat domain locate inside the 
hydrophobic core of the β-propeller structure and result in partial unfolding of KEAP1, 
weakening of its binding to Nrf2. While unraveling the biological effects of disease-related 
mutations on KEAP1 is crucial, there is still a lack of detailed quantitative understanding 
of the KEAP1/Nrf2 binding interaction. In this chapter, I discuss our efforts to address this 
question.  
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4.1.2 Additivity in biochemistry 
According to thermodynamics, any interactions or reactions between atoms or 
molecules involve change in free energies. For example, in a chemical reaction, the 
difference in the stability of the initial state and  final state defines the change in free energy 
of this process, independent of other factors such as temperature or solvation.228,229 This 
principle can also be applied to most cases of non-covalent protein-protein interactions. If 
we interrogate the protein binding energetics using mutations, the sum of the binding free 
energy changes derived from the single mutations is relatively equivalent to the free energy 
change measured in the higher-order mutations. Exceptions occur under conditions where 
the mutated residues interact with each other, either through direct contact or indirect 
mechanisms, e.g. electrostatic interactions or structural perturbations. As a result, such 
simple additivity is violated.230  
 
4.1.3 Double-mutant cycles 
Scientists have investigated the principle of additivity in biochemistry using 
multiple strategies. One of the most widely employed approaches is double-mutant cycle 
analysis.230-242 Alan Fersht and coworkers evaluated the structure and function of Tyrosyl-
tRNA synthetase by simultaneously mutating two active site residues and comparing the 
outcomes to the energetic effects of the individual mutants.241 In a double-mutant cycle the 
wild-type protein could be converted to the double mutant via two paths, depending on 
which residue was mutated first (Scheme 4.1). 
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Scheme 4.1 Scheme for a double-mutant cycle on a single protein (adapted from Fersht et al.).210,235,241 WT 
represents a wild-type protein, mut A and mut B represent the single mutants with residue A and B being 
mutated, respectively. The cycle comprises wild-type protein (WT), two single mutants (mut A and mut B) 
and the corresponding double mutant (mut AB). ΔG(A), ΔG(A’), ΔG(B), and ΔG(B’) are the measured free 
energy differences between two thermodynamic states. 
 
In this analysis, they described two distinct situations: 
(1) Simple additive, shown in Eq. 4.1. The free energy of substrate binding of two 
residues could be fully additive when the two sites are independent, that is: the 
presence or absence of mutation A does not affect the outcome of mutation B, and 
vise versa. They concluded that such additive effect can be observed when the 
active site is rigid and mutations of the two residues do not induce structural 
changes.235,241 
 
ΔΔG(A) = ΔΔG(A’)  and  ΔΔG(B) = ΔΔG(B’) 
ΔΔG(AB) = ΔΔG(A) + ΔΔG(B)    Eq. 4.1 
 
(2) Non-additive, shown in Eq. 4.2 and Eq. 4.3. The free energy of substrate binding 
of two residues could be non-additive when either mutation induces extensive 
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structural perturbation. The changes in the binding energy of one mutation could 
vary depending on the presence or absence of the other mutation. 
 
ΔΔG(A) ≠ ΔΔG(A’)  and  ΔΔG(B) ≠ ΔΔG(B’) 
ΔGI(A, B) = ΔΔG(A) – ΔΔG(A’)= ΔΔG(B) – ΔΔG(B’)  Eq. 4.2 
ΔGI(A, B) = ΔΔG(A) + ΔΔG(B) - ΔΔG(AB)   Eq. 4.3 
 
In Eq. 4.2, ΔGI(A, B) measures the energy difference between the double mutant and 
the sum of the two single mutants. The authors defined this term as the coupling energy 
between the two mutations, A and B. A non-zero coupling energy indicates that two 
residues may either directly interact with each other in the folded wild-type protein 
structure, or indirectly affect each other through long distance. For instance, mutation of A 
can create a conformational change that can be propagated to B via neighboring residues 
or backbone distortion.240 Thus, if the presence or absence of one residue alters the binding 
of another residue at a second site for better or worse, then there exists a non-zero coupling 
energy between the two. 
The coupling energy introduced by Fersht et al. provides a quantitative approach to 
distinguishing the additive/non-additive effects of the combination of mutations on PPI 
targets. 
 
  
128 
4.1.4 Rationale of additivity and non-additivity 
From the large data base of mutagenesis studies on proteins and enzymes, additivity 
still holds true for the majority of the cases.230 Exceptions occur when two residues on the 
same protein directly interact with each other, or indirectly affect each other via structural 
perturbations or long-range electrostatic interactions, or functional cooperatively (e.g. in a 
catalytic triad).230 In those cases, the changes in binding free energy of the double mutant 
no longer equal the sum of changes in binding free energy in the single mutants,230 leading 
to a non-zero coupling energy.241 In analysis study by Lydia Gregoret and Robert Sauer,242 
the authors developed a binomial mutagenesis strategy to evaluate the additivity of residues 
on the N-terminal domain of λ repressor. By randomly mutating 11 residues to alanine and 
analyzing the mutant activity, they observed that the majority of the paired residues that 
exhibited energetic additivity were making no direct contact in the crystal structure. For 
the three non-additive pairs, the side-chain atoms were within van der Waals contact 
distances. Therefore, they rationalized that non-additive effects stemmed from the direct 
physical contacts between the two residues in question. Ken Dill also concluded that non-
additivity corrections are required owing to the non-uniformity of the neighboring 
environment of the mutation sites.229  
 
4.1.5 Application of double-mutant cycles with two mutations on two protein-protein 
binding partners 
Our current understanding of the effects of combinations of mutations is still 
incomplete. As mentioned above, the effects of double mutations on a given protein have 
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been described extensively using “double-mutant cycles” in 1980s and 1990s. Recently, 
the scope of this analysis has been extended to the study of combinations of mutations at 
the interface of two interacting proteins.237,239,243,244 In the analysis of Barnase-Barstar 
interface, Fersht et al., concluded that residues separated by less than 7 Å generally interact 
co-operatively, i.e. the mutational effect on the binding energy is non-additive; meanwhile, 
the additivity is usually observed for distant mutations on a binding interface that is inferred 
to be rigid (i.e. neither mutation induces significant conformational change at the binding 
interface).230,239,241,245 By evaluating the effect of pairwise mutations on α-Neurotoxins and 
their receptors, Taylor and coworkers also concluded that an additive effect could only 
being observed, when there was no structural change induced by either mutation.237  
Schreiber et al., have extended the understanding of this coupling effect by constructing a 
clustering map of the residues at the protein-protein interaction interfaces.243,244 Clustering 
of residues was based on their interactions defined by using the CSU software package.246 
In brief, two atoms that fall within a predefined threshold in distance and comprise suitable 
biochemical compositions were considered as interacting in the CSU program. From there, 
two residues were defined as interacting if their atoms were interacting. They demonstrated 
that a protein-protein interface was built in a modular architecture, and showed that 
mutating two residues within the same cluster, no matter if they were on the same protein 
or not, would likely result in non-additivity; whereas mutating two residues located in 
different clusters would lead to additivity. Based on the clustering map they constructed, 
the authors validated that residues within the same cluster were closely interconnected, 
forming an elaborate network of interactions, while very little interplay between residues 
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from different clusters were observed. They concluded that the higher organization of the 
binding sites served as a major driving force for binding. 
 
4.1.6 Aims 
Site-directed mutagenesis has been used for years to investigate the molecular 
details of protein-substrate recognition and protein-protein interactions.44,176,199,209,247 
Specifically, alanine scanning mutagenesis has been broadly applied to mapping the 
binding epitopes on PPI interfaces, facilitating the rational inhibitor design.44,209 Indeed, 
this is a robust and rapid method for mapping the origin of binding energetics, and 
complemented by current structural biology efforts, such as X-ray crystallography, 
provides molecular details of the protein-protein interfaces. However, there still remains a 
major fundamental question of how the residues at the recognition interface are connected 
to each other. Decades of efforts have already been made to understand the cooperativity 
effect among residues, including introducing the concept of coupling energy,236,239-241 and 
demonstrating that residues at protein-protein interfaces are interconnected in a modular 
architecture.243 However, in most of the cases, when scientists investigate the combination 
of mutations, they tend to only interpret the outcome in a binary manner – whether they 
are additive or not. Besides, when a non-additive outcome is observed, it is usually 
interpreted only to the extent of being associated with an unspecified conformational effect. 
A notable exception is the work of Schreiber and coworkers who were able to provide a 
more systematic macroscopic explanation for the observed additivity effect by categorizing 
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the residues at protein-protein interface into several interconnected clusters. Yet a more 
detailed understanding from a microscopic perspective is required.243,244 
In the previous chapter, I described the effect of systematic mutations of Nrf2 on 
its binding to KEAP1. In this chapter, I focus on the analysis of the effects of mutations in 
KEAP1, on both protein function and protein structure. The ultimate goal of this analysis 
is to construct a comprehensive map of the interaction energetics at the KEAP1/Nrf2 
interface. 
I also describe a methodology to quantitatively categorize the mutational additivity 
and non-additivity, using KEAP1/Nrf2 protein-protein interaction as an exemplary model. 
Furthermore, I extensively discuss the structural basis for the mutational additive/non-
additive effect. In doing so, our aim unravels in two folds – (i) we hope to gain quantitative 
understanding of the binding energetics at KEAP1/Nrf2 interface; (ii) we hope to use the 
information as guidelines to construct a general framework of how to understand and 
interpret the effects of combination of mutations. 
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4.2 Materials and Methods 
4.2.1 Site-directed mutagenesis on KEAP1 
All site-directed mutagenesis in bacterial expression plasmids for KEAP1 were 
generated by following a 2-round PCR procedure to improve the success in codon change 
using the wild-type KEAP1 Kelch repeat domain (312-624) construct as the template. A 
similar protocol was described in Chapter 3. In the first round of reaction, depending on 
the location of the desired mutagenesis, two strategies were used for primer design: (1) if 
the mutation site is closer to the 5’ end, a forward primer encompassing the mutation and 
an universal T7 reverse primer were designed; (2) if the mutation needs to happen towards 
the 3’ end of the DNA template, a T7 promoter forward primer and a reverse primer 
encompassing the mutation were designed. The paired primers were used to create a mega-
primer containing the mutation using the following the condition: 98 ̊C for 30 s, 35 cycles 
of 98 ̊C for 10 s, 60 ̊C for 30 s, 72 ̊C for 30 s, followed by 72 ̊C for 2 min for final extension 
at the completion of the cycles, and then kept at 4 ̊C until the run was manually stopped. 
Components of PCRs were as described above. The products of the first round PCR 
reaction were then purified and used as mega-primers for the second round of reaction, 
under a slight different condition: 98 ̊C for 30 s, 35 cycles of 98 ̊C for 10 s, 72 ̊C for 4 min, 
followed by 72 ̊C for 2 min for final extension at the completion of the cycles, and then 
4 ̊C until the run was manually stopped. After PCR, the products were purified, then 1 µL 
of DpnI was added and the samples were incubated at 37 ̊C for 1 h. A volume of 2 µL 
reaction was then transformed into DH5α competent cells. Plasmids with the successful 
mutagenesis were selected and confirmed by sequencing as described above. 
  
133 
4.2.2 Protein expression and purification 
All the wild-type and mutant KEAP1 constructs were expressed and purified as 
described in the previous chapter (Chapter 2). In brief, large scale protein expression was 
carried out using BL21(DE3) Competent E.coli cells (New England Biolabs, Ipswich, 
MA). Cells were grown in the presence of Ampicillin (100 µg/mL) until the OD600 reached 
0.4 - 0.6, then induced by 1 mM isopropyl-beta-D-thiogalactoside (IPTG, GoldBio, St. 
Louis, MO) and expressed at 20 ̊C overnight with shaking (200 rpm). Cells were pelleted 
by centrifugation and stored at -80  ̊C before purification. 
KEAP1 variants were all purified following the protocol described in Chapter 2. In 
brief, protein constructs with an N-terminal His6-TEV tag were purified using a volume of 
2 mL HisPur Ni-NTA resin, followed TEV proteolysis reaction overnight at 4 ̊C to remove 
the His6 tag. Reaction mixtures were then applied to the 2 mL Ni-NTA resin again to 
separate the untagged proteins from the Histidine tag and the TEV site. The cleaved 
proteins were then purified by gel filtration using HiPrep 26/60 Sephacryl S-300 column 
(GE Healthcare, Sunnyvale, CA) to obtain the monomeric homogenous species. Purified 
proteins were then concentrated and quantified using the absorbance at 280 nm (NanoDrop, 
Thermo Fisher Scientific, Waltham, MA), aliquoted, flash-frozen and stored at -80 ̊C for 
future use. 
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4.2.3 KEAP1 mutants characterization by SDS-PAGE, analytical gel filtration 
chromatography and mass spectrometry 
All the KEAP1 variants were characterized using sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis (SDS-PAGE). In brief, 5 µM of wild-type KEAP1 or 
mutants were incubated with SDS sample buffer in the presence of 0 mM, 10 mM or 100 
mM DTT with boiling for 5 min before being loaded on to the 10% Tris-tricine gel. 
The homogeneity of KEAP1 variants were determined using analytical gel 
filtration. A sample of wild-type or mutant KEAP1 was purified using the standard protocol 
described above. Instead of loading on to the Sephacryl S-300 protein-preparation column 
after 2-step of Ni-NTA purification, an aliquot of each variant was loaded directly onto the 
Superose 6 10/30 GL analytical gel filtration column. Proteins were eluted over 2.0 column 
volumes (CV) at a flow rate of 0.4 mL/min in storage buffer (25 mM Tris, 2.5 mM DTT, 
pH 8.0). Protein elution was monitored using the absorbance at 280 nm. Superose 6 10/30 
GL analytical gel filtration column was calibrated in the 20 mM sodium phosphate, 150 
mM NaCl, pH 7.4, using the following standard proteins to construct a standard curve: 
Blue Dextran (2000 kDa), Albumin (66 kDa), Ovalbumin (45 kDa), Carbonic Anhydrase 
(29 kDa) and Myoglobin (17.3 kDa). 
To confirm the identity of each KEAP1 mutants, all the proteins were characterized 
using liquid chromatography-mass spectrometry (LC-MS). An aliquot of each purified 
KEAP1 construct at 40 µM was desalted into water using Zeba™ Spin Desalting Columns 
(7K MWCO, 0.5 mL, Thermo Fisher Scientific) following the manufacturer’s protocol. 
Desalted protein was then quantified using absorbance at 280 nm (NanoDrop, Thermo 
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Fisher Scientific) and diluted to 4 µM in water. Protein samples were loaded onto a reverse-
phase Atlantis dC18 HPLC column (100 Å, 3 µM, 2.1× 30 mm, Waters, Milford, MA)  
using a binary solvent system of water/acetonitrile with 0.1% formic acid, within a gradient 
from 90% water to 10% water, before being directed into the mass spectrometry (Waters 
qTOF Premier LCMS, Milford, MA). Data were acquired by use of MassLynx Mass 
Spectrometry Software (Waters, Milford, MA).  
 
4.2.4 Characterization by circular dichroism 
 CD spectra of wild-type KEAP1 and mutants were measured using an Applied 
Photophysics CS/2 Chirascan instrument with a 1 mm path length quartz cuvette at a scan 
speed of 0.5 nm/s. The CD spectra were collected at 5 µM of KEAP1 variants in 25 mM 
Tris, 2.5 mM DTT buffer, pH 8.0, at 20 ̊C from 180 to 260 nm. The buffer background was 
subtracted. The measured ellipticity in millidegrees (θ) was normalized to mean residue 
ellipticity (θMRE) using the following equation: 
 
θ#$% = θ10Cnl 
 
where C is the molar concentration of protein, l is the length path in centimeters and n is 
the number of residues.  
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4.2.5 KEAP1 mutants binding assay 
  The FA binding assays of KEAP1 variants were carried out as described in the 
previous chapters (Chapter 2). In brief, a volume of 200 µL binding assay contained four 
components: 50 µL of water, 50 µL of 4X assay buffer (final concentration 50 mM HEPES, 
150 mM NaCl, 0.01% v/v Triton, 2.5 mM DTT, pH 7.4), 50 µL of FITC-labeled tracer 
Nrf2 peptide at 20 nM, to give a final constant concentration at 5 nM, and 50 µL of KEAP1 
proteins at varying concentrations. The assay mixtures were incubated at 25 ̊C for 30 min, 
which control experiments showed was sufficient time to reach equilibrium, prior to 
fluorescence anisotropy reading. Anisotropy and KD values were calculated as described 
above. 
The evaluation of KEAP1/Nrf2 double mutant binding was carried out using the 
competition FA assay. In the competition assay, FITC-Nrf2 peptide was kept at 5 nM and 
KEAP1 variants were kept at the concentration of their KD, which were determined from 
the direct binding assay. The unlabeled wild-type and mutant Nrf2 proteins were then 
added into each well by two-fold serial dilutions. Data analysis was conducted using the 
competitive binding model in DYNAFIT 4, as described in previous chapters. Due to the 
weak binding activity between certain pairs of mutants, the unlabeled Nrf2 variants 
(competitor) were added up to a concentration of 50 µM. Higher protein concentrations 
were avoided in FA assays to eliminate the artifacts caused by increased viscosity. Error 
bars were calculated to show the range of duplicate measurements. Each pair of double 
mutants were tested in at least three independent experiments. 
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4.2.6 Thermal denaturation analysis of mutational effect on protein stability 
ThermoFluor experiments were performed using a Realplex EP Mastercycler RT 
PCR instrument (Eppendorf) in a 96-well PCR plate format. A total assay volume of 20 
µL contains 10 µM of KEAP1 variants and Sypro Orange dye (25X, Thermo Fisher 
Scientific) in storage buffer (25 mM Tris, 2.5 mM DTT, pH 8.0). The plate was then sealed 
with clear seal film to prevent evaporation. The assay mixtures were incubated at 20 ̊C until 
reaching temperature stabilization. Results were collected by monitoring the fluorescence 
at 520 nm as the temperature ramped up to 90 ̊C at a rate of 1 ̊C/min. The Tm values were 
derived from the first derivative of the melting curve using Realplex software version 2.2. 
 
4.2.7 Chemical denaturation analysis of mutational effect on protein stability 
 Chemical denaturation experiments of wild-type KEAP1 and R380A mutant were 
carried out using the intrinsic tryptophan fluorescence (excitation at 280 nm, emission at 
336 nm) in a 96-well plate format. A total assay volume of 100 µL contains 4 µM KEAP1 
variants in assay buffer (20 mM HEPES, 150 mM NaCl, 100 mM DTT, pH 7.5) was 
incubated with varying concentration of urea at 25 ̊C, ranging from 0 M to 7.2 M with 0.5 
M increments. Readings were taken using a SpectraMax M5 microtiter plate reader 
(Molecular Devices, Sunnyvale, CA) at different time points (1, 2, 4, 6 and 12 hours) to 
confirm the completion of denaturation. The final results were reported using normalized 
fluorescence readout at 6 h as a function of urea concentration, by comparing to the 
maximal signal at 0 M (native) and minimal signal at 7.2 M (fully denatured) to calculate 
the percent unfolding. The value of [urea]50 represents the concentration of urea that is 
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required to unfold half of the protein, as a means to report the stability of the specific 
protein construct. Due to the fact that, this unfolding process by urea is irreversible, ΔΔG 
values of unfolding cannot be predicted using this set of data. 
 
Percent	unfolding = signal − minmax − min 	×100% 
4.2.8 Hydrogen/deuterium exchange by mass spectrometry 
 The Hydrogen/deuterium exchange (HDX) experiments by mass spectrometry 
were conducted by Peilu Liu in Prof. Alan Marshall’s lab at Department of Chemistry, 
Florida State University. Experimental details are adapted as follows: 
Stock solution of 40 µM wild-type KEAP1 and 40 µM wild-type KEAP1/Nrf2 
9mer (Ac-LDEETGEFL-NH2) complex were prepared in 150 mM NaCl and 20 mM 
HEPES, and 2.5 mM TCEP buffer (pH 8.0). HDX experiments were automated with an 
HTC Pal autosampler (Eksigent Technologies, Dublin, CA). 5 µL of each sample was 
mixed with 45 µL of D2O (deuterium oxide, heavy water) buffer to initiate 
hydrogen/deuterium exchange. HDX incubation periods were 0.5, 1, 4, 15, 30, 60, and 480 
min.  For the control experiment, the initial dilution was made in H2O buffer without D2O 
exposure. HDX reaction was performed in triplicate on cold microplate (MéCour 
Temperature Control, Groveland, MA) to reduce back-exchange. After incubation, each 
sample was quickly quenched by mixing with 25 µL of 8M urea and 200 mM TCEP in 1 
% formic acid solution. Then, sample was digested by 25 µL of a 2.5 fold dilution of 
  
139 
saturated protease XIII solution in 0.1% formic acid for 3 min at 0.4 ̊C. Each HDX assay 
was monitored by on-line LC-MS.   
On-line LC FT-ICR MS. After proteolysis, peptides were desalted and separated 
on a Pro-Zap MS C18 column (Dr. Maisch Gmbh, Ammerbuch-Entringen, Germany) with 
Jasco liquid chromatography (Jasco, Easton, MD). The LC eluent was directed to a custom-
built Velso Pro (Thermo Scientific, San Jose, CA) 21 T FT-ICR mass spectrometer. Mass 
spectra were collected from 400 < m/z < 1300 at high mass resolving power (m/∆m50% = 
200,000 at m/z 400, in which ∆m50% is mass spectral peak full width at half-maximum 
peak height). Data was acquired by use of Xcalibur (Thermo Scientific, San Jose, CA) and 
analyzed by a custom analysis package. The average relative deuterium uptake difference 
(ARDD) between free and complexed protein was calculated by the following equation: 
 
ARDD= q rs ;t	(rs)t(rs)s  
 
A is the deuterium uptake for wild-type KEAP1-Nrf2 9mer complex at a specific time (ti) 
and B is the deuterium uptake for wild-type KEAP1 at a specific time (ti). 
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4.3 Results 
4.3.1 Initial design of KEAP1 mutants 
To investigate the binding energetics at the KEAP1 binding interface, a careful 
visual examination of the Kelch repeat domain of KEAP1 was carried out using a reported 
Nrf2-bound KEAP1 crystal structure (PDB 4IFL) in PyMOL. Initially, a defined cutoff of 
4 Å from the DxETGE motif on Nrf2 was applied to objectively search for residues on 
KEAP1 suitable for alanine scanning mutagenesis, which resulted in the identification of 
11 amino acid located in the KEAP1 binding site. Among those, from a visual inspection, 
a subset that were solvent-accessible and likely to make direct physical contact with Nrf2 
DxETGE peptide were selected for the alanine scanning mutagenesis, while a few residues 
that were mostly buried from the solvent and might function through maintaining the 
internal architecture of the protein were marked to be avoided in the alanine scan. Mutation 
of the latter could perturb the protein binding through destabilizing the protein folding, 
which would not reflect the true binding energetics at the interaction interface. A list of 
residues that were selected or avoided in the alanine scanning mutagenesis of KEAP1 is 
shown in Table 4.1. Figure 4.1 illustrates the locations of those chosen residues in the 
KEAP1 Kelch repeat domain. 
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Table 4.1 Eleven residues on KEAP1 within 4 Å from DxETGE motif on Nrf2 
Category KEAP1 residues Selected for ASM? 
Solvent exposed R380, R415, R483, Q530 Yes 
Partially exposed N382, S508, S555, S602 Yes 
Mostly buried I416, L484, N381 No 
 
 
 
Figure 4.1 KEAP1 residues selected for alanine scanning mutagenesis. The side chains of selected residues 
are shown in spheres, color coded as: solvent exposed residues in orange, partially solvent exposed residues 
in yellow, and buried residues in pink. Only residues that are fully or partially solvent exposed are mutated 
and examined in the binding assays. (A) top-down view, (B) side view. 
 
4.3.2 Preparation and characterization of KEAP1 mutants 
We first applied the alanine scanning mutagenesis on the KEAP1 binding site, and 
generated seven single mutants. S602A, one of the residues selected in the initial alanine 
scan design, was dropped due to the lack of success in cloning it. Wild-type KEAP1 (312-
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624) was used as template to generate all alanine mutants by site-directed mutagenesis for 
the subsequent studies. All the constructs were subcloned into a pET15b vector for 
bacterial expression, which appends an N-terminal His6 tag followed by a tobacco etch 
virus (TEV) cleavage site. Constructs were expressed in E.Coli and purified using a Ni-
NTA affinity chromatography, followed by TEV protease cleavage to remove the His6 tag. 
All the protein constructs were also purified using S-300 gel filtration column to remove 
the protein aggregates.  
The wild-type KEAP1 and all the mutants were characterized using SDS-PAGE to 
verify the purity, shown in Figure 4.2 A. As mentioned in the previous chapter, the KEAP1 
constructs (312-624) used in this analysis contain a double mutation, E540A/E542A, that 
does not affect Nrf2 ligand binding, but does allow us to crystallize the protein in a form 
that has the active site free and available for soaking. We also introduced four other 
mutations (C319S, C613S, C622S and C624S) to improve expression and reduce 
aggregation, leaving seven other native cysteine residues at positions 368, 395, 406, 434, 
489, 513, 518, 583. Only Cys434 is solvent exposed, the other seven cysteines are all buried 
inside the protein structure (Chapter 2). No disulfide linkage between two KEAP1 proteins 
was observed. Therefore, the KEAP1 variants were insensitive to the presence of reducing 
agent (DTT) in SDS-PAGE – they all appeared to be at the size of a monomer (35 kDa) 
under the denaturing conditions. 
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Figure 4.2 SDS-PAGE and gel filtration chromatogram of KEAP1 variants. (A) Reducing SDS-PAGE of 
purified KEAP1 variants. All the KEAP1 variants appeared to have a size of monomer with a molecular 
weight of ~35 kDa in both reducing (10 mM DTT) and non-reducing (gel not shown) conditions. (B) 
Analytical size exclusion chromatography of wild-type KEAP1 and R380A mutant. Before loading on to the 
Superose 6 10/30 GL analytical gel filtration column, proteins were purified using Ni-NTA affinity column 
with the TEV tag removed (as described above). The major peak corresponds to the monomeric form for 
both wild-type and the mutant. The minor peak with a slower migrating rate corresponds to protein 
aggregates, which are removed by gel filtration purification in a regular protein preparation.  
 
To better understand the homogeneity of KEAP1 variants under the native 
conditions (25 mM Tris, 2.5 mM DTT, pH 8.0), wild-type KEAP1 and all mutants were 
evaluated using a Superose 6 10/30 GL analytical gel filtration column. An example of 
analytical size exclusive chromatography profile of freshly prepared wild-type KEAP1 and 
R380A mutant by Ni-NTA affinity chromatography is shown in Figure 4.2 B. Both 
constructs displayed a major peak eluting around 16 mL, corresponding to an apparent 
molecular weight of ~ 40 kDa, as compared to the elution times of globular molecular 
weight standards. The minor peak with a slower migrating rate corresponds to protein 
aggregates, which are removed by gel filtration purification in a regular protein 
preparation. The identity of all the KEAP1 variants was confirmed by their intact mass 
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using mass spectrometry (Waters qTOF Premier LCMS, Milford, MA; spectra shown in 
Appendix II). 
 The relative secondary structure contents of KEAP1 variants were evaluated using 
circular dichroism (CD) spectroscopy. This method was also applied as a means to assess 
whether the single point mutation perturbs the global protein folding substantially. As 
shown in Figure 4.3, the CD spectra (normalized to the concentration) of alanine mutants 
appeared overlapping with that of the wild-type KEAP1, indicating that no substantial 
structural perturbations were introduced by those mutations. Collectively, these results 
validated that all the alanine mutants of KEAP1 selected for mutational analysis were all 
structurally similar to the wild-type protein. 
 
 
Figure 4.3 Circular dichroism spectra of wild-type KEAP1 and alanine mutants. The normalized spectra of 
the alanine mutants appeared overlapping with the wild-type, suggesting no significant changes occurred in 
the protein secondary structure content upon the introduction of the mutations. 
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4.3.3 Effects of single mutations of KEAP1 
To probe the molecular origins of the binding energetics on KEAP1 binding 
interface, we systematically evaluated the contribution made by each residue that is either 
fully or partially solvent exposed at the binding site using alanine scanning mutagenesis. 
The binding activities of the seven KEAP1 mutants were evaluated in the FA binding assay 
described in Chapter 3, using the (FITC) labeled Nrf2 nonamer (FITC-LDEETGEFL-NH2, 
76-84) synthetic peptide encompassing the DxETGE region. The KD and the corresponding 
ΔΔG values of each KEAP1 mutant for Nrf2 tested in the FA assay are shown in Table 4.2 
and Figure 4.4.  
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Figure 4.4 Alanine scanning mutagenesis of KEAP1. (A) Binding curves for wild-type KEAP1 and the seven 
alanine mutants. Solid lines are best fit of the data to a quadratic fitting equation, using GraphPad. (B) The 
changes in KEAP1/Nrf2 interaction energy for each KEAP1 alanine mutant in comparison to the wild-type 
KEAP1, calculated from ΔΔG = -RTln (KDWT/KDmut). Error bars in binding curves show the range of duplicate 
measurements. Results shown are in each case representative of at least three independent experiments. 
Standard deviations of ΔΔG are calculated from at least three independent experiments. 
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Table 4.2 Binding affinities (KD) and free energies (ΔΔG) between KEAP1 mutants and FITC-Nrf2 peptide 
evaluated in FA binding assay 
KEAP11 WT R380A N382A R415A R483A S508A Q530A S555A 
KD (nM) 10 ± 2 578 ± 46 12 ± 3 
(5.4 ± 1.0) 
×104 
600 ± 39 444 ± 41 15 ± 6 24 ± 7 
ΔΔG 
(kcal/mol) 
0 2.3 ± 0.1 0.1 ± 0.0 5.1 ± 0.1 2.3 ± 0.1 2.2 ± 0.1 0.2 ± 0.1 0.5 ± 0.1 
1. Results shown in each case are representative of at least three independent experiments. Standard deviations 
are calculated from at least three independent experiments. 
 
The results showed that on KEAP1, three solvent exposed arginine residues, 
namely R380, R415 and R483, and a partially buried residue S508 contribute substantially 
to the stability of the complex. Mutation any of R380, R483 and S508 to alanine weakened 
the binding by approximately 60-fold (KDmut/KDWT ≈ 60), corresponding to a loss of 
approximately 2.3 kcal/mol (ΔΔG ~ 2.3 kcal/mol) of binding energy. Notably, these three 
residues contributed to the binding energy to similar extent. This observation has been 
confirmed in at least three independent replicate experiments using proteins from different 
preparations, coupled with validation of the mutants’ identities by mass spectrometry. 
Three partially exposed residues, N382, Q530 and S555, exhibited negligible effect on the 
stability of the complex when mutated to alanine, supported by the fact that KDmut values 
were indistinguishable compared to the KDWT (ΔΔG < 0.5 kcal/mol). However, R415, a 
surface exposed residue joining the two major binding sites defined by R380, S508 and 
R483, was confirmed to be the major energetically crucial residue on KEAP1, evidenced 
by the loss of binding energy greater than 5.0 kcal/mol (ΔΔG > 5.0 kcal/mol) when solely 
mutated to alanine (KDmut/KDWT > 5000). The experimental alanine scanning mutagenesis 
results were mapped on the KEAP1 surface, shown in Figure 4.5. 
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Figure 4.5 KEAP1 structure with the binding energetics mapped on the surface. Residues are color-coded 
following Figure 4.4 (A). The conformations of the side chain of Arg415 in both apo and Nrf2 peptide-bound 
KEAP1 are illustrated in the figure. Crystal structure of unbound and Nrf2 peptide-bound wild-type KEAP1 
solved by Dr. Andrew Lynch and Dr. James Carolan in the Allen lab. 
 
4.3.4 Double-mutant cycle analysis of KEAP1/Nrf2 complex 
While the contributions of each amino acid on the interface of KEAP1/Nrf2 to the 
binding energy have been analyzed in detail in the previous section, whether and how the 
mutations interact with each other remain unknown. The answer to this question will 
facilitate our construction of a comprehensive map of the interaction energetics at the 
KEAP1/Nrf2 interaction interface. To address this question, we performed the double-
mutant cycle analysis by evaluating the binding activity between KEAP1 mutants and 
Nrf234-100 mutants. Each protein in this analysis contained a single mutation that was 
determined to be energetically important in the earlier single mutation experiments. Among 
the four energetically important residues on KEAP1 (R380, R415, R483 and S508), only 
the two arginine-to-alanine mutants were chosen for double-mutant cycle analysis. We 
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reasoned that since R415A bound to Nrf2 DxETGE region with such low affinity (KD = 54 
± 10 µM, Table 4.2), quantification of the even weaker binding between this mutant and 
an Nrf2 mutant could exceed the capacity of the FA competition assay. Therefore, to build 
a double-mutant matrix of amenable size, two KEAP1 mutants (R380A, R438A) and four 
Nrf234-100 mutants (D77A, E79A, T80A, E82A) were assessed using the double-mutant 
cycle analysis. Results are shown in Table 4.3. KD values were obtained by fitting the data 
to a competitive binding model using DYNAFIT 4, as described in Chapter 3. The changes 
in binding free energy of the double mutant (ΔΔGmut AB) were calculated from: ΔΔGmut AB 
= -RTln (KDWT/ KDmut AB). For certain pairs of mutants, due to the energetic importance of 
both residues at the interaction interface, I was unable to achieve 50% inhibition even in 
presence of high concentration of the competitor (20 or 50 µM of the Nrf2 mutants). 
Therefore, in those cases, I only reported a lower limit of ΔΔGmut AB values, assuming that 
the highest concentrations tested in the assay were equal to the IC50. 
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Table 4.3 Binding energetics of association of KEAP1 mutants and Nrf2 mutants 
ΔΔG (kcal/mol) comparing to the wild-type KEAP1/Nrf2 binding1 
Nrf234-100 WT D77A E78A E79A T80A E82A F83A 
KEAP1 
WT 
0 2 3.5 ± 0.3 0.5 ± 0.1 3.0 ± 0.1 4.5 ± 0.4 4.4 ± 0.4 0.3 ± 0.1 
KEAP1 
R380A 
2.3 ± 0.1 4.2 ± 0.1 / 4.4 ± 0.1 >>5.0 3 4.1 ± 0.3 / 
KEAP1 
R483A 
2.3 ± 0.1 >>5.0 2 / 3.4 ± 0.1 >>5.0 3 >>5.0 3 / 
1. Results shown are in each case representative of at least two independent experiments. Standard deviations 
are calculated from at least two independent experiments. 
2. All the ΔΔG (kcal/mol) values of the mutant binding were obtained by comparing to the free energy value 
of the wild-type KEAP1/Nrf2 binding. 
3. Certain double-mutant combinations were too weak to be measured in the FA competition binding assay 
(less than 50% inhibitory activity could be achieved even at 50 µM of the competitor). Therefore, only a 
lower limit of KD and ΔΔG values could be interpreted in those cases, assuming that the highest 
concentrations tested in the assay are equal to IC50. 
 
  To enable the analysis, we first needed to justify the errors associated with the 
binding measurements of two nonequivalent sites located on either site of the protein 
partners. Experimental errors directly from the measurements are shown in Table 4.3 as 
standard deviation (σ). Systematic errors that are introduced by factors such as the 
deviations in protein concentration, the nature of the binding assay or the fitting cannot be 
accurately quantified in this case. Therefore, if we assume that the true value of the 
dissociation constant for the interaction is within a factor of 2 of the KD obtained from the 
direct or competitive binding assays, the binding energy we report will have an associated 
error of ± 0.42 kcal/mol. Because of the cumulative errors when summing ΔΔG of single 
mutants, this uncertainty will become 0.8-0.9 kcal/mol. 
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From the above set of data, it is notable that a few pairs of mutants represent certain 
types of additive/non-additive behavior, as described below. For this discussion we group 
the pairs of mutations based on their additive/non-additive behavior, and discuss each 
group separately. 
In the pair of KEAP1R380A-Nrf2E79A double mutant, the ΔΔG value of the double 
mutant (ΔΔG R380A/E79A = 4.4 kcal/mol) approximates the sum of the ΔΔG of single mutants 
(ΔΔG R380A + ΔΔG E79A = 5.3 kcal/mol), as shown in Figure 4.6 B. The result suggests that 
the effect of the two mutations on the binding free energy are additive within experimental 
errors. The interaction energy of the side chain of R380 on KEAP1 and E79 on Nrf2 are 
both moderate, 2.3 kcal/mol and 3.0 kcal/mol, respectively.  When both residues were 
mutated to alanine, a greater loss of binding energy was observed in this pair of mutants 
(4.4 kcal/mol). This value is close to the sum of the ΔΔG of the two single mutants (5.3 
kcal/mol), within experimental uncertainty. R380A on KEAP1 and E79A on Nrf2 are 
located at two binding sites that are approximately 11 Å apart at the binding interface, 
indicating no direct physical contact (Figure 4.6 A). With the observation in ΔΔG and the 
structural information, it is reasonable to assume that R380 on KEAP1 and E79 on Nrf2 
are independent from each other. To be more specific, the presence or absence of the side 
chain of one residue does not affect the binding energy of the other residue, and vice versa. 
Therefore in the double-mutant cycle analysis, this pair behaves in an additive fashion. 
In the pair of KEAP1R380A-Nrf2D77A double mutant, the ΔΔG value of the double 
mutant (ΔΔG R380A/D77A = 4.2 kcal/mol) is smaller than the sum of ΔΔG of single mutants 
(ΔΔG R380A + ΔΔG D77A = 5.8 kcal/mol), yet substantially greater than that of the individual 
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mutant (ΔΔG R380A = 2.3 kcal/mol; ΔΔG D77A = 3.5 kcal/mol), as shown in Figure 4.6 C. 
The difference is significant even considering possible experimental error. The result 
indicates a more complicated relationship of R380 on KEAP1 and D77 on Nrf2. According 
to our earlier calculation of the SASA of side chain atoms on Nrf2 in both the unbound and 
bound forms, D77 appears to make relatively little contact with KEAP1, burying only 16 
Å2 of SASA upon binding to KEAP1 (Chapter 3). It is proposed to mostly form 
intramolecular interactions with neighboring residues on Nrf2 and contribute to the binding 
energy via an indirect mechanism. Therefore, this partially additive effect can be 
potentially explained by this indirect binding mechanism. To be more specific, removing 
the side chain of D77 on Nrf2 disrupts the intramolecular interaction, leading to a less 
favored ligand conformation, and subsequently perturbs the direct contacts between Nrf2 
and KEAP1 in the neighboring regions (e.g. the direct interaction between E79 on Nrf2 
and residues on KEAP1). In consequence, the change in the binding free energy upon the 
single mutation D77A on Nrf2 (3.5 kcal/mol) actually comprises at least two parts: (i) the 
loss of stabilization energy for the optimal loop conformation and (ii) the loss of interaction 
energy due to the reduced contacting area with KEAP1. Thus when the second mutation 
(R483A on KEAP1) was introduced in addition to the first one (D77A on Nrf2), a smaller 
loss of binding energy was observed than expected. Together, the result of this pair of 
double mutant suggests that R380 on KEAP1 and D77 on Nrf2 influence each other via a 
network of interaction among neighboring residues, and the presence or absence of the side 
chain of one residue indirectly affects the binding of the other. Herein, we define this effect 
between KEAP1R380A and Nrf2D77A as an indirect communication. 
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In the double mutant pairs of KEAP1R380A-Nrf2E82A and KEAP1R483A-Nrf2E79A, 
ΔΔG caused by the double mutant is no greater than the larger ΔΔG of the single mutants 
(ΔΔGR380A/E82A = 4.1 kcal/mol versus ΔΔGE82A = 4.4 kcal/mol; ΔΔGR483A/E79A = 3.4 
kcal/mol versus ΔΔGE79A = 3.0 kcal/mol), shown in Figure 4.6 D and E. In both cases, 
mutations on KEAP1 caused a smaller effect on binding energy than mutations on Nrf2. 
However, both pairs of double mutants had similar binding energy compared to their 
corresponding Nrf2 single mutant/ wild-type KEAP1 pairs. In other words, ΔΔG(AB) = 
the larger of ΔΔG(A) or ΔΔG(B). In the Nrf2-bound KEAP1 crystal structure, E79 on Nrf2 
protrudes directly into a subpocket, and mediates interactions with multiple residues 
including R415, R483 and S508 on KEAP1, dominating the binding energy at this site. 
Mutation of E79 on Nrf2 to alanine will completely remove all the side chain interactions, 
leading to a substantial loss of binding energy at this location, whereas mutation of R483 
would only partially weaken the binding. Therefore, the contribution of binding free energy 
from R483 on KEAP1 is completely dependent on whether or not the side chain of E79 on 
Nrf2 is present. Likewise, E82 on Nrf2 projects its side chain into a subpocket formed by 
S363 and R380, and dominates the binding energy, leading to a similar effect. 
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Figure 4.6 Outcomes of pairs of KEAP1/Nrf2 double mutant evaluated in double-mutant cycle analysis with 
structural basis. (A) Structural illustration of the interactions between KEAP1 (grey) and Nrf2 (green), side 
chains are shown in sticks. E79 and E82 on Nrf2 are in close proximity to directly interact with R483 and 
R380 on KEAP1, respectively. Residue E79 and E82 interact with two subpockets that are 10.6 Å away from 
each other. Histograms showing the results of association of pairs of KEAP1/Nrf2 double mutant. (B) 
KEAP1R380A-Nrf2E79A, ΔΔG value of the double mutant is close to the sum of the ΔΔG values of the single 
mutants. ΔΔG(AB) = ΔΔG(A) + ΔΔG(B). (C) KEAP1R380A-Nrf2D77A, ΔΔG of the double mutant is greater 
than individual single mutant, but smaller than the sum of the two. ΔΔG(A) or ΔΔG(B) < ΔΔG(AB) < 
ΔΔG(A) + ΔΔG(B); (D) KEAP1R380A-Nrf2E82A and (E) KEAP1R483A-Nrf2E79A, ΔΔG of the double mutant is 
equivalent to the larger of the single mutant. ΔΔG(A) < ΔΔG(AB) = ΔΔG(B). ΔΔG(A) is represented in red, 
ΔΔG(B) in blue, ΔΔG(A) + ΔΔG(B) as stacked columns, ΔΔG(AB) in blue diagonal lines. Results shown 
here represent at least two independent experiments. 
 
4.3.5 Ligand-binding and mutational effect on the protein stability 
In the previous section, it has been shown that the single site mutations included in 
this analysis did not influence the protein secondary structure. Nevertheless, one surprising 
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observation is that certain single site mutations to alanine could cause a substantial 
stabilization effect on the KEAP1 (312-624) protein folding, as shown in Figure 4.7. 
 
 
Figure 4.7 Protein stability upon single site mutation. (A) Thermal denaturation curves of all the KEAP1 
variants by ThermoFluor assay. The melting curves were fitted using four parameter logistic regression to 
interpret Tm values, shown in the table below. Results shown above represent at least two independent 
experiments. (B) Unfolding curves of wild-type and R380A KEAP1 in chemical denaturation. Normalized 
intrinsic Trp fluorescence was plotted against varying concentration of urea. Same method as (A) to interpret 
the [urea]50 values. Results shown in the table below represent four independent experiments, with a p-value 
< 0.0001. 
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Evaluation of stability of KEAP1 mutants in response to thermal denaturation using 
a ThermoFluor assay revealed that the KEAP1 variants showed a range of melting 
temperatures, yet none of the mutations destabilized the protein by significant extent, as 
shown in Figure 4.7 A. Interestingly, certain arginine-to-alanine mutations on KEAP1, i.e. 
R380A and R415A, substantially elevated the protein’s melting temperature (Tm), 
suggesting that removal of an exposed positively charged side chain on KEAP1 may either 
improve the protein stability, or decrease the tendency for protein self-association and 
aggregation.  
As an attempt to further understand the mechanism of this stabilization effect 
induced by single site mutation, we evaluated the stability of KEAP1 R380A in urea-
induced chemical denaturation by monitoring intrinsic tryptophan fluorescence upon 
unfolding, using wild-type KEAP1 as a control. Unlike the thermal denaturation process, 
which is incapable of separating protein unfolding and aggregating steps, chemical 
denaturation, especially urea-induced denaturation, can provide information of the 
equilibrium between the folded and unfold states of the protein.248,249 Both proteins were 
incubated with varying concentrations of urea ranging from 0 to 7.2 M at 25 ̊C, and the 
denaturation process was monitored over 16 hours to confirm completion. As shown in 
Figure 4.7 B, KEAP1 R380A required a higher concentration of urea to reach half 
denaturation ([urea]50 = 3.6 ± 0.1 M). One notion is that denaturation was not reversible 
under our conditions. Two approaches were attempted to refold the KEAP1 protein after 
denaturation at high urea concentration: (1) denatured protein in 6 M urea was slowly 
diluted 10-fold into a refolding buffer (20 mM HEPES, 150 mM NaCl, 2.5 mM DTT, pH 
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7.5), allowing the protein to gradually refold at low concentration of urea (~ 0.6 M); (2) 
denatured protein in 7.2 M urea was dialyzed against the refolding buffer at 4 ̊C overnight, 
allowing the urea to be slowly removed from the protein solution. Both approaches resulted 
in no significant recovery of the tryptophan fluorescence in the assay readout, indicating 
the unsuccessful refolding. Consequently, we were unable to interpret the free energy of 
this unfolding process from [urea]50 values, since under our experimental conditions the 
protein denaturation process was not a reversible thermodynamic process.250 Nevertheless, 
the observation of an elevated [urea]50 upon R380A mutation supports the assumption that 
mutating certain solvent exposed arginine residues on KEAP1 can stabilize the folding of 
the protein, instead of only preventing protein aggregation at high temperatures. 
Another interesting observation is that, KEAP1 becomes more rigid upon Nrf2 
peptide binding. This was initially discovered by Dr. Andrew Lynch in his efforts of 
crystallizing both unbound and bound KEAP1.139 In the crystal structure of unbound 
KEAP1, there are two asymmetric chains – one with an open active site for ligand soaking 
and another with the active site being occupied by a loop protruding from the neighboring 
chain. Notably, the B-factors, a measure of relative vibrational motion and disorder of the 
protein, have relatively higher values in the KEAP1 molecule with the open binding site in 
the apo crystal structure. In the Nrf2 peptide bound structure, ligand binding induces a 
substantial reduction of the B-factors of certain spatially distal loops on KEAP1 from the 
active binding site, indicating an allosteric effect on protein flexibility (loss of 
flexibility).139 
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To further interrogate the molecular details of this allosteric effect on KEAP1 
stability induced by either ligand-binding or mutagenesis, we collaborated with Prof. Alan 
Marshall’s lab at Florida State University using Hydrogen-deuterium exchange (HDX) 
mass spectrometry. Peilu Liu, a graduate student in the Marshall lab, performed the HDX 
experiments by mass spectrometry on three KEAP1 variants: wild-type unbound KEAP1, 
wild-type KEAP1-Nrf2 peptide complex, and KEAP1 R380A mutant provided by me. The 
average relative deuterium uptake difference (ARDD) values of complexed KEAP1 and 
R380A mutant using the unbound wild-type KEAP1 as a reference were reported as a 
measure of solvent (D2O) accessibility. Regions that have negative ARDD values are 
interpreted to be less accessible for solvent exchange. This is especially informative in 
mapping protein-protein interaction epitopes or ligand-induced allosteric conformational 
change. For binding epitopes, an ARRD value < -30% is usually seen; for allosteric regions 
with conformational changes, an ARRD value between -15% to -20% is usually 
observed.251 ARDD results are mapped on the crystal structure in color-gradient (Figure 
4.8). The results showed that, besides the active binding site, several loops in blade 4 and 
5, which are spatially remote from the active binding site, were stabilized upon Nrf2 ETGE 
peptide binding (Figure 4.8 A). A similar allosteric effect on protein dynamics was also 
captured in HDX experiments when R380 was mutated to alanine, corresponding to the 
earlier observation of the stabilization effect in both thermal and chemical denaturation 
experiments. The results from the HDX experiments confirmed our previous observation 
of increased protein stabilities upon ligand-binding or single site mutations in biochemical 
denaturation assays and X-ray crystallography B-factors, and further identified the specific 
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regions that were affected. The figure with detailed ARDD values of each residue is 
provided in Appendix VIII. 
 
 
Figure 4.8 HDX results mapped on KEAP1 structure. (A) ARDD of the KEAP1/Nrf2 complex in comparison 
to unbound wild-type KEAP1 mapped on the complex structure. (B) ARDD of the R380A mutant in 
comparison to wild-type KEAP1 mapped on the unbound wild-type KEAP1 structure. Protein structure is 
shown in cartoon, in grey. Peptide in green. ARDD values are indicated in various shades of blue, reference 
values are shown in the bar at the right bottom. 
 
Based on the results of the biochemical denaturation assay, X-ray crystallography 
B-factors, and HDX results, we conclude that (1) none of the mutations evaluated in this 
study substantially destabilize the KEAP1 folding; (2) both ligand-binding and point 
mutation of certain arginine residues at the active site can reduce the protein flexibility of 
KEAP1, and (3) this effect is potentially regulated by an allosteric mechanism. 
  
  
160 
4.4 Discussion 
The results of the systematic examination of the effects of single mutations on 
KEAP1 described in this chapter provide new insight into the binding energetics at the 
KEAP1/Nrf2 interface. Investigation of the combinations of mutants, one on each protein 
binding partner, using double-mutant cycles also adds to our understanding of the 
mechanism of mutational additivity effects at the molecular level. 
 
4.4.1 Binding energetics on KEAP1 
 The results and interpretations of the alanine scanning mutagenesis on Nrf2 have 
been described extensively in the previous chapter (Chapter 3). In this subsection, I mainly 
focus on the outcomes of the single mutations on KEAP1 binding interface. 
The three residues shown to make moderate contributions to the binding energy 
(R380, R483, S508) reside in two distal binding subpocket on KEAP1 (Figure 4.6). Among 
those, R483 and S508 are located in a pocket directly interacting with the carboxyl group 
of E79 on Nrf2. Meanwhile R380 is in close proximity to the carboxyl group of E82 on 
Nrf2, allowing electrostatic and hydrogen bonding interactions. These results perfectly 
match our findings of the binding energetics on Nrf2 described in Chapter 3. Interestingly, 
one single mutation, R415A, results in a substantial destabilization of the complex (ΔΔG 
> 5.0 kcal/mol). It is observed that the side chain of Arg415 exhibit multiple different 
orientations depending on the ligand – several ligands induce a “side” conformation, in 
which R415 points towards the binding pocket that accommodates the side chain of E79, 
others induce a “up” conformation that forces the arginine side chain to move away from 
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the binding pocket and point upwards to a more solvent exposed pose. This mobility of 
R415 has been extensively discussed in Chapter 3 (3.3.4). Given the crucial role of R415 
in both binding energy and regulation of the accessibility of one major hot spot on KEAP1 
(Hot spot A by FTMap, Chapter 3), exploring an approach to regulate the conformation of 
this arginine residue should be taken into consideration in the future inhibitor design for 
this PPI target. 
Our results are majorly consistent with the observations by Lo et al. that three 
arginine residues (R380, R415, R483) were required for Nrf2 binding and for repression 
of Nrf2-dependent gene transcription in cells, using co-immunoprecipitation and ARE-
dependent luciferase reporter gene assays. However, the authors observed that individual 
alanine substitutions of the four serine residues, Ser363, Ser508, Ser555, and Ser602, had 
negligible effect on the ability of KEAP1 to bind to Nrf2 or to repress Nrf2-dependent gene 
expression. We determined that the substitution of S508 with alanine weakened the binding 
between the two proteins by approximately 60-fold (KDS508A/KDWT ≈ 60), to a similar extent 
as the two arginine-to-alanine mutants. In addition, Lo et al. also reported that N382A on 
KEAP1, one of the mutations that showed no effect on binding in our analysis, completely 
suppressed the Nrf2 signaling in cell. This inconsistency in findings can be explained by 
the discrepancy in assay techniques – we directly examine the binding energy of protein 
constructs in solution from a biochemical perspective, instead of a biological outcome in 
the cellular context.  
In summary, the identified energetic key residues on the KEAP1 binding interface 
are mostly polar/charged residues. This result perfectly matches the ASM mapping on the 
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corresponding binding site on Nrf2: the key residues are mostly polar/negatively charged 
residues. Hence, we can conclude that, unlike some other cases where the binding energy 
is dominated by hydrophobic interactions, this PPI interface is dominated by polar 
interactions.  
 
4.4.2 Hypothetical outcomes from pairwise mutations 
In the past two decades, double-mutant cycles on the same protein have been 
extensively applied to understand protein functions and structures.229,230,235-240,242,243,245,252 
In most of the studies, the non-additive effects have been interpreted to be associated with 
certain extents of conformational change; however, no further structural details have been 
discussed. Here, I use KEAP1/Nrf2 as a model to explore the energetic effects of 
combinations of mutations and discuss the structural basis of these effects in order to 
construct a more systematic theoretical framework to understand mutational additivity 
effects. 
I propose here, in a hypothetical double-mutant cycle on both protein binding 
partners, the outcome of combining two mutations (one on each side of the protein) can 
fall into one of the five following categories (Table 4.4 and Figure 4.9): 
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Table 4.4 Possible outcomes from combining two mutations 
 ΔΔG of the double mutant in comparison to ΔΔG of the single mutants and their sum 1 
Relationship 
between mutations 
a ΔΔG(AB) > ΔΔG(A) + ΔΔG(B) Synergistic 
b ΔΔG(AB) = ΔΔG(A) + ΔΔG(B) Additive 
c ΔΔG(AB) > ΔΔG(A), > ΔΔG(B); < ΔΔG(A) + ΔΔG(B) Partially additive 
d ΔΔG(AB) > the larger of ΔΔG(A) or ΔΔG(B) Subordinate 
e ΔΔG(AB) < ΔΔG(A) or < ΔΔG(B) Compensatory 
1. In this table, ΔΔG(AB) represents the ΔΔG of the double mutant, when residue A on one protein and residue 
B on the other protein both being mutated at the same time. ΔΔG(A) and ΔΔG(B) each represents the binding 
free energy change of the single mutants compared to wild-type, and ΔΔG(A) + ΔΔG(B) is the sum of the 
free energy loss of the single mutants. 
 
 
Figure 4.9 Histogram illustrating the relationship of the ΔΔG values between the single mutants and double 
mutant in different categories in our hypothetical model. ΔΔG(A) (red), ΔΔG(B) (blue) and ΔΔG(AB) 
(diagonal line pattern) are the measured binding free energy changes of each individual single mutant or the 
double mutant, comparing to the wild-type interaction. ΔΔG(A) + ΔΔG(B) is the sum of the binding free 
energy changes of the two single mutants. 
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Each of the outcome listed above may be the result of a distinct mechanism. The 
simplest case here is the (b) additive, where the two binding sites are hypothesized to be 
completely independent, mutation at one site should not perturb the binding of another. 
Detailed proposed mechanism of each case will be discussed in 4.4.6. 
 
4.4.3 Classes of the outcomes of the double mutations on KEAP1/Nrf2 
 Combinations of KEAP1/Nrf2 mutants analyzed using double-mutant cycles in this 
study are categorized by our hypothetical model, shown in Table 4.5.(1)  
 
Table 4.5 Combinations of KEAP1/Nrf2 mutants categorized by our hypothetical model 
Mutation 
A 
(KEAP1) 
Mutation 
B 
(Nrf2) 
ΔΔG(A) ΔΔG(B) ΔΔG(A) + ΔΔG(B) ΔΔG(AB) Additivity
1 Structural relationship2 
R380A E79A 2.3 ± 0.1 3.0 ± 0.1 5.3 ± 0.2 4.4 ± 0.1 Additive No direct contact 
R380A D77A 2.3 ± 0.1 3.5 ± 0.3 5.8 ± 0.4 4.2 ± 0.1 Partially additive Indirect 
R380A E82A 2.3 ± 0.1 4.4 ± 0.4 6.7 ± 0.5 4.1 ± 0.3 Subordinate Direct 
R483A E79A 2.3 ± 0.1 3.0 ± 0.1 5.3 ± 0.2 3.4 ± 0.11 Subordinate Direct 
1. Definitions can be found in Table 4.4 
2. Definitions of structural relationship can be found below. In brief, “direct” means that there is direct 
physical contact between residues A and B; “no direct contact” means that residues A and B are too far apart 
to make direct interaction; “indirect” means that one residue affects the binding of the other via an indirect 
mechanism through a network of interactions. 
                                                
(1) Hereafter, in structural relationship in Table 4.5, “direct” indicates that there exists a direct physical contact 
between the side chain of the residues A and B; “no direct contact” means that A and B are remotely apart 
from each other and no direct interaction can be made; “indirect” suggests that residues A and B are 
interconnected with each other via a network of interactions among neighboring residues in proximity or 
backbone atoms, and through these interactions A can indirectly contributes to the behavior of B, and vice 
versa. 
  
165 
According to our results, two pairs of double mutant of KEAP1/Nrf2 belong to the 
class of subordinate, i.e. KEAP1R380-Nrf2E82 and KEAP1R483-Nrf2E79, in which one residue 
dominates the binding energy. Shown in the bound crystal structure (Figure 4.6 A), both 
E79 and E82 make direct contact with KEAP1 by protruding the side chain into a subpocket 
and interacting with multiple residues on KEAP1.  
In the case of KEAP1R380-Nrf2D77 double mutant, our calculations earlier support 
the hypothesis that D77 contributes to the binding energy by mediating 
indirect/intramolecular interactions, instead of making direct physical contact with residues 
on KEAP1, yet the actual mechanism remains unclear. Nevertheless, structural information 
from the Nrf2 peptide-bound KEAP1 crystal shows that the carboxylate of D77 on Nrf2 
and the guanidine group of R380 on KEAP1 are separated by ~7 Å, indicating that the two 
residues may interact with each other through an indirect mechanism, e.g. electrostatic 
interactions. Therefore, this pair of double mutant belongs to the class of the partially 
additive. 
In the case of KEAP1R380-Nrf2E79 double mutant, if we take both the experimental 
and systematic errors into consideration, this pair belongs to the class of additive. In the 
Nrf2 peptide-bound KEAP1 crystal structure, the two residues reside in two distal binding 
sites that are approximately 11 Å apart, making no direct contact. Similar observation was 
captured in the case study of Barnase-Barstar by Fersht and coworkers – when the two 
mutations occurred at locations that were more than 8 Å apart, no significant cooperativity 
was detected.239 This result supports the assumption that an additive effect requires two 
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mutation sites to be completely independent (no direct or indirect contact or coupling 
effect), as explained below. 
4.4.4 Double-mutant cycle and coupling energy 
As described earlier in the introduction, in a classic double-mutant cycle analysis 
on the same protein (Scheme 4.1), a pair of mutations are additive if ΔΔG(A) = ΔΔG(A’) 
and ΔΔG(B) = ΔΔG(B’), meaning that residues A and B are independent of each other in 
the sense that ΔΔG(A) is unaffected by whether residue B is the wild-type or mutant amino 
acid, and vice versa. If this is not the case, then there is a coupling effect between A and B, 
where coupling energy is defined as ΔΔG(A) - ΔΔG(A’), which necessarily equals ΔΔG(B) 
- ΔΔG(B’), as described in Section 4.1.3. Scheme 4.1 for the double-mutant cycle was 
originally used to describe the effects of two mutations on the same protein.241 A similar 
scheme can be drawn for the situation when the two mutations occur on different protein 
partners in a protein-protein complex, shown in Scheme 4.2.237-239,243 
 
 
Scheme 4.2 Double-mutant cycle scheme (adapted from Fersht et al., 1984)241. In this analysis, we discuss 
the situation when the each protein partner bearing a single mutation on the binding interface. ΔΔG(AB), 
ΔΔG(A) and ΔΔG(B) are measured experimentally.  
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In a double-mutant cycle analysis involving mutations on both binding partners, we 
can define a term, ΔΔΔG, as the energy difference between the double mutant and the sum 
of the two single mutants, ΔΔΔG can be expressed as: 
 
ΔΔΔG = ΔΔG(AB) - ΔΔG(A) + ΔΔG(B)   Eq. 4.4 
 
In the case where mutations A and B are additive, ΔΔG(AB) equals to the sum of 
ΔΔG(A) and ΔΔG(B), leading to ΔΔΔG = 0, corresponding to no energetically significant 
interaction between A and B upon mutagenesis of either or both. In a non-additive case, 
the value of ΔΔΔG indicates the extent of the energetic impact of A and B on each other 
upon mutagenesis. If ΔΔΔG > 0, mutations A and B are synergistic; if ΔΔΔG < 0, mutations 
A and B lack additivity. ΔΔΔG can be a measure of the extent of the interaction between 
the two mutations in question, namely “communication energy” between mutation A and 
B. The underlying interpretation from the measurement of ΔΔΔG is to understand whether 
the absence or presence of one residue has an effect (local or allosteric) on the other residue. 
However, a more informative way other than ΔΔΔG is needed to correlate the additivity 
with structural basis. Herein, we propose an Additivity Index, as a means to provide a 
context for linking the measured ΔΔG values with the molecular causes of those effects. 
We further discuss how to quantify the Additivity Index, and rationalize the structural basis 
of the energy propagation, even amplification, between two residues below. 
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4.4.5 Quantifying degrees of additivity 
 According to the double-mutant cycle discussed above (Scheme 4.2), when 
mutations A and B are additive, the presence or absence of the side chain of A has no effect 
on residue B (and vice versa), and ΔΔΔG is 0, and ΔΔG(A) = ΔΔG(A’) = ΔΔG(AB) - 
ΔΔG(B). The equation can also be expressed as below: 
 
∆∆v 7w ;xxy(t)xxy(q) = 1     Eq. 4.5 
 
If we define a term, Additivity Index, as the ratio of ΔΔG(A’) and ΔΔG(A) in a 
double-mutant cycle, interpreted from experimentally determined values, we get the 
following equation: 
 𝐴𝑑𝑑𝑖𝑡𝑖𝑣𝑖𝑡𝑦	𝐼𝑛𝑑𝑒𝑥 = ∆∆v 7w ;xxy(t)xxy(q)     Eq. 4.6 
 
In calculating Additivity Index, we assign the smaller ΔΔG value as ΔΔG(A), and 
the larger as ΔΔG(B). In general, ΔΔG(A) and ΔΔG(B) are interchangeable without 
altering the final outcome. For instance, if A and B are synergistic, by definition ΔΔG(AB) 
> ΔΔG(A) + ΔΔG(B) (Table 4.4), therefore 
 ∆∆𝐺 𝐴𝐵 − ΔΔG BΔΔG A > 1	𝑎𝑛𝑑	 ∆∆𝐺 𝐴𝐵 − ΔΔG(A)ΔΔG(B) > 1 
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Between A and B, whichever goes to the denominator does not affect whether the 
Additivity Index will have a value greater than 1 or not, that is closely associated with the 
outcome of category in relationship between mutations. This also applies to additive 
(ΔΔG(AB) = ΔΔG(A) + ΔΔG(B), Additivity Index = 1), partially additive (ΔΔG(A) or 
ΔΔG(B) < ΔΔG(AB) < ΔΔG(A) + ΔΔG(B), 0 < Additivity Index < 1) and compensatory 
(ΔΔG(AB) < ΔΔG(A) or ΔΔG(B), Additivity Index < 0). The only exception to the 
interchangeability of the assignments of ΔΔG(A) and ΔΔG(B) exists in the case of 
Subordinate mutations. In this case, ΔΔG(AB) = the larger of ΔΔG(A) and ΔΔG(B). If we 
assume ΔΔG(B) is the larger of the two, then: 
 ∆∆𝐺 𝐴𝐵 − ΔΔG BΔΔG A = ∆∆𝐺 𝐵 − ΔΔG BΔΔG A = 0, 
while, ∆∆𝐺 𝐴𝐵 − ΔΔG AΔΔG B = ∆∆𝐺 𝐵 − ΔΔG AΔΔG B ≠ 0 
 
Hence, to simplify the future discussion, the defined Additivity Index is based on 
the premise that ΔΔG(B) is the larger value of the two. A list summarizing this proposed 
quantitative method to assess the degree of additivity at protein-protein interfaces is shown 
in Table 4.6. 
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Table 4.6 Quantifying the degree of additivity 
 
Relationship between 
mutations 
Calculated additivity index 
(ΔΔG(AB)-ΔΔG(B))/ΔΔG(A) 
a Synergistic > 1 
b Additive = 1 
c Partially additive (0, 1) 
d Subordinate = 0 
e Compensatory < 0 
 
 
Figure 4.11 shows 3D diagrams illustrating this proposed concept for each single 
category. The double-mutant cycle, same as Scheme 4.2, is shown as the square at the 
bottom (x and y axes). Complexes that are destabilized by either one or both mutations 
exhibit an elevated ΔG comparing to the wild-type complex, and the value of ΔΔG is 
indicated on the z-axis. Thus, experimentally measured ΔΔG(AB), shown in different 
shades of blue on the z-axis, can be directly compared to the benchmark value, ΔΔG(A) + 
ΔΔG(B) marked with the braces. The Additivity Index is calculated using Equation 4.6. 
The value of Additivity Index varies, depending on which category the pair of double 
mutant belongs to. 
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Figure 4.10 3D diagrams illustrating degrees of additivity in each individual hypothetical categories. The 
diagram has three dimensions. The square at the bottom (the x and y axes) represent the double-mutant cycles, 
similar to Scheme 4.2. The vertical z-axis represents the scale of free energy change (ΔΔG) of each mutation. 
The degree of additivity can be determined by comparing the scale of the region shaded in blue (ΔΔG (AB)) 
on the mut A·B axis, to the benchmark value, ΔΔG(A) + ΔΔG(B). Five hypothetical categories are labeled 
in different shades of blue, shown in the legend. 
 
If mutations A and B are synergistic, ΔΔG(AB) > ΔΔG(A) + ΔΔG(B); Additivity 
Index >1, shown in Figure 4.10 A. ΔΔG(AB) in white is greater than the benchmark value 
ΔΔG(A) + ΔΔG(B). If mutations A and B are additive, ΔΔG(AB) = ΔΔG(A) + ΔΔG(B); 
Additivity Index =1, shown in Figure 4.10 B. ΔΔG(AB) in light blue is equal to the 
benchmark value. If mutations A and B are partially additive, ΔΔG(A) or ΔΔG(B) < 
ΔΔG(AB) < ΔΔG(A) + ΔΔG(B); Additivity Index ∈  (0,1), shown in Figure 4.10 C. 
ΔΔG(AB) is lower than the benchmark value. If mutations A and B are subordinate, 
ΔΔG(AB) = ΔΔG(B); Additivity Index = 0, shown in Figure 4.10 D. ΔΔG(AB) is lower 
than the benchmark value but equivalent to ΔΔG(B). If mutation A and B are 
compensatory, ΔΔG(AB) < ΔΔG(A) or ΔΔG(B); Additivity Index < 0, shown in Figure 
4.10 E. ΔΔG(AB) in dark blue is smaller than either of ΔΔG(A) or ΔΔG(B). 
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 The combined 3D diagram for illustrating the degree of additivity is shown in 
Figure 4.11 below.  
 
 
Figure 4.11 Combined 3D diagrams illustrating degrees of additivity. Five hypothetical categories are labeled 
in different shades of blue, shown in the legend. 
 
4.4.6 Structural basis for different categories of outcome 
 In this subsection, I discuss the hypothetical structural basis that correlates with 
each of the five different outcomes mentioned above in details. 
Starting with the simplest scenario, where mutations A and B are (b) additive, ΔΔG 
of the double mutant is equivalent to the sum of the ΔΔG of the single mutants (ΔΔG(AB) 
= ΔΔG(A) + ΔΔG(B); Additivity Index = 1; Figure 4.12). One way this outcome can occur 
is if residue A and B, from different protein partners, are far apart from each other and have 
no direct physical contact. Additionally, A and B are not making indirect contact, meaning 
that the presence or absence of the side chain of A has no effect on the structure or dynamics 
of B, and vice versa. It is not necessary to assume that both binding subpockets are rigid 
and not being conformationally disturbed by the mutation (see discussion 4.4.7). Certain 
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extent of local conformational change induced by mutating A is allowed, as long as this 
structural perturbation has no impact on B. 
 
 
Figure 4.12 Structural basis of additive effect. (A) Illustration of structural basis and (B) histograms of the 
changes in binding free energies of single and double mutant in a hypothetical additive double-mutant cycles. 
A simplified cartoon illustrating possible structural basis of the additivity observations is shown on the left. 
Black curves represent protein surface, both concave and convex. Squares represent residues on the interface, 
dashed squares represent mutated residues with side-chain atoms removed. Grey dashed lines represent the 
favored interactions. (B) Histograms show the ΔΔG values of each hypothetical situation. ΔΔG(A), ΔΔG(B) 
and ΔΔG(AB) are the measured binding free energy changes in each single mutant or the double mutant, 
comparing to the wild-type interaction. ΔΔG(A) + ΔΔG(B) is the sum of the free energy changes of the two 
single mutants. 
When mutations A and B are (a) Synergistic, the double mutant has a greater effect 
on binding energies than the sum of the single mutants (ΔΔG(AB) > ΔΔG(A) + ΔΔG(B); 
additivity index > 1; Figure 4.13). This effect can be explained by a model where residue 
A and B are located on two different proteins, but both are involved in a mutual interaction 
network that also involves C and D. In other words, A, B, C and D are in proximity, forming 
a closely interconnected cluster, as defined by Schreiber et al.243 The synergistic effect can 
be accounted for in two closely related but distinct scenarios. In the first scenario 
(compensatory effect, Figure 4.13A), bystander residues C and D do not interact with each 
other in the wild-type proteins. Upon the mutation of A, the change in local structure allows 
  
174 
a new interaction between C and D, which partially compensates for the loss in binding 
energy caused by mutation A. The same compensatory interaction can form when B is 
mutated alone. However, when both A and B are mutated, the compensatory interactions 
between C and D can only form once, and so there is less overall energetic compensation 
than expected by adding the effects in the two single mutants. The net effect is that the two 
separate mutations exert a bigger effect (i.e. are subject to less compensation) in the double 
mutant relative to either of the single mutants. The degree of synergy between the 
mutations will be exacerbated if the compensatory interaction is for any reason weaker in 
the double mutant than in the single mutants, for example due to increased local flexibility 
or disorder. In the second scenario (cooperative effect, Figure 4.13 B), the interaction 
between C and D contributes to the local interaction network by connecting A and B. 
Mutating either A or B individually will weaken the overall binding to a certain extent, 
however, the remaining residue (B or A) will still be capable of maintaining the mutual 
interaction network (i.e. the interaction between C and D remains). When both residues are 
mutated, the local interaction network is completely disrupted, the clusters of residues that 
used to be tightly bound to each other now collapse, resulting in an enlarged effect on the 
binding energy comparing to the sum of the two single mutants, due to the additional loss 
of interaction energy between C and D. 
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Figure 4.13 Structural basis of synergistic effect. Illustration of (A) compensatory effect, (B) cooperative 
local interaction network effect and (C) histograms of the changes in binding free energies of single and 
double mutant in a hypothetical synergistic double-mutant cycle. All the representations remain the same as 
in Figure 4.12. 
 
When mutations A and B are (c) Partially additive, ΔΔG(AB) is greater than either 
of the individual single mutations, yet smaller than the sum of the two (ΔΔG(AB) < 
ΔΔG(A) + ΔΔG(B), and ΔΔG(AB) > ΔΔG(A) or ΔΔG(B); 0 < additivity index < 1; Figure 
4.14). The mechanism of this situation can be complicated, and we only discuss two 
representative possibilities here. In the first case (Figure 4.14 A), A and B both exist in the 
same local interaction network, and meanwhile have direct physical contacts with each 
other. Truncation of the side chain of residue A by mutating to alanine results in the loss 
of interaction to B as well as to some other residues in the cluster (e.g. residue C). Then 
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both ΔΔG(A) and ΔΔG(B) include the loss of the interaction energy between residue A 
and B, leading to an exaggerated value when summing the two. While in the double mutant, 
the loss of interaction energy between A and B can only be counted once, and so there is 
less overall energetic changes of in the double mutant, resulted in a smaller ΔΔG(AB) than 
ΔΔG(A) + ΔΔG(B).  
In the second, slightly more complicated case (Figure 4.14 B), there exists a 
compensatory effect from the neighboring residues, namely C and D in the figure, that can 
occur in the double mutant but not in either of the single mutants. Although mutation of 
each individual residue causes a substantial loss of binding energy, when both are mutated, 
the neighboring residues are affected in a way that new interactions are formed that can 
partially attenuate the impartment in the binding energy. The gross outcome of this 
compensatory effect is a smaller ΔΔG(AB) of the double mutant than expected by summing 
the ΔΔG of the single mutant. 
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Figure 4.14 Structural basis of partially additive effect. Illustration of (A) regular or (B) compensatory effect 
and (C) histograms of the changes in binding free energies of single and double mutant in a hypothetical 
partially additive double-mutant cycle. All the representations remain the same as in Figure 4.12. 
 
When mutations A and B belong to the category of (d) Subordinate, the double 
mutant has an effect on the binding free energy that is equivalent to the larger of the two 
single mutant effects (ΔΔG(AB) = the larger of ΔΔG(A) or ΔΔG(B); additivity index = 0; 
Figure 4.15). In one subpocket, when one residue mediates interactions with multiple 
residues on the partner protein (for example, B protrudes into a site that is formed by 
residue A and C), this residue dominates the binding energy in this site. Mutation of A 
would only result in a partial loss of the binding energy, whereas mutation of B can 
completely disrupt all of the interactions. Thus, A is subordinate to the contribution of B, 
shown in Figure 4.15 A. In a special case, when A and B only interact solely with each 
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other, then the free energy contribution of A and B are the same. As a result, ΔΔG(AB) = 
ΔΔG(A) = ΔΔG(B). 
 
 
Figure 4.15 Structural basis of subordinate effect.(A) and (B) are illustration of two proposed models of this 
effect, (A) The model when B is the predominate one regulating the binding energy. (B) A special model, 
when A and B only interact with each other, leading to the contribution of A and B are equivalent. (C) 
Histograms of the changes in binding free energies of single and double mutant in a hypothetical subordinate 
double-mutant cycle. All the representations remain the same as in Figure 4.12. 
 
When mutations A and B are (e) Compensatory, the effect of the double mutant is 
smaller than either of one or both the single mutants (ΔΔG(AB) < ΔΔG(A) and/or ΔΔG(B); 
additivity index < 0; Figure 4.16). Mutation of either A or B weakens the binding, yet the 
double mutation can substantially restore the binding activity, such that at least one 
mutation becomes stabilizing to the interaction (ΔΔG is negative) when introduced in the 
presence of the other mutation. The result is an attenuated effect of the double mutation on 
the binding energy compared to one or both of the single mutants. One explanation for this 
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kind of observation could be that some disfavored repulsive interactions induced by A or 
B are removed due to mutations, leading to the formation of a more strongly favored 
interaction between peripheral residues that is absent in the native wild-type protein (Figure 
4.16). Although this compensatory effect is rarely seen in protein-protein interactions, it 
has been reported in protein-substrate recognition.241  
 
 
Figure 4.16 Structural basis of compensatory effect. (A) The model that C and D can form a new strong 
interaction when both A and B are mutated, shown as the double dashed line. Red arrows represent the 
potential repulsive interactions. (B) Histograms of the changes in binding free energies of single and double 
mutant in a hypothetical compensatory double-mutant cycle. All the representations remain the same as in 
Figure 4.12. 
 
4.4.7 Rigid interfaces, local and long-range conformational changes  
Among the five hypothetical outcomes of interaction effects in a double mutant 
cycle, three require a certain extent of conformational change (synergistic, partially 
additive and compensatory), as described above. Mutating a residue to alanine and 
removing the atoms beyond the Cβ usually generates a cavity on the protein surface. This 
structural perturbation will likely be accompanied by the entry of solvent water molecules, 
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to compensate for the loss of the side chain atoms, and sometimes also by the relaxation of 
the surrounding protein structure into a new conformation. If any conformational relaxation 
of this kind occurs, it may affect binding to the protein binding partner, either by partially 
mitigating the effects of the mutation or by weakening the binding even further. The 
question of whether a given mutation is accompanied by any local or global alterations in 
the protein structure is therefore critical to interpreting its effects.43,199 Investigation of pairs 
or combinations of mutations provides a method to probe this question. In particular, it has 
been widely assumed that additivity of the effects of multiple mutations implies that the 
protein is relatively rigid, and that even local conformational disruption resulting from a 
mutation will result in non-additivity in its combinations with others.230,239,241,245 However, 
additivity does not require a rigid binding interface, as long as any structural perturbation 
or relaxation is local and not communicated between the sites of the two mutations, as 
discussed below. 
If mutation of a residue to alanine at site B occurs at a rigid binding interface, a 
cavity is formed at the site of the mutation, but other atoms in the protein are not perturbed 
(Figure 4.17). Assuming no long range solvation effects, the loss of binding energy due to 
the mutation, ΔΔG(B), stems directly from the local loss of interaction energy of the 
deleted side chain atoms with the partner protein, through mechanisms such as van der 
Waals interactions, hydrogen bonding etc. A different alanine mutation at site A, which is 
remote from B will similarly result in a loss of interaction energy, ΔΔG(A). If the protein 
is rigid, the magnitude of ΔΔG(A) will be unaffected by the presence or absence of the side 
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chain atoms of the distal residue B, and vice versa. Consequently, ΔΔG for the double 
mutant is simply equivalent to the sum of the ΔΔG values for the single mutants: 
 
ΔΔG(A) + ΔΔG(B) = ΔΔG(AB) 
 
Figure 4.17 Energy diagram illustrating the relationship of mutations at a rigid interface. The y-axis 
represents the overall energy of the components. Protein and ligand are shown in blue and pink, respectively. 
The cavity on the protein surface caused by mutation A and B are shown as triangular-shaped and rectangular-
shaped cavities, respectively. ΔΔG is defined as the difference between the interaction energy of the mutant 
complex and the wild-type complex. ΔΔG(A) is indicated in blue, ΔΔG(B) in red, and ΔΔG(AB) in green. 
 
In reality, proteins are generally not rigid. If mutation B induces a local 
conformational change among the surrounding residues, illustrated in Figure 4.18 by the 
transformation of B to B* with a differently-shaped cavity, then the initial unbound state 
of mutant B before complex formation is stabilized relative to a conformation state of the 
protein in which this structural relaxation had not occurred. The extent of this stabilization 
effect is equal to the free energy of the conformational change from B to B* (ΔG(B*)conf). 
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This conformational change may or may not affect binding to the partner protein. 
Therefore, the loss of binding energy observed for the mutant with new conformation is 
defined as ΔΔG(B*). Importantly, assuming that the structural perturbation affects only 
local regions surrounding mutation B, and is not propagated to the distal region of the 
interface where residue A binds, ΔΔG(A) will be independent of whether residue B is 
present or mutated, and vice versa. Thus, despite the fact that mutation B causes some local 
conformational disruptions, the effects of mutations A and B will still be additive, because 
there is no communication between the two mutations. The energetic effect of the double 
mutant AB will therefore remain the same as the sum of ΔΔG(A) and ΔΔG(B). 
 
ΔΔG(B*) = ΔΔG(B) 
ΔΔG(A) + ΔΔG(B*) = ΔΔG(AB) 
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Figure 4.18 Energy diagram illustrating how local conformational changes affect the relationship of 
mutations. The local conformational change upon mutation B is illustrated by the transformation of B to B* 
with a round-shaped cavity. ΔΔG(B*)conf  represents the free energy of mutation-induced conformational 
change. All representations remain the same as in Figure 4.17. 
 
If mutation B induces a long-range conformational change that is propagated to the 
region where residue A binds, non-additivity of the mutational effects is observed. The 
communication between mutation A and B can be mediated by side-chain motions of 
several residues in close proximity that are interconnected with both A and B via an 
interaction network, or through a more global allosteric mechanism involving backbone 
distortion. For example, in a simplified example shown in Figure 4.19, mutating B induces 
both a local (i.e. square-shaped cavity converted to round-shaped) and a long-range 
conformational change (i.e. the triangular-shaped protrusion occurs at a distal site where 
residue A on the partner protein binds), resulting in a new initial state of the unbound 
protein designated B**. A result of this conformational change is to disrupt the binding 
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interface in the region where residue A binds, such that this distal site is no longer 
complementary to A.  Additional effect of this new conformation, B**, is to further weaken 
binding beyond the level expected due to the loss of interaction with the side-chain atoms 
of mutated residue B. In this case, ΔΔG(B**) comprises several components: (i) ΔΔG(B), 
the loss of interaction energy due to the reduced direct contacts at the location of mutation 
B in the bound complex, the same as seen in B and B*; (ii) ΔΔG(A), the loss of interaction 
energy due to the reduced direct contacts at the location where residue A is supposed to 
bind in the bound complex, as seen in mutant A; and possibly  (iii) ΔΔG(Int), the loss of 
interaction energy due to the reduced direct contacts at intervening regions that are also 
affected by this long-range conformational change (shown in purple).  
 
ΔΔG(B**) = ΔΔG(B) + ΔΔG(A) + ΔΔG(Int) 
 
Figure 4.19 Energy diagram illustrating how long-range conformational changes affect the relationship of 
mutations. The long-range conformational change upon mutation B is illustrated by the local round-shaped 
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cavity and an additional triangular-shaped protrusion at a distal site on B**. ΔΔG(B**) represents the loss 
of interaction energy rooting from the reduced direct physical contacts. ΔΔG(Int) in purple represents loss of 
interaction energy rooting from the reduced direct physical contacts at intervening regions. All 
representations remain the same as in Figure 4.17. 
 
However, in this hypothetical example, when A is mutated in addition to mutation 
B, it generates a complementary cavity on the partner protein to accommodate the new 
conformation seen in B** (fourth column, Figure 4.19). Therefore, mutating A in the 
presence of mutation B is less deleterious than mutating A alone. Indeed, mutating A in 
the presence of mutation B could have no effect at all, or could even make binding stronger 
by eliminating unfavorable steric contacts and enable proper complementation of 
intervening regions of the interface, as shown in the figure above.  This example illustrates 
that when a conformational perturbation upon mutation is propagated to the site of a second 
mutation, additivity of the mutational effects will disappear.  
In this non-additive scenario, the relationship of ΔΔG(AB) to ΔΔG(A) and ΔΔG(B) 
depends on the extent to which mutation B changes the interaction energy at site A, which 
(following Fersht et al.)241 can be described using ΔΔΔG. 
 
ΔΔΔG = ΔΔG(AB) - ΔΔG(A) + ΔΔG(B)    Eq. 4.4 
 
However, the observation of a negative value for ΔΔΔG, by itself, does not 
distinguish among the scenarios where a mutation at site B weakens, completely abolishes 
or disfavors the interaction at site A. To be more specific, ΔΔΔG, is not informative in 
distinguishing the following categories: partially additive, subordinate or compensatory 
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(see 4.4.4). Nevertheless, if we apply the Additivity Index as an approach to measure this 
lack-of-additive effect, depending on whether the allosteric regulation is beneficial or 
deleterious, the outcomes can be distinguishable.  
Specifically, if there is no allosteric communication between the sites then 
ΔΔG(AB) = ΔΔG(A) + ΔΔG(B), corresponding to an Additivity Index = 1, which identifies 
the mutations as additive. If allosteric change associated with mutation B serves to partially 
weaken the binding at site A, then ΔΔG(AB) will lie somewhere between ΔΔG(B) (the 
larger among the two individual mutations) and ΔΔG(A) + ΔΔG(B), and the Additivity 
Index ∈ (0,1), identifying the mutations as partially additive. If conformational changes 
associated with mutation B serve to completely abolish the interaction at site A, then 
ΔΔG(AB) = ΔΔG(B) and Additivity Index = 0, identifying mutation A as subordinate to 
mutation B. If conformational changes associated with mutation B serve to render the 
interaction at site A energetically unfavorable, then ΔΔG(AB) < ΔΔG(B) and Additivity 
Index < 0, identifying the mutations as mutually compensatory. Finally, if conformational 
changes associated with mutation B serve to strengthen the interaction energy at site A, 
then ΔΔG(AB) > ΔΔG(A) + ΔΔG(B) and Additivity Index > 1, identifying the mutations 
as mutually Synergistic.  
Therefore, the Additivity Index can be used as a simple means to categorically 
distinguish mutations based on different allosteric interaction mechanisms between the 
mutation sites, providing an approach to relate experimental mutational effects to 
underlying structural causes in a manner that is not achieved by existing theoretical 
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frameworks. Comparison of ΔΔΔG and Additivity Index as means to report the structural 
basis of the allosteric effects is shown in Table 4.7. 
 
Table 4.7 ΔΔΔG versus Additivity Index in reporting the structural basis of the allosteric effects 
Relationship 
between 
mutations 
ΔΔΔG Additivity 
Index 
Structural Basis of allosteric effect 
Synergistic > 0 > 1 Mutation B allosterically strengthens binding at site A 
Additive = 0 = 1 No allosteric communication between mutation sites 
Partially additive < 0 (0, 1) Mutation B allosterically weakens binding at site A 
Subordinate < 0 = 0 Mutation B allosterically abolishes binding at site A 
Compensatory < 0 < 0 Mutation B allosterically renders binding at A unfavorable 
 
The entries in the table above illustrate that interpreting the value of Additivity 
Index provides additional information about how the different remote sites on a protein-
protein complex might interact with each other, which would not be obvious just by 
analyzing ΔΔΔG values. The proposed approach using Additivity Index can be applied to 
map the allosteric interactions through the structure of the target protein-protein complex, 
specifically, to discover which allosteric sites on the protein can regulate or induce a 
specific function at the active binding site. For example, this approach can experimentally 
probe the remote sites on complementarity determining regions (CDRs) of antibodies that 
might affect the antigen recognition, which could have potential utility to guide the protein 
engineering, especially antibody engineering, for higher affinity and selectivity. 
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4.4.8 Allosteric communication on KEAP1 
 An interesting finding in this study reveals that several arginine-to-alanine mutants 
on KEAP1 can induce a substantial stabilization effect, observed in both thermal and 
chemical denaturation experiments. A notable feature of KEAP1 is that the Nrf2 binding 
site is highly positively charged, to complement the highly negatively charged DxETGE 
motif on Nrf2. One possible explanation for the stabilization is that mutation of the three 
arginine residues in the active site of KEAP1 may reduce repulsive electrostatic 
interactions, thereby stabilizing the protein and increasing its resistance to thermal and 
chemical denaturation. To test the plausibility of this hypothesis, I calculated the energy 
resulting from the electrostatic interactions between Arg380, Arg415 and Arg483 on 
KEAP1 using Coulomb’s law: 
𝐸 = 𝑘𝑞B𝑞>𝑟 = 14𝜋𝜀 ×𝑞B𝑞>𝑟 	(𝐽𝑜𝑢𝑙𝑒) 
 
Then the electrostatic energy was converted to kcal/mol for comparison. The list of 
electrostatic interaction energies between the arginine residues on KEAP1 are shown in 
Table 4.8: 
 
Table 4.8 Calculated electrostatic interaction energies between key arginine residues on KEAP1 
 Distance (Å) Electrostatic repulsion in vacuum (kcal/mol) 
Electrostatic repulsion in 
water 25 ̊C (kcal/mol) 
R380 vs R415 10.1 32.8 0.420 
R380 vs R483 15.4 21.5 0.276 
R415 vs R483 8.6 38.5 0.494 
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Figure 4.20 Illustration of the structural relationships of the three arginine residues and how the distance of 
the charge being measured. Crystal structure of unbound wild-type KEAP1 (by Dr. Andrew Lynch and Dr. 
James Carolan, Allen lab) was used for this measurement. 
 
As for the proper dielectric constant to use in this calculation, while there is a 
consensus in the community that a dielectric constant of 78 is appropriate for describing 
dielectric properties of bulk water, the optimal value of the protein dielectric constant is 
still an ongoing debate in the literature. Values from as low as 1 to as high as 40 have been 
used in modeling.253-258 So results calculated using both ε = 1 and 78 are provided here. 
 
The assumption is that, if an arginine residue is involved in a strong electrostatic 
repulsive interaction with the other two, removal of the charged side chain will partially 
cancel this disfavored interaction, and as a result, stabilize the protein. Results shown above 
do not directly correlate with the observation of the Tm shifts in thermal denaturation assay. 
The mutation that causes the greatest Tm shift (R380A) is not the one involved in the 
greatest electrostatic interactions. This can be explained by the fact that in the experimental 
measurements, a lot of other charged residues on KEAP1, including both positively and 
negatively charged ones, are cooperatively influencing each other via electrostatic 
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interactions. The simplified calculation cannot precisely represent the network of this long-
range electrostatic effect. It has been shown that the electrostatic component of the protein 
association and protein folding can be assessed by means such as electrostatic 
screening.259,260 Measuring protein association or folding/unfolding in various salt 
concentrations, to see if the ionic strength would have an impact on the thermodynamics 
or kinetics, is one of the future directions of our work. The results from the simplified 
calculation suggest that the repulsive electrostatic interaction energy among the three 
arginine residues in the active site of  KEAP1 is substantial, thereby, removing the charged 
side chain by mutating to alanine can stabilize the protein and increase its resistance to 
denaturation. 
Results from HDX experiments and observations of B-factors in X-ray 
crystallography provide more detailed structural information of the ligand-binding or 
single site mutation induced protein structure stabilization. In general, HDX results show 
that KEAP1 Kelch repeat domain functions as an integrated dynamic unit, in the sense that 
perturbing the protein in one regions can alter the dynamics in other remote regions. The 
information obtained from the HDX experiments helps to trace this allosteric effect, both 
in case of ligand binding and single site mutation. The results of several different 
experiments discussed here become convergent – thermal and chemical denaturation 
experiments revealed a stabilization effect on KEAP1 Kelch repeat domain upon 
mutagenesis; observations of B-factors in X-ray crystallography indicated a loss of 
flexibility in certain distal loops from the active binding site upon ligand binding; and HDX 
experiment confirmed those observations and identified the specific allosteric regions on 
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KEAP1 that were affected by ligand-binding or mutagenesis. In summary, we conclude 
that occupying the active site with a moiety of the opposite charge (e.g. Glu on Nrf2) or 
removing the charged residues can have the same allosteric effect on KEAP1 Kelch repeat 
domain. Neutralization of the charge of the arginine side chain appears to be the origin of 
this effect. 
It is worth mentioning that the dimerization of KEAP1 Kelch repeat domain in 
crystal structure is likely an artifact. We have extensively validated that KEAP1 exists as 
a monomer in solution using analytical gel filtration. In the unbound wild-type KEAP1 
protein, R380 resides in a loop distant from the region that is allosterically affected. 
Whether this allosteric regulation effect on the Kelch repeat domain plays a role in the 
protein biological functions remains unclear at this stage. 
 
4.4.9 Conclusions and future directions 
In this chapter, a comprehensive alanine scanning mutagenesis at the KEAP1 
binding interface revealed that R380, R415, R483 and S508 are four key residues that 
contribute to the binding energy of the interaction with Nrf2. A detailed investigation of 
the stabilization effect on KEAP1 induced by ligand-binding and mutagenesis unraveled 
an allosteric regulation of protein dynamics. Based on the double-mutant cycle analysis on 
KEAP1/Nrf2, we introduced the term “Additivity Index” and proposed a model to 
categorize the double mutant additive/non-additive behavior in a quantitative manner. In 
addition, I discussed the potential structural causes for each type of additivity behavior. 
Future examination of our model on other protein-protein interactions using the double-
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mutant cycles can bring insight into a better understanding of the additivity effect and the 
binding energetics at PPI interfaces.
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APPENDICES 
 
Appendix I. Primers used for cloning and site-directed mutagenesis 
No. Name Primer Sequence Notes 
1 T7-pET15b FWD ttaatacgactcactataggggaattgtgagcggata 
Use with all the 
mutation REV 
2 T7term-pET15b REV tcaagacccgtttagaggccccaaggggttatgctag 
Use with all the 
mutation FWD 
3 Nrf21-100 pET15b gatatacaTATGATGGACTTGGAGC Use with 05 
4 Nrf234-100 pET15b gatatacaTATGCGAGAAGTATTTG Use with 05 
5 Nrf2 pET15b REV taGGATCCttaGGCAGATCCACT Use with 03 and 04 
6 Nrf2 D77A REV AATTCACCTGTCTCTTCGGCTAGTTGTAACTGAGCGAAA Use with 03 and 04 
7 Nrf2 E78A REV AGAAATTCACCTGTCTCGGCATCTAGTTGTAACTGAGCG Use with 03 and 04 
8 Nrf2 E79A REV GGGAGAAATTCACCTGTGGCTTCATCTAGTTGTAACTGA Use with 03 and 04 
9 Nrf2 T80A REV ATTGGGAGAAATTCACCTGCCTCTTCATCTAGTTGTAAC Use with 03 and 04 
10 Nrf2 T80S REV ATTGGGAGAAATTCACCTGACTCTTCATCTAGTTGTAAC Use with 03 and 04 
11 Nrf2 E82A REV GGCTGAATTGGGAGAAAGGCACCTGTCTCTTCATCTAGT Use with 03 and 04 
12 Nrf2 F83A REV GCTGGCTGAATTGGGAGAGCTTCACCTGTCTCTTCATCT Use with 03 and 04 
13 KEAP1 R380A FWD GCTGTACGCAGTTGGCGGTGCCAATAACAGCCCGGACGG Use with 02 
14 KEAP1 N382A FWD CGCAGTTGGCGGTCGCAATGCCAGCCCGGACGGCAATAC Use with 02 
15 KEAP1 R415A FWD ATGAGTGTGCCGCGCAATGCCATCGGTGTGGGCGTTATT Use with 02 
16 KEAP1 R483A REV ACACTCGGCGCTGTTCAGAGCGTTGGTGCCATCAAAGCC Use with 01 
17 KEAP1 Q530A REV AGCGTTCAACGCTGTTCAGCGCGTCCTGACCGTCGTAAC Use with 01 
18 KEAP1 S555A REV GCACGGTAATACCTAAGGCGGCGCGACGGTGTTTCATCG Use with 01 
19 KEAP1 S508A REV GCACACAAACGCCGGCGCCGGCACGGATGGTATTCATGG Use with 01 
20 KEAP1 C434A FWD GTGGGCGGCAGCCACGGCGCTATCCACCATAACAGCGTG Use with 02 
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Appendix II. Sequences and mass spectra of KEAP1 variants 
II.A Sequence alignment of KEAP1 variants 1, 2 
WT 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
R380A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGANNS 383 
N382A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNAS 383 
R415A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
R483A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
S508A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
Q530A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
S555A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
C434A 312 GHMKPTQVMPSRAPKVGRLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSGLAGCVVGGLLYAVGGRNNS 383 
    
WT 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
R380A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
N382A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
R415A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNAIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
R483A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
S508A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
Q530A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
S555A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVERYEPERDEWHLVAPMLT 458 
C434A 384 PDGNTDSSALDCYNPMTNQWSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGAIHHNSVERYEPERDEWHLVAPMLT 458 
    
WT 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
R380A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
N382A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
R415A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
R483A 459 RRIGVGVAVLNRLLYAVGGFDGTNALNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
S508A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRAGAGVCVLHNCIYAAGGYDGQDQLNS 533 
Q530A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDALNS 533 
S555A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
C434A 459 RRIGVGVAVLNRLLYAVGGFDGTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHNCIYAAGGYDGQDQLNS 533 
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WT 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
R380A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
N382A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
R415A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
R483A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
S508A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
Q530A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
S555A 534 VERYDVATATWTFVAPMKHRRAALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
C434A 534 VERYDVATATWTFVAPMKHRRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTDTWSEVTRMTSGRSGVGVAV 608 
    
WT 609 TMEPSRKQIDQQNSTS 624 
R380A 609 TMEPSRKQIDQQNSTS 624 
N382A 609 TMEPSRKQIDQQNSTS 624 
R415A 609 TMEPSRKQIDQQNSTS 624 
R483A 609 TMEPSRKQIDQQNSTS 624 
S508A 609 TMEPSRKQIDQQNSTS 624 
Q530A 609 TMEPSRKQIDQQNSTS 624 
S555A 609 TMEPSRKQIDQQNSTS 624 
C434A 609 TMEPSRKQIDQQNSTS 624 
 
1. Residues that are underlined and colored in blue are the ones engineered for crystallization purpose, yet not 
affecting the protein function (see 2.2.1). Residues shadowed in greens are residuals from the TEV 
proteolysis reaction. 
2. Residues highlighted in red are the ones mutated in alanine scanning mutagenesis analysis. 
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II.B Mass spectra of KEAP1 variants 
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Keap1 Theoretical Mass spec 
WT 34586.84 34589 
R380A 34501.73 34504 
N382A 34543.81 34545 
R415A 34501.73 34503 
R483A 34501.73 34504 
S508A 34570.84 34574 
Q530A 34529.79 34532 
S555A 34570.84 34572 
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Appendix III. Sequences and mass spectra of Nrf2 variants 
III.A Sequence and calculated molecular weight of each Nrf2 variant 
Nrf2 Sequence 
Theoretical 
mass 
Actual 
mass 
WT1-100 
GHMMDLELPPPGLPSQQDMDLIDILWRQDIDLGVSREVFD
FSQRRKEYELEKQKKLEKERQEQLQKEQEKAFFAQLQLDE
ETGEFLPIQPAQHIQSETSGSA 
11970.30 11970 
WT34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEETGEFLPIQPAQHIQSETSGSA 8367.20 8368 
D77A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLAEETGEFLPIQPAQHIQSETSGSA 8323.26 / 
E78A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDAETGEFLPIQPAQHIQSETSGSA 8309.23 8309 
E79A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEATGEFLPIQPAQHIQSETSGSA 8309.23 8309 
T80A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEEAGEFLPIQPAQHIQSETSGSA 8337.24 8337 
T80S34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEESGEFLPIQPAQHIQSETSGSA 8353.24 8353 
E82A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEETGAFLPIQPAQHIQSETSGSA 8309.23 8309 
F83A34-100 
GHMREVFDFSQRRKEYELEKQKKLEKERQEQLQKEQEKAF
FAQLQLDEETGEALPIQPAQHIQSETSGSA 8291.17 8291 
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III.B Mass spectra of Nrf2 variants 
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Appendix IV. Known inhibitors of KEAP1, with variable Arg415 poses 
PDB ID Ligand R415 pose References 
Unbound 
KEAP1 No Down / 
Nrf2 9mer 
peptide bound 
KEAP1 
LDEETGEFL Side / 
ZT0256-bound 
KEAP1 
 
Side / 
ZT0017-bound 
KEAP1 
 
Side / 
ZT0633-bound 
KEAP1 
 
Down 
(two side 
chain 
poses) 
/ 
1U6D No Down  
1ZGK No Down 173 
2FLU AFFAQLQLDEETGEFL Down 137 
3VNG 
(co-
crystalized) 
3VNH 
(soaking) 
 
 
Down 261 
3ZGC Cyclic GDEETGE Side 172 
3ZGD No Down 172 
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4IFJ No Down  
4IFL AFFAQLQLDEETGEFL Side  
4IFN 
 
Up  
4IN4 
 
Up 170 
4IQK 
 
Up 170 
4L7B 
 
Up 217 
4L7C 
 
Up 217 
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4L7D 
 
Up 217 
4N1B 
 
Up 217 
4XMB 
 
Up 218 
Astex Fragments Bound Mouse KEAP1 
5FNQ 
 
(Fragment 1) 
Up 171 
5FZJ 
 
(Fragment 2) 
Side 171 
5FZN 
 
(Fragment 3) 
Side 171 
  
  
206 
Appendix V. All fragment hits, with chemical structures and results observed in 
ThermoFluor and FA assays. 
Compound 
No. Structure 
% inhibition in FA 
assay 
ΔTm in ThermoFluor 
Assay (̊C) 
ZT0256 
 
85.5 + 4.6 
ZT0633 
 
50.5 + 2.8 
ZT0802 
 
75.7 + 1.3 
ZT0204 
 
90.5 + 0.5 
ZT0391 
 
95.2 + 0.3 
ZT0418 
 
89.0 + 0.2 
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ZT0589 
 
62.0 + 0.2 
ZT0191 
 
51.8 + 0.0 
ZT0017 
 
Not testable 
poor solubility 
+ 4.8 
ZT0372 
 
Not testable 
Fluorescence 
interference 
+4.2 
ZT0010 
 
Not testable 
poor solubility 
+ 3.9 
ZT0707 
 
25.8 +3.8 
ZT0676 
 
Not testable 
Fluorescence 
interference 
+3.1 
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ZT0563 
 
94.5 / 
ZT0602 
 
90.3 / 
ZT0740 
 
84.6 / 
ZT0356 
 
83.6 / 
ZT0199 
 
81.6 / 
ZT0039 
 
77.8 / 
ZT1664 
 
77.2 / 
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ZT0588 
 
73.1 / 
ZT0274 
 
71.5 / 
ZT0642 
 
70.3 / 
ZT0478 
 
70.0 / 
ZT0747 
 
67.0 / 
ZT0732 
 
65.9 / 
ZT0861 
 
63.7 / 
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ZT0852 
 
62.5 / 
ZT0074 
 
60.7 / 
ZT0450 
 
58.4 / 
ZT1680 
 
58.2 / 
ZT0045 
 
57.8 / 
ZT0373 
 
56.5 / 
ZT0709 
 
55.4 / 
ZT0173 
 
55.1 / 
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ZT0730 
 
55.0 / 
ZT0546 
 
54.4 / 
ZT0040 
 
52.4 / 
ZT0687 
 
52.1 / 
ZT0724 
 
52.1 / 
ZT0772 
 
51.5 / 
ZT0600 
 
50.5 / 
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Appendix VI. Tethering hits, with chemical structures and DR50 values 
No. SMDC_ID Structure Adduct mass %label DR50 (M) 
1 917833 
 
411.741 95.2 3.62E-05 
2 917837 
 
383.687 84.7 7.15E-05 
3 917809 
 
394.687 96.8 6.31E-05 
4 917173 
 
239.493 90.7 8.65E-05 
5 917726 
 
375.472 94.9 3.23E-05 
6 917794 
 
383.505 89.3 1.08E-04 
7 917198 
 
234.479 97.7 4.64E-05 
8 917261 
 
331.595 95.3 4.98E-05 
9 917916 
 
290.582 97.5 6.18E-05 
10 917994 
 
402.666 89.8 8.68E-05 
11 917244 
 
372.607 90.9 1.12E-04 
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Appendix VII. Sequence alignments of Nrf2 and KEAP1 paralogs 
Appendix VII.A Sequence alignment of Nrf2 paralogs 
   D x E T G E    
Homo sapiens 76 L D E E T G E F L 84 
Pongo abelii 60 L D E E T G E F L 68 
Bos taurus 76 L D E E T G E F L 84 
Macaca mulatta 76 L D E E T G E F L 84 
Rattus norvegicus 76 L D E E T G E F L 84 
Myotis davidii 166 L D E E T G E F L 174 
Myotis brandtii 82 L D E E T G E F L 90 
Fukomys damarensis 60 L D E E T G E F L 68 
Heterocephalus glaber 245 L D E E T G E F L 253 
Cricetulus griseus 60 L D E E T G E F L 68 
Pteropus alecto 60 L D E E T G E F L 68 
Capra hircus 60 L D E E T G E F L 68 
Mauremys reevesii 71 L D E E T G E F I 79 
Pelodiscus sinensis 71 L D E E T G E F V 79 
Amazona aestiva 71 L D E E T G E F V 79 
Alligator mississippiensis 68 L D E E T G E F V 76 
Xenopus tropicalis 75 L D E E T G E F I 83 
Anas platyrhynchos 88 L D E E T G E F V 96 
Mus musculus 76 L D E E T G E F L 84 
Coturnix coturnix 60 L D E E T G E F V 68 
Gallus gallus 60 L D E E T G E F V 68 
Oncorhynchus kisutch 75 L D E E T G E F V 83 
Ctenopharyngodon idella 75 L D E E T G E F V 83 
Larimichthys crocea 114 L D E E T G E Y I 122 
Salmo salar 75 L D E E T G E F V 83 
Xenopus laevis 75 L D E E T G E F I 83 
Danio rerio 75 L D E E T G E F L 83 
 
Appendix VII.B Conservation of human sequence in KEAP1 paralogs 1 
 
1. Frequency of human amino acid at each position is shown. Four energetically crucial residues that are 
identified in this study are almost all 100% conserved in 34 paralogs, except for R483 – a glutamine is found 
at this position in Scleropages formosus instead. 
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Appendix VIII. Allosteric effect mapping on KEAP1 by ARDD 
 
Appendix VI. A HDX results illustrated by mapping ARDD values on KEAP1 residues. ARDD values are 
calculated relative to the wild-type unbound KEAP1 protein, greater value indicates a more significant 
difference in protein dynamics. ARDD values are plotted against the residue number of KEAP1. ARDD of 
complex minus unbound KEAP1 shown as blue dashed line, ARRD of R380A minus unbound KEAP1 shown 
as red dashed line. 
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Appendix IX. DYNAFIT scripts for competitive binding model 
[task] 
   data = equil 
   task = fit 
 
[mechanism] 
 L + P <==> P.L : Kd1 dissoc ; L represents *Nrf2, P 
is Keap1 
 C + P <==> P.C : Kd2 dissoc ; N represents Nrf2 
mutant 
 
[concentrations] 
 L = 5 
 P = 10 
[constants] 
 Kd1 = 10 
 Kd2 = 50 ? 
 
[responses] : Specific molar response of *Nrf2 
 P.L = 50 ? 
[equil] 
variable C 
 
file ./test/data/datafile_name.txt 
[output] 
   directory    ./test/output 
 
[end] 
 
  
216 
Appendix X. Python scripts used in PyMOL for SASA calculation 
 
from pymol import cmd, stored 
 
def SASA_by_resi( userSelection ): 
 cmd.set('dot_solvent', 1) 
 cmd.set('dot_density', 3) 
 stored.residues = [] 
 cmd.iterate('name ca', 'stored.residues.append(resi)') 
 sasa_by_resi = [] 
 for i in stored.residues: 
  tmp = cmd.get_area(userSelection + ' and resi %s'  
%i) 
  sasa_by_resi.append(tmp) 
  if tmp != 0: 
   print 'Residue ', i, ' ', ':', tmp 
  
 print 'Total SASA of selection: ', sum(sasa_by_resi) 
 print 'Total SASA of all: ', cmd.get_area('all') 
  
 
cmd.extend( "SASA_by_resi", SASA_by_resi ); 
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Appendix XI. Examples of macrocyclization improving target binding 
Target Macrocyclic compound Linear compound 
CHK1 
  
 IC50 = 10 nM IC50 = 22 nM 
BACE-1 
  
 IC50 = 2.9 µM IC50 > 100 µM 
FTase 
 
 
IC50 = 5490 nM 
 
IC50 = 0.1 nM IC50 = 2 nM 
BACE-1 
  
 
IC50 = 5.9 nM (R = 2-pyridyl) 
IC50 = 2.5 nM (R = N-
pyrrolidinoyl) 
IC50 = 120 nM (R = 2-pyridyl) 
IC50 = 10 nM (R = N-
pyrrolidinoyl) 
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Grb2 SH2 
domain 
  
 KD = 100 nM ΔSo = 17.7 kcal∙mol-1∙K-1 
KD = 154 nM 
ΔSo = 9.9 kcal∙mol-1∙K-1 
HCV NS3 
Protease 
  
 IC50 = 4 µM IC50 = 130 µM 
HCV NS3 
Protease 
  
 IC50 = 27 nM IC50 = 400 nM 
MLL-1 
  
 Ki = 23.8 nM Ki = 2170 nM 
  
219 
HCV NS5B 
RNA 
polymerase 
 
 
KD = 4.0 nM 
 
 KD = 136 nM KD = 2.4 nM 
Urokinase-
type 
plasminogen 
activator (uPA) 
 
 
KD = 2.1 µM 
 
 KD = 8.0 µM KD = 0.36 µM 
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Appendix XII. Quantifying the Chameleonic Properties of Macrocycles and other 
High Molecular Weight Drugs 
Research Highlights 
o “Chameleonic” behavior is key for the bioavailability of certain macrocyclic drugs. 
o Some chameleonic behavior is likely required for most oral drugs with MW > 600 Da. 
o Compounds require chameleonic behavior if TPSA <0.23MW, or MPSA >140 Å2. 
o Chameleonic behavior may explain the properties of high MW Bcl-xL inhibitors. 
o Effective chameleonic behavior requires a change in PSA of ≥ 0.23MW - 140 Å2. 
Attached full manuscript is published in Drug Discovery Today, 2016, 21 (5), 712 - 717. 
Reprinted from Drug Discovery Today, 21 (5), Whitty, A.; Zhong, M.; Viarengo, L.; 
Beglov, D.; Hall, D. R.; Vajda, S., Quantifying the Chameleonic Properties of Macrocycles 
and other High Molecular Weight Drugs, 712 – 717. Copyright (2016), with permission 
from Elsevier. 
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